
<html lang="en"     class="pb-page"  data-request-id="9bab414f-dd3b-4f39-95af-292fd54997a8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00413;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents" /></meta><meta name="dc.Creator" content="Xiaopeng  Peng" /></meta><meta name="dc.Creator" content="Jingxuan  Chen" /></meta><meta name="dc.Creator" content="Ling  Li" /></meta><meta name="dc.Creator" content="Zhiqiang  Sun" /></meta><meta name="dc.Creator" content="Jin  Liu" /></meta><meta name="dc.Creator" content="Yichang  Ren" /></meta><meta name="dc.Creator" content="Junli  Huang" /></meta><meta name="dc.Creator" content="Jianjun  Chen" /></meta><meta name="dc.Description" content="Novel dual HDAC3/tubulin inhibitors were designed and efficiently synthesized by combining the pharmacophores of SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), among which compound 15c was ..." /></meta><meta name="Description" content="Novel dual HDAC3/tubulin inhibitors were designed and efficiently synthesized by combining the pharmacophores of SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), among which compound 15c was ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00413" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00413" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00413" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00413" /></link>
        
    
    

<title>Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00413" /></meta><meta property="og:title" content="Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0023.jpeg" /></meta><meta property="og:description" content="Novel dual HDAC3/tubulin inhibitors were designed and efficiently synthesized by combining the pharmacophores of SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), among which compound 15c was found to be the most potent and balanced HDAC3/tubulin dual inhibitor with high HDAC3 activity (IC50 = 30 nM) and selectivity (SI &gt; 1000) as well as excellent antiproliferative potency against various cancer cell lines, including an HDAC-resistant gastric cancer cell line (YCC3/7) with IC50 values in the range of 30–144 nM. Compound 15c inhibited B16-F10 cancer cell migration and colony formation. In addition, 15c demonstrated significant in vivo antitumor efficacy in a B16-F10 melanoma tumor model with a better TGI (70.00%, 10 mg/kg) than that of the combination of MS-275 and SMART. Finally, 15c presented a safe cardiotoxicity profile and did not cause nephro-/hepatotoxicity. Collectively, this work shows that compound 15c represents a novel tubulin/HDAC3 dual-targeting agent deserving further investigation as a potential anticancer agent." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00413"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00413">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00413&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00413&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00413&amp;href=/doi/10.1021/acs.jmedchem.1c00413" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8447-8473</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00404" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00414" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaopeng Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaopeng Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaopeng++Peng">Xiaopeng Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingxuan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingxuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingxuan++Chen">Jingxuan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ling Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Li">Ling Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiqiang Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiqiang Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiqiang++Sun">Zhiqiang Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Liu">Jin Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yichang Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichang Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichang++Ren">Yichang Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junli Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junli Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junli++Huang">Junli Huang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1c767f7479722e2d5c6f716932797869327f72"><span class="__cf_email__" data-cfemail="264c454e4348141766554b5308434253084548">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Chen">Jianjun Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5668-6572" title="Orcid link">https://orcid.org/0000-0001-5668-6572</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00413&amp;href=/doi/10.1021%2Facs.jmedchem.1c00413" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8447–8473</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 7, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 March 2021</li><li><span class="item_label"><b>Published</b> online</span>7 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8447%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaopeng%2BPeng%252C%2BJingxuan%2BChen%252C%2BLing%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00413%26title%3DEfficient%2BSynthesis%2Band%2BBioevaluation%2Bof%2BNovel%2BDual%2BTubulin%252FHistone%2BDeacetylase%2B3%2BInhibitors%2Bas%2BPotential%2BAnticancer%2BAgents%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8473%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00413"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">765</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00413" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaopeng&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Jingxuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhiqiang&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yichang&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Junli&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8447-8473&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00413&quot;},&quot;abstract&quot;:&quot;Novel dual HDAC3/tubulin inhibitors were designed and efficiently synthesized by combining the pharmacophores of SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), among which compound 15c was found to be the most potent and balanced HDAC3/tubulin dual inhibitor with high HDAC3 activity (IC50 = 30 nM) and selectivity (SI &gt; 1000) as well as excellent antiproliferative potency against various cancer cell lines, including an HDAC-resistant gastric cancer cell line (YCC3/7) with IC50 values in the range of 30–144 nM. Compound 15c inhibited B16-F10 cancer cell migration and colony formation. In addition, 15c demonstrated significant in vivo antitumor efficacy in a B16-F10 melanoma tumor model with a better TGI (70.00%, 10 mg/kg) than that of the combination of MS-275 and SMART. Finally, 15c presented a safe cardiotoxicity profile and did not cause nephro-/hepatotoxicity. Collectively, this work shows that compound 15c represents a novel tubulin/HDAC3 dual-targeting agent deserving further investigation as a po&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00413&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00413" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00413&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00413" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00413&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00413" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00413&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00413&amp;href=/doi/10.1021/acs.jmedchem.1c00413" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00413" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00413" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26pmid%3D34097389%26genre%3Darticle%26aulast%3DPeng%26date%3D2021%26atitle%3DEfficient%2BSynthesis%2Band%2BBioevaluation%2Bof%2BNovel%2BDual%2BTubulin%252FHistone%2BDeacetylase%2B3%2BInhibitors%2Bas%2BPotential%2BAnticancer%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292232" title="Polymerization">Polymerization</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Novel dual HDAC3/tubulin inhibitors were designed and efficiently synthesized by combining the pharmacophores of SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), among which compound <b>15c</b> was found to be the most potent and balanced HDAC3/tubulin dual inhibitor with high HDAC3 activity (IC<sub>50</sub> = 30 nM) and selectivity (SI > 1000) as well as excellent antiproliferative potency against various cancer cell lines, including an HDAC-resistant gastric cancer cell line (YCC3/7) with IC<sub>50</sub> values in the range of 30–144 nM. Compound <b>15c</b> inhibited B16-F10 cancer cell migration and colony formation. In addition, <b>15c</b> demonstrated significant <i>in vivo</i> antitumor efficacy in a B16-F10 melanoma tumor model with a better TGI (70.00%, 10 mg/kg) than that of the combination of MS-275 and SMART. Finally, <b>15c</b> presented a safe cardiotoxicity profile and did not cause nephro-/hepatotoxicity. Collectively, this work shows that compound <b>15c</b> represents a novel tubulin/HDAC3 dual-targeting agent deserving further investigation as a potential anticancer agent.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Epigenetic regulation is essential to many biological processes and is associated with the onset and progression of various human diseases such as cancer.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Among the numerous epigenetic enzymes, histone deacetylases (HDACs) have been extensively explored for decades due to their significance in a variety of diseases, including cancer,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> inflammation,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> neurological disorders,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> and infections.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> HDACs are grouped into four classes based on their homology: class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), and class IV (HDAC 11), which are enzymatically active <i>via</i> a Zn<sup>2+</sup>-dependent mechanism, whereas class III HDACs (SIRT1-7) are NAD-dependent and are associated with aging.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Overexpression of HDACs is commonly observed in different types of cancers such as liver, breast, lung, and gastric cancers.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Therefore, HDACs are regarded as promising antitumor drug targets. So far, HDAC inhibitors (HDACi) have achieved great success as cancer therapeutics for the treatment of various cancers.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> To date, five HDAC inhibitors (<b>1</b>-SAHA, <b>2</b>-Belinostat, <b>3</b>-Panobinostat, <b>4</b>-Romidepsin, and <b>5</b>-Chidamide, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have been approved by FDA for treating hematologic malignancies.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21 ref22">(16−22)</a> Among them, <b>1</b> (SAHA, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is used clinically in patients with central T cell lymphoma. In addition, benzamide containing HDAC inhibitor <b>2</b> (MS-275, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a highly effective and selective inhibitor of HDAC1 and HDAC3, is currently under investigation in clinical trials to treat advanced multiple myeloma.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Despite the great success HDAC inhibitors have enjoyed clinically, and their further use was hindered by the almost inevitable drug-resistance and dose-limiting adverse effects (e.g., cardiotoxicity).<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Moreover, current HDAC inhibitors have not shown significant efficacy against solid tumors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, the search for new strategies that can potentially overcome these challenges has been intensified in the past decade, for example, the development of isoform-selective HDAC inhibitors, which have the potential to reduce toxicities associated with pan-HDAC inhibitors. In particular, HDAC3 is an HDAC isoenzyme that plays an important role in cancer, inflammation, and neurodegenerative diseases. Several reports have demonstrated the significant role of HDAC3 and its downstream signaling pathways in cancer.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Therefore, the development of selective HDAC3 inhibitors would be of great importance for cancer treatment. In addition to the development of isoform-selective HDAC inhibitors, combination therapies using HDACi and other anticancer agents (e.g., kinase inhibitors, HSP90 inhibitors, tubulin inhibitors) are also developed to enhance the antitumor efficacies.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> However, the polypharmacological nature of drug cocktails is often associated with poor patient compliance, complex dosing, unpredictable pharmacokinetics and pharmacodynamics, and drug–drug interactions.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pharmacophore model of marketed HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of tubulin/HDAC dual inhibitors. (A) Docking analysis of SMART in the colchicine-binding site of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>). (B) 90° clockwise rotation of tubulin in complex with SMART along the <i>x</i>-axis. (C) Design strategy of SMART-based HDAC and Tubulin dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An alternative strategy is to develop single molecules with multitargeting capabilities, which may provide more robust and durable therapeutic effects as well as benign toxicity profiles.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> In the past decade, numerous HDAC-based multitargeting antitumor agents have been discovered,<a onclick="showRef(event, 'ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45">(38−45)</a> some of them have entered clinical trials; for instance, CUDC-101, a small molecule EGFR/HDAC dual inhibitor currently undergoing phase I clinical trials, showed excellent antitumor efficacy in a variety of preclinical models.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a></div><div class="NLM_p">It has been reported that the combination of SAHA and vincristine (a tubulin inhibitor) could achieve synergistic effects in leukemia,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> which provides a theoretical basis for designing dual tubulin/HDAC inhibitors. Several groups have reported the discovery of novel tubulin/HDAC dual inhibitors in recent years.<a onclick="showRef(event, 'ref30 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref30 ref49 ref50 ref51 ref52 ref53">(30,49−53)</a> For instance, Diana and co-workers designed dual tubulin/HDAC inhibitors that demonstrated potent anticancer activities.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Despite these advancements, the therapeutic value of dual tubulin/HADC inhibitors (in particular, dual inhibitors with HDAC-isoform-selectivity) remains to be further explored.</div><div class="NLM_p last">Microtubules, composed of α/β-tubulin, play a key role in multiple cellular processes such as mitotic spindle formation and are regarded as an important target for anticancer therapeutics.<a onclick="showRef(event, 'ref55 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57 ref58">(55−58)</a> We have previously reported several types of tubulin inhibitors targeting the colchicine-binding site with high anticancer activities, for example, SMART, ABI, and SAI.<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> We also explored tubulin-based dual-targeting molecules recently by designing a series of novel tubulin/PD-L1 inhibitors, which showed good target engagement and excellent antitumor activities <i>in vivo</i>.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In a continuation of our research interest in tubulin-based dual-targeting strategies, we designed tubulin/HDAC3 dual inhibitors based on SMART and MS-275. We confirmed for the first time that these dual-targeting compounds exhibited more potent anticancer activities <i>in vitro</i> and <i>in vivo</i> than the drug combination of single-target compounds, as detailed below.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Structure-Based Design of Novel Tubulin/HDAC Dual Inhibitors</h3><div class="NLM_p last">The rationale for designing new tubulin/HDAC dual inhibitors commenced by analyzing the docking poses of SMART in the colchicine-binding site of tubulin [PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>].<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B, the para-position on the phenyl A-ring of the SMART core is directly exposed to the solvent, thus could serve as the reaction site for conjugating <i>via</i> a linker with the HDAC pharmacophore (e.g., the hydroxamic acid moiety). Our previous structure–activity relationship studies of SMART also indicated that different substituents, including bulky groups at the phenyl A-ring, were well tolerated.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> In addition, at the binding pocket of HDACs, there is a large hydrophobic domain that can accommodate a variety of structures and to which the CAP group of HDAC inhibitors bind. Therefore, it is conceivable that the CAP moiety in the pharmacophore model of HDAC inhibitors could be substituted by SMART to generate new classes of tubulin/HDAC molecules. Based on the above analysis, we designed two series of target compounds by combining SMART with the zinc-binding group (ZBG) of SAHA or MS-275, as shown below in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76015" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76015" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The approach we previously used for the synthesis of SMART was based on a five-step process, which includes the synthesis of the Weinreb amides followed by reacting with appropriate lithium reagents or Grignard reagents under harsh reaction conditions (−78 °C, strictly waterless).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Although the method is efficient to prepare various SMART analogues for initial biological screening, the harsh reaction conditions and the use of highly water-reactive/flammable/explosive organo-metallic reagents limited the preparation of SMART and analogues at a large scale. Therefore, more practical strategies for accessing structurally diversified SMART are still desirable. Hence, we developed a new procedure for the efficient synthesis of SMART and the key SMART analogues (<b>7a</b>/<b>7b</b>/<b>7c</b>) as illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, commercially available 3,4,5-trimethoxyaniline <b>1</b> was converted to 3,4,5-trimethoxy iodobenzene <b>2</b> under Sandmeyer reaction conditions. Second, a Sonogashira coupling of intermediate <b>2</b> with propyne afforded intermediate <b>3</b> in high yields (74%). Subsequently, the oxidation of the alkyne group of <b>3</b> using hyper-iodonium reagents provided the diketone derivative <b>4</b>, followed by treatment with CuBr<sub>2</sub> to obtain the brominated intermediate <b>5</b>, which was cyclized with various substituted-thiobenzamides <b>6</b> to produce the key SMART analogues (<b>7a</b>/<b>7b</b>/<b>7c</b>) with 39–41% overall yield, higher than that (16–18%) of our previous procedure to obtain SMART compounds.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0015.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Novel procedure to SMART analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) i: NaNO<sub>2</sub>, HCl, THF, 0 °C; ii: KI, 92%; (b) CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 90 °C, 74%; (c) RuCl<sub>3</sub>, PhI(OAc)<sub>2</sub>, dichloromethane (DCM)/H<sub>2</sub>O = 4/1, rt, 64%; (d) CuBr<sub>2</sub>, CHCl<sub>3</sub>/ethyl acetate = 1/2, 78 °C, 98%; and (e) EtOH, 87 °C, 89–96%.</p></p></figure><div class="NLM_p">The syntheses of target compounds <b>10a–i</b> and <b>12a–h</b> were carried out following the synthetic route outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The reaction of the phenol group of SMART analogue <b>7a</b> with halo-substituted esters yielded the corresponding alkyl aryl ethers <b>8</b> in high yield (73%). Hydrolysis of the alkyl ester of <b>8</b> generated the respective carboxylic acids, followed by coupling with <i>o</i>-phenylenediamine to give target compounds <b>10a–i</b> or with NH<sub>2</sub>OTHP to obtain amides <b>11</b>. The removal of the THP-protecting group by hydrochloric acid provided target compounds <b>12a–h</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0016.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>10a–i</b> and <b>12a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 73%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 93%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 88%; and (e) HCl/1,4-doxane, DCM, rt, 96%</p></p></figure><div class="NLM_p">The preparation of target compounds <b>15a–i</b> and <b>17a–i</b> is illustrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Amidation of the amine group of SMART analogue <b>7b</b> with carboxylate, using EDCI/HOBt as the coupling reagent, led to the formation of ester intermediates <b>13</b>, which were converted to the corresponding acids <b>14</b> in the presence of LiOH solution. Using a similar protocol shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, target compounds (<b>15a–i</b> and <b>17a–i</b>) were prepared according to the procedures outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0017.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a–i</b> and <b>17a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) EDCI, HOBt, triethylamine, DMF, rt, 95%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, Triethylamine, DMF, rt, 91%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 85%; and (e) HCl/1,4-dioxane, DCM, rt, 97%</p></p></figure><div class="NLM_p">The procedure for synthesizing target compounds <b>20a–c</b> and <b>22a–c</b> is depicted in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. First, coupling of SMART analogue <b>7b</b> with haloalkane esters afforded the corresponding esters <b>18</b>, which were hydrolyzed to the acid intermediates <b>19</b>, followed by a similar reaction shown in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a> to produce target compounds <b>20a–c</b> and <b>22a–c</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0018.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>20a–c</b> and <b>22a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) KI, K<sub>2</sub>CO<sub>3</sub>, MeCN, 59%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 93%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 87%; and (e) HCl/1,4-dioxane, DCM, rt, 91%</p></p></figure><div class="NLM_p">The target compounds <b>25a</b>, <b>27a</b>, <b>30a</b>, and <b>32a</b> were synthesized according to the procedures presented in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. In <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, coupling of the bromo-substituted SMART analogue <b>7c</b> with terminal alkyne esters resulted in the formation of the corresponding esters <b>23</b> with good yield (71%) under standard Sonogashira coupling conditions. Hydrolysis of <b>23</b> gave the carboxylic acid <b>24</b>, which was condensed with <i>o</i>-phenylenediamine to afford target compound <b>25a</b>. In addition, intermediate <b>24</b> could also undergo a coupling reaction with NH<sub>2</sub>OTHP, followed by deprotection of the THP-protecting group to produce target compound <b>27a</b>, in a manner similar to that described above. As shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, the acrylate derivative <b>28</b> was obtained in modest yield (52%) by reacting the corresponding aryl halide SMART analogue <b>7c</b> with methyl acrylate, utilizing the Mizoroki–Heck cross-coupling reaction. The acrylate compound <b>28</b> was transformed into target compounds <b>30a</b> and <b>32a</b> using a procedure similar to that described for compounds <b>25a</b> and <b>27a</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0019.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>25a</b> and <b>27a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, DMF, 90 °C, 71%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 96%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 89%; and (e) HCl/1,4-dioxane, DCM, rt, 94%</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0020.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>30a</b> and <b>32a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, triethylamine, DMF, 110 °C, 52%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 91%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 83%; and (e) HCl/1,4-dioxane, DCM, rt, 94%</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">4.  Biological Evaluation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4.1.  <i>In Vitro</i> Antiproliferative Assay</h3><div class="NLM_p">The newly synthesized compounds were evaluated by an MTT assay for their antiproliferative activities against four cancer cell lines, including HCT-116 (human colon cancer cell), B16-F10 (mouse melanoma cell), Jurkat (human T lymphocyte cell), and A549 (human lung cancer cell) cells. The two single-target compounds, SMART (tubulin inhibitor) and MS-275 (HDAC inhibitor), were used as reference drugs. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, most of the tested compounds exhibited modest to high cytotoxic activities with IC<sub>50</sub> values in the low nanomolar to low micromolar range. First, we analyzed the impact of linkers on the activities. Changing the linker from phenolic ether (e.g., <b>10f</b>) or phenylamine (e.g., <b>20a</b>, <b>20b</b>) to an amide (<b>15a–h</b>) led to increased activity (e.g., average IC<sub>50</sub> values of 1.50 μM 1.56 μM, and 75.5 nM for <b>10f</b>, <b>20a</b>, <b>15c</b>, respectively). Interestingly, the chain length of the linker had a negative influence on the antiproliferative activity (<b>15c</b> vs <b>15d, 15e, 15f</b>), and the best antiproliferative activity was achieved for compounds with three carbons, for example, compound <b>15c</b> (average IC<sub>50</sub> = 75.5 nM), which was more potent than the two positive controls (SMART and MS-275 average IC<sub>50</sub> = 317 nM, 1.59 μM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiproliferative Activity of Target Compounds against Four Cancer Cell Lines (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0021.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0022.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent assays, presented as mean ± standard deviation (SD).</p></div></div><div></div></div><div class="NLM_p">We also synthesized several new analogues bearing an alkene or alkyne linker (e.g., <b>15h</b>, <b>17h</b>, <b>30a</b>, and <b>32a</b>), as alkenes are widely used as the linker in HDAC-based multitargeting agents. The derivatives with an alkene linker (<b>15h</b>, <b>17h</b>, <b>30a</b>, and <b>32a</b>) exhibited modest antiproliferative activities (average IC<sub>50</sub> ranging from 0.94 to 5.68 μM). In particular, compounds <b>30a</b> and <b>32a</b> with an alkene linker displayed more potent activity (average IC<sub>50</sub> = 0.94, 2.96 μM) than the corresponding alkyne linker-bearing compound <b>25a</b> (average IC<sub>50</sub> = 5.67 μM). In addition, the impact of rigidity of linkers was studied, and no improvement of the antiproliferative activity was observed for compounds (e.g., <b>15h, 15i, 17h, 17i</b>) with a rigid linker (e.g., phenyl ring, thiophene).</div><div class="NLM_p">Next, we investigated the effects of ZBG on the activity. In general, compounds containing the benzamide <i>N</i>-phenylamine ZBG showed better activity toward four cancer cell lines, and the potency decreased slightly when the ZBG was switched from the benzamide <i>N</i>-phenylamine group (e.g., Series <b>15</b>, average IC<sub>50</sub> = 1.36 μM) to the hydroxamic acid moiety (e.g., Series <b>17</b> compounds, average IC<sub>50</sub> = 3.28 μM).</div><div class="NLM_p">Finally, most hybrid compounds (in particular, compound <b>15c</b>) displayed higher or comparable antiproliferative activity on all studied cell lines when compared to the single-target HDACi (MS-275) or a tubulin inhibitor (SMART).</div><div class="NLM_p last">In summary, the combination of the two pharmacophores (tubulin inhibitors and HDAC inhibitors) is beneficial for improving antiproliferative potency.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2.  Comparison of Antiproliferative Effects between Dual-Acting HDAC/Tubulin Inhibitors and Combination of Single-Target Agents</h3><div class="NLM_p">To confirm the beneficial effects of the dual-acting compounds, we evaluated the antiproliferative activities using four different regimens: SMART, MS-275, <b>15c</b>, and the combination of SMART + MS-275, against B16-F10 cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, MS-275 exhibited low activity with an IC<sub>50</sub> value of 2.38 μM, SMART displayed moderate activity with an IC<sub>50</sub> value of 910 nM, while the combination of SMART and MS-275 (half the dose) demonstrated nearly equal potency with an IC<sub>50</sub> value of 1.15 μM. To our delight, the dual-acting compound <b>15c</b> was significantly more active than the combination of SMART and MS-275 with an IC<sub>50</sub> value of 73 nM. These results suggest that the hybrid compound <b>15c</b> may achieve synergetic effects by targeting HDAC and tubulin simultaneously and, thus, may be advantageous over the cocktail therapy (SMART and MS-275) in terms of pharmacokinetics and pharmacodynamics as aforementioned.</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of SMART, MS-275, SMART + MS-275, and <b>15c</b> on the B16-F10 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.3.  Effects of HDAC/Tubulin Dual Inhibitors on HDAC Inhibitor-Resistant Gastric Cancer Cells</h3><div class="NLM_p">Previous studies indicate that HDAC inhibitors showed low activity against gastric cancer cell lines due to the overexpression of multidrug-resistance proteins.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> To experimentally validate whether the newly synthesized HDAC/tubulin dual inhibitors possessed the ability to overcome resistance to HDAC inhibitors, we examined the antiproliferative activity of several compounds in an HDAC inhibitor-resistant cancer cell line (YCC3/7) and the corresponding sensitive cell line (YCC11), with MS-275 as a positive control. As presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, MS-275 was less active against YCC3/7 cells (IC<sub>50</sub> = 12.91 μM) compared to YCC11 (IC<sub>50</sub> = 5.56 μM). SMART showed moderate activity against both lines (IC<sub>50</sub> = 1.69 and 1.94 μM for YCC11 and YCC3/7), while compound <b>15c</b> retained high activities against both cell lines with IC<sub>50</sub> values of 0.30 and 0.56 μM for YCC11 and YCC3/7, respectively, and a resistance index (RI) of 1.9. Compound <b>15c</b> was 23-fold and 7-fold more active than MS-275 and SMART in the YCC3/7 cells, suggesting a clear and definite advantage of this dual-acting molecule. A similar trend was also observed in compounds <b>12c</b>, <b>15f</b>, and <b>32a</b>. Taken together, these results indicate that the dual-acting molecules could potentially overcome resistance to HDAC inhibitors and may offer therapeutic advantages over MS-275.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activity of Compounds against HDAC Inhibitor-Resistant Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">YCC11</th><th class="colsep0 rowsep0" align="center" char="±">YCC3/7</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MS-275</td><td class="colsep0 rowsep0" align="char" char="±">5.56 ± 1.21</td><td class="colsep0 rowsep0" align="char" char="±">12.91 ± 2.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMART</td><td class="colsep0 rowsep0" align="char" char="±">1.69 ± 0.61</td><td class="colsep0 rowsep0" align="char" char="±">1.94 ± 0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.92 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">1.28 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.30 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.56 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15f</b></td><td class="colsep0 rowsep0" align="char" char="±">3.68 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">5.31 ± 1.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="char" char="±">4.09 ± 1.11</td><td class="colsep0 rowsep0" align="char" char="±">6.14 ± 2.13</td></tr></tbody></table></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.4.  Inhibition of HDACs and HDAC-Isoform Selectivity</h3><div class="NLM_p">Having identified the high antiproliferative activities of the hybrid inhibitors, we next investigated the inhibitory activity of the newly synthesized compounds against several recombinant HDAC enzymes, including HDAC1, HDAC3, HDAC6, HDAC7, and HDAC8, at a concentration of 1 μM. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, compounds containing an <i>o</i>-phenylenediamine group (series <b>10</b>, <b>15</b>, <b>20, 25, 30</b>) exhibited potent and selective inhibition against HDAC3 (>70% at 1 μM) over other four HDAC isoforms, whereas the compound bearing the hydroxamic acid moiety (series <b>12</b>, <b>17</b>, <b>32a</b>) displayed an HDAC6 (>50% inhibition at 1 μM) preference over HDAC1/3/7/8. SMART and MS-275 were used as positive controls in this assay. As expected, the tubulin inhibitor SMART did not inhibit any HDAC isoforms at a tested concentration of 1 μM, while the HDAC inhibitor MS-275 was more potent on HDAC1/3 isoforms than other isoforms, which is consistent with previous reports.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a></div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition profiles of the newly synthesized compounds (1 μM) against HDAC isoforms 1, 3, 6, 7, and 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequently, we determined the IC<sub>50</sub> values of these compounds against different HDAC isoforms. As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, all <i>o</i>-phenylenediamine-bearing compounds demonstrated potent HDAC3 inhibition with IC<sub>50</sub> values in the nanomolar range (30–3960 nM) and relatively high selectivity indices (SI > 22). The structure–activity relationship (SAR) studies indicated that the conjugated compounds bearing a long linker (6-carbon, <b>15f</b>) or an aromatic ring (<b>15g</b>) or an olefin chain (<b>15h</b>) could interfere with the recognition by and binding of the CAP group to the binding pocket of the HDAC3 enzyme, finally leading to a weak inhibitory activity against HDAC3. Compounds bearing rigid linkers, such as an aromatic ring (<b>15g</b>) or an olefin chain (<b>15h</b>), could increase the inhibitory activity and selectivity against HDAC8 (anti-HDAC8 IC<sub>50</sub> = 2.08 and 0.80 μM for <b>15g</b> and <b>15h</b>). Notably, compared to the positive control MS-275, compound <b>15c</b> showed a dramatically improved potency against HDAC3 (IC<sub>50</sub> = 0.03 vs 0.83 μM) and excellent selectivity over the other HDAC isoforms with a >1000-fold selectivity over HDAC6/7 and a >300-fold selectivity over HDAC1/8. In addition, the hydroxamic acid-bearing molecules (series <b>12</b>, <b>17</b>, and <b>32</b>) showed significantly lowered activity against HDAC3 with a moderate selectivity for HDAC6 (SI: 21–40). Taken together, the results suggest that these compounds, in particular compound <b>15c</b> with high antiproliferative and selective HDAC3 activity, deserve further investigation.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Inhibition of Recombinant HDACs 1, 3, 6, 7, and 8 by the Newly Synthesized Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">IC<sub>50</sub> (μM) ± SD<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC3</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">HDAC7</th><th class="colsep0 rowsep0" align="center">HDAC8</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">7.49 ± 1.17</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.12</td><td class="colsep0 rowsep0" align="left">27.13 ± 7.11</td><td class="colsep0 rowsep0" align="left">47.51 ± 8.43</td><td class="colsep0 rowsep0" align="left">7.49 ± 1.17</td><td class="colsep0 rowsep0" align="char" char=".">101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">6.27 ± 0.94</td><td class="colsep0 rowsep0" align="left">9.56 ± 0.06</td><td class="colsep0 rowsep0" align="left">1.15 ± 0.12</td><td class="colsep0 rowsep0" align="left">43.22 ± 8.09</td><td class="colsep0 rowsep0" align="left">8.84 ± 1.25</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left">7.19 ± 1.03</td><td class="colsep0 rowsep0" align="left">12.60 ± 3.11</td><td class="colsep0 rowsep0" align="left">1.98 ± 0.39</td><td class="colsep0 rowsep0" align="left">40.05 ± 7.99</td><td class="colsep0 rowsep0" align="left">7.98 ± 1.31</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="left">6.86 ± 0.99</td><td class="colsep0 rowsep0" align="left">8.86 ± 1.13</td><td class="colsep0 rowsep0" align="left">2.07 ± 0.45</td><td class="colsep0 rowsep0" align="left">37.55 ± 6.52</td><td class="colsep0 rowsep0" align="left">7.10 ± 1.02</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">4.07 ± 0.86</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.27</td><td class="colsep0 rowsep0" align="left">21.06 ± 2.36</td><td class="colsep0 rowsep0" align="left">49.78 ± 9.14</td><td class="colsep0 rowsep0" align="left">12.02 ± 2.10</td><td class="colsep0 rowsep0" align="char" char=".">139</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15c</b></td><td class="colsep0 rowsep0" align="left">9.04 ± 1.49</td><td class="colsep0 rowsep0" align="left">0.03 ± 0.01</td><td class="colsep0 rowsep0" align="left">31.04 ± 6.44</td><td class="colsep0 rowsep0" align="left">42.71 ± 9.52</td><td class="colsep0 rowsep0" align="left">11.62 ± 3.23</td><td class="colsep0 rowsep0" align="char" char=".">1423</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="left">8.12 ± 1.26</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.05</td><td class="colsep0 rowsep0" align="left">36.37 ± 7.18</td><td class="colsep0 rowsep0" align="left">58.28 ± 7.60</td><td class="colsep0 rowsep0" align="left">8.74 ± 2.21</td><td class="colsep0 rowsep0" align="char" char=".">323</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15e</b></td><td class="colsep0 rowsep0" align="left">8.53 ± 1.75</td><td class="colsep0 rowsep0" align="left">0.39 ± 0.11</td><td class="colsep0 rowsep0" align="left">27.25 ± 7.91</td><td class="colsep0 rowsep0" align="left">45.26 ± 10.07</td><td class="colsep0 rowsep0" align="left">8.50 ± 2.17</td><td class="colsep0 rowsep0" align="char" char=".">116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15f</b></td><td class="colsep0 rowsep0" align="left">9.88 ± 1.91</td><td class="colsep0 rowsep0" align="left">1.73 ± 0.50</td><td class="colsep0 rowsep0" align="left">29.15 ± 6.90</td><td class="colsep0 rowsep0" align="left">44.11 ± 8.70</td><td class="colsep0 rowsep0" align="left">10.16 ± 2.97</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15g</b></td><td class="colsep0 rowsep0" align="left">10.53 ± 2.05</td><td class="colsep0 rowsep0" align="left">3.46 ± 0.71</td><td class="colsep0 rowsep0" align="left">36.26 ± 10.06</td><td class="colsep0 rowsep0" align="left">46.20 ± 9.73</td><td class="colsep0 rowsep0" align="left">2.08 ± 0.67</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15h</b></td><td class="colsep0 rowsep0" align="left">14.39 ± 3.07</td><td class="colsep0 rowsep0" align="left">3.96 ± 0.85</td><td class="colsep0 rowsep0" align="left">30.22 ± 9.36</td><td class="colsep0 rowsep0" align="left">43.01 ± 9.05</td><td class="colsep0 rowsep0" align="left">0.80 ± 0.12</td><td class="colsep0 rowsep0" align="char" char=".">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="left">7.36 ± 1.41</td><td class="colsep0 rowsep0" align="left">12.33 ± 2.11</td><td class="colsep0 rowsep0" align="left">1.86 ± 0.23</td><td class="colsep0 rowsep0" align="left">46.66 ± 9.04</td><td class="colsep0 rowsep0" align="left">5.14 ± 1.02</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="left">10.12 ± 2.21</td><td class="colsep0 rowsep0" align="left">13.62 ± 2.53</td><td class="colsep0 rowsep0" align="left">1.73 ± 0.16</td><td class="colsep0 rowsep0" align="left">37.15 ± 6.83</td><td class="colsep0 rowsep0" align="left">6.32 ± 1.63</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17d</b></td><td class="colsep0 rowsep0" align="left">16.61 ± 3.53</td><td class="colsep0 rowsep0" align="left">13.07 ± 2.37</td><td class="colsep0 rowsep0" align="left">2.55 ± 0.23</td><td class="colsep0 rowsep0" align="left">35.70 ± 6.05</td><td class="colsep0 rowsep0" align="left">3.28 ± 0.91</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17e</b></td><td class="colsep0 rowsep0" align="left">19.10 ± 5.42</td><td class="colsep0 rowsep0" align="left">12.24 ± 2.03</td><td class="colsep0 rowsep0" align="left">1.94 ± 0.22</td><td class="colsep0 rowsep0" align="left">32.31 ± 5.89</td><td class="colsep0 rowsep0" align="left">4.17 ± 1.28</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17h</b></td><td class="colsep0 rowsep0" align="left">17.46 ± 4.50</td><td class="colsep0 rowsep0" align="left">12.97 ± 2.78</td><td class="colsep0 rowsep0" align="left">1.05 ± 0.13</td><td class="colsep0 rowsep0" align="left">28.27 ± 5.52</td><td class="colsep0 rowsep0" align="left">3.90 ± 1.04</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">9.80 ± 1.42</td><td class="colsep0 rowsep0" align="left">1.76 ± 0.79</td><td class="colsep0 rowsep0" align="left">27.07 ± 6.88</td><td class="colsep0 rowsep0" align="left">41.60 ± 10.27</td><td class="colsep0 rowsep0" align="left">9.11 ± 2.20</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left">10.71 ± 2.24</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.10</td><td class="colsep0 rowsep0" align="left">23.78 ± 5.39</td><td class="colsep0 rowsep0" align="left">38.67 ± 9.56</td><td class="colsep0 rowsep0" align="left">8.28 ± 1.79</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">9.77 ± 1.71</td><td class="colsep0 rowsep0" align="left">1.98 ± 0.83</td><td class="colsep0 rowsep0" align="left">20.23 ± 4.86</td><td class="colsep0 rowsep0" align="left">30.61 ± 8.56</td><td class="colsep0 rowsep0" align="left">6.55 ± 1.08</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="left">11.04 ± 3.07</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.05</td><td class="colsep0 rowsep0" align="left">22.53 ± 3.45</td><td class="colsep0 rowsep0" align="left">47.46 ± 7.53</td><td class="colsep0 rowsep0" align="left">3.11 ± 0.75</td><td class="colsep0 rowsep0" align="char" char=".">280</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">8.49 ± 1.19</td><td class="colsep0 rowsep0" align="left">19.12 ± 4.79</td><td class="colsep0 rowsep0" align="left">1.59 ± 0.10</td><td class="colsep0 rowsep0" align="left">63.21 ± 9.80</td><td class="colsep0 rowsep0" align="left">2.71 ± 0.25</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMART</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MS-275</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.83 ± 0.17</td><td class="colsep0 rowsep0" align="left">9.32 ± 1.73</td><td class="colsep0 rowsep0" align="left">39.56 ± 7.25</td><td class="colsep0 rowsep0" align="left">17.84 ± 4.58</td><td class="colsep0 rowsep0" align="char" char=".">209</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent assays, presented as mean ± SD.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">SI = maximum value/minimum value.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">NA = not active.</p></div></div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.5.  <i>In Vitro</i> Tubulin Polymerization Assay</h3><div class="NLM_p">To confirm whether the newly synthesized dual-acting compounds could inhibit tubulin polymerization as that of SMART,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> we evaluated the inhibitory effects of selected compounds on tubulin polymerization with the two known tubulin inhibitors, colchicine and SMART, as positive controls. These compounds (<b>10f</b>, <b>12c</b>, <b>15a</b>, <b>15c, 15d</b>, <b>15e</b>, <b>15h</b>, <b>20b</b>, <b>30a</b>, <b>32a</b>) were chosen based on their balanced HDAC-inhibitory activity, HDAC3 selectivity, and antiproliferative potency. At a concentration of 10 μM, all of the compounds inhibited tubulin polymerization to some extent with the inhibition rate ranging from 18 to 70% (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B, inhibition rate = 18, 39, 65, 70, 28, 24, 67, 19, 30, 47% for <b>10f</b>, <b>12c</b>, <b>15a</b>, <b>15c, 15d</b>, <b>15e</b>, <b>15h</b>, <b>20b</b>, <b>30a</b>, <b>32a</b>, respectively, after 20 min treatment), as compared to the vehicle control. Among them, compound <b>15c</b> showed the highest tubulin-inhibitory activity with an inhibition rate of 70%, which is comparable to that of colchicine (59%) and SMART (78%). Next, we further assessed the tubulin-inhibitory activity of compound <b>15c</b> and SMART at various concentrations (0, 0.8, 1.5, 3, 6, 12.5, 25 μM). <b>15c</b> potently inhibited tubulin polymerization with an IC<sub>50</sub> value of 12.2 μM, similar to that of SMART (IC<sub>50</sub> = 7.9 μM, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Moreover, compound <b>15c</b> inhibited tubulin polymerization in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E,F), which correlated well with its antiproliferative effects.</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of tubulin polymerization <i>in vitro</i>. (A, B) Tubulin was exposed to 10 μM of selected compounds: vehicle control (5% dimethyl sulfoxide (DMSO)), colchicine, SMART, <b>10f</b>, <b>12c</b>, <b>15a</b>, <b>15c</b>,<b>15d</b>, <b>15e</b>, <b>15h</b>, <b>20b</b>, <b>30a</b>, and <b>32a</b>. (C) Inhibition of tubulin polymerization by SMART. (D) Inhibition of tubulin polymerization by compound <b>15c</b>. (E) SMART exhibited a dose-dependent inhibition of tubulin polymerization. (F) Compound <b>15c</b> exhibited a dose-dependent inhibition of tubulin polymerization..</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.6.  Antimicrotubule Effects in B16-F10 Cells</h3><div class="NLM_p">Microtubule dynamics play an important role in cell growth, especially in the proliferation of cancer cells.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> To further confirm whether the dual-acting molecules maintain the mechanisms of action as tubulin polymerization inhibitors, <b>15c</b> was investigated for its <i>in vitro</i> microtubule polymerization activity in B16-F10 cells by immunofluorescence staining assay and SMART was employed as the positive control. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, the microtubule network of cells in the control group (DMSO, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) demonstrated normal organizations and arrangements with the hair-like microtubule network of the slim/fibrous microtubules (green) wrapping around the nucleus (blue) of cells. In contrast, when the cells were treated with SMART (100 nM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) and <b>15c</b> (100 nM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) for 6 h, the microtubule network was disrupted effectively. These results implied that compound <b>15c</b> could destabilize microtubules by inhibiting tubulin polymerization and disturbing microtubule networks, similar to SMART.</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of SMART and compound <b>15c</b> on microtubules. B16-F10 cells were treated with vehicle control 0.1% DMSO (A), compound SMART (100 nM) (B), and compound <b>15c</b> (100 nM) (C) for 6 h. Microtubules were visualized with an anti-β-tubulin antibody (green), and the cell nucleus was visualized with DAPI (blue). Fluorescence images were collected using an LSM 880 laser confocal microscope (Carl Zeiss, Germany).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.7.  Inhibition of Cancer Cell Migration and Colony Formation</h3><div class="NLM_p">Cancer cells are able to migrate to distant organs, leading to the formation of metastasized tumors.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Our previous studies and other research groups have shown that microtubules play an important role in cell migration and motility and that SMART could inhibit cancer cell migration efficiently.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Therefore, we performed a wound-healing assay to confirm the effects of compound <b>15c</b> on cell migration in comparison with SMART. B16-F10 cells were treated with 0, 25, 50, and 100 nM compound <b>15c</b> and SMART (100 nM) for 24 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, the cells in the control group were able to migrate into the wound channel, recovering 53.27 ± 3.18% of the area. When treated with 25, 50, and 100 nM of compound <b>15c</b> and SMART (100 nM), the ratio of the wound area was 27.32 ± 3.56, 17.63 ± 2.79, 7.18 ± 1.01, and 16.24 ± 2.93%, respectively. The results revealed that compound <b>15c</b> displayed a better inhibitory effect on cancer cell migration than SMART. Furthermore, the wound closure was potently suppressed by <b>15c</b> in a dose-dependent manner, as compared to the control (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). In the colony formation assay using B16-F10 cells, compound <b>15c</b> was able to suppress the formation of colonies in a dose-dependent manner, with the colony-forming ability of B16-F10 cells being totally suppressed after 24 h treatment with 100 nM of compound <b>15c</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). In addition, the suppressing effects of compound <b>15c</b> were stronger than that of SMART (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C).</div><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects on the B16-F10 cells migration and colony formation. (A) Representative images of the wound area in a wound-healing assay. Images were obtained at 0 h and 24 h after treatment with compound <b>15c</b> with 0, 25, 50, and 100 nM and SMART (100 nM). (B) Histograms display the length of the scratches at 0 h and 24 h after treatments with compound <b>15c</b> with 0, 25, 50, and 100 nM and SMART (100 nM) (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control). (C) Histograms display the number of colonies at different concentrations after treatments with compound <b>15c</b> (0, 25, 50, 100 nM) and SMART (0, 25, 50, 100 nM) (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control). (D) Number of colonies was counted after treating B16-F10 cells with the indicated concentrations of compound <b>15c</b> and SMART for 24 h (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.8.  Effect of Compound <b>15c</b> on the Cell Cycle and Apoptosis</h3><div class="NLM_p">Tubulin polymerization inhibitors and HDAC inhibitors have been previously reported to disrupt cell mitosis and induce cell cycle arrest.<a onclick="showRef(event, 'ref65 ref70 ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref65 ref70 ref71 ref72 ref73 ref74">(65,70−74)</a> To probe the effects of compound <b>15c</b> on the cell cycle, a flow cytometry analysis was performed (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). B16-F10 cells were treated with vehicle, compound <b>15c</b>, or reference compounds (MS-275 and SMART). As compared to the vehicle (ratio of the G2/M phase is 5.76%), treatment of MS-275 and SMART at 100 nM for 48 h led to an increase of the G2/M phase of the cell cycle to 42.17 and 76.58%, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), which is in line with the previous reports.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The percentages of the G2/M phase cell cycle arrested by compound <b>15c</b> at concentrations of 25, 50, and 100 nM were 15.98, 66.32, and 83.26%, respectively. At a concentration of 100 nM, compound <b>15c</b> significantly induced cell cycle arrest in the G2/M phase with the effects being more prominent than that of SMART and MS-275, indicating that hybridization of the pharmacophores of HDAC inhibitors and tubulin inhibitors to a single molecule could efficiently increase the percentage of cell cycle arrest at the G2/M phase (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0009.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell cycle arrest and apoptosis induced by MS-275, SMART, and <b>15c</b>. (A) MS-275, SMART, and <b>15c</b> induced G2/M arrest in B16-F10 cells. B16-F10 cells were incubated with MS-275 (100 nM), SMART (100 nM), or varying concentrations of <b>15c</b> (25, 50, and 100 nM) for 48 h. Cells treated with DMSO were used for comparison. (B) Histograms display the percentage of cell cycle distribution after treatment with <b>15c</b> and reference compounds. (C) Compound <b>15c</b> induced apoptosis in B16-F10 cells. B16-F10 cells were exposed to MS-275, SMART, and the increasing concentrations of compound <b>15c</b> (25, 50, and 100 nM) for 48 h. Cells treated with DMSO were used for comparison. The percentages of cells in each stage of cell apoptosis were quantified by flow cytometry: necrosis cells (upper left quadrant); late apoptotic cells (upper right quadrant); live cells (bottom left quadrant); and early apoptotic cells (bottom right quadrant). (D) Histograms displayed the percentage of cell cycle distribution after treatment with compound <b>15c</b> and reference compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Previous studies demonstrated that the inhibition of HDAC and/or tubulin activity could induce apoptosis of cancer cells.<a onclick="showRef(event, 'ref43 ref75'); return false;" href="javascript:void(0);" class="ref ref43 ref75">(43,75)</a> To investigate whether our compounds could cause cell death by inducing apoptosis, B16-F10 cells were treated with DMSO, MS-275, SMART, or various concentrations of compound <b>15c</b> for 48 h, stained with Annexin V-FITC and PI, and analyzed by flow cytometry. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C, compounds <b>15c</b> caused a dose-dependent induction of apoptosis in B16-F10 cells. The percentages of apoptotic cells for compound <b>15c</b> were 10.9, 39.3, and 67.1% at the concentrations of 25, 50, and 100 nM, respectively. Notably, at the same concentration of 100 nM, the apoptosis-inducing abilities of <b>15c</b> in B16-F10 (percentage of apoptotic cells: 67.1%, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D) cells were significantly higher than MS-275 and SMART (38.7 and 29.6%, respectively). These results suggest that the new HDAC/tubulin dual inhibitors could efficiently induce apoptosis of B16-F10 cells and achieve synergistic effects at cellular levels.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.9.  Western Blot Analysis of Acetyl-Histone 3 Levels in B16-F10 Cells</h3><div class="NLM_p">Western blot analysis was performed to confirm the intracellular effects of compound <b>15c</b> on HDAC3. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, similarly to MS-275, compound <b>15c</b> increased the intracellular levels of the HDAC3 substrate acetyl-histone H3 (Ac-H3) in a dose-dependent manner. It is worth noting that at a low concentration of 200 nM, the effect of <b>15c</b> on acetyl-histone H3 was comparable to that of MS-275 at a high concentration (1.0 μM). Furthermore, the results were in line with the enzyme inhibition results shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> that <b>15c</b> possessed superior HDAC3-inhibitory activity to MS-275.</div><figure id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0010.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) B16-F10 cells were treated with dimethyl sulfoxide (DMSO) or compound <b>15c</b> (20, 50, 100, and 200 nM) and MS-275 (1.0 μM) for 12 h. The levels of Ac-H3 and Histone 3 were determined by immunoblotting. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. Data are representative of three independent experiments. (B) ImageJ was used to quantify the Western blot data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">4.10.  Molecular Docking of <b>15c</b> in Tubulin and HDAC3</h3><div class="NLM_p">To investigate the binding interactions of compound <b>15c</b> with tubulin and HDAC3, molecular docking studies were performed. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A,B, compound <b>15c</b> binds well to HDAC3. The benzamide group of compound <b>15c</b> chelates Zn<sup>2+</sup> in a bidentate manner and forms a hydrogen bond with Leu-29, the aliphatic chains occupy the hydrophobic channel, and the TMP (3,4,5-trimethoxyphenyl) group of the CAP moiety forms additional hydrogen bonds with the Phe-199 residue at the entrance of the active site. The aliphatic linker is projected into the hydrophobic cavity of HDAC3. Moreover, the benzamide group of the ZBG section formed π–π stacking interaction with Tyr-107 of HDAC3.</div><figure id="fig10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0011.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding interactions between compound <b>15c</b> and target proteins (HDAC3 and Tubulin): (A) proposed binding mode of <b>15c</b> in the active site of HDAC3 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>); (B) 90° clockwise rotation of the dimeric HDAC3 in complex with <b>15c</b> along the x-axis. (C) Proposed binding mode of <b>15c</b> in the active site of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>); (D) 90° clockwise rotation of tubulin in complex with <b>15c</b> along the x-axis. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The binding mode of compound <b>15c</b> in the colchicine site of tubulin is displayed in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C,D. The benzamide ZBG moiety interacts with the terminal NH<sub>2</sub> group of Val-257 <i>via</i> a hydrogen bond. In addition, the linker extends out of the binding site and forms a hydrogen bond with Lys-352. The TMP (3,4,5-trimethoxyphenyl) group of the scaffold is engaged in a hydrogen-bonding network with Cys-241 and Val-238. The well-defined binding modes of <b>15c</b> in HDAC3 and tubulin may explain the high inhibitory activities against HDAC3 and tubulin.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.11.  <i>In Vivo</i> Antitumor Efficacy Studies</h3><div class="NLM_p">Having identified the high activity at both cellular and enzymatic/biochemical levels, we next evaluated the <i>in vivo</i> antitumor potency of compound <b>15c</b> in a B16-F10 tumor. C57BL/6 mice bearing melanoma tumors were divided into 5 groups and administered intraperitoneally for 14 consecutive days with the following regimen: vehicle control, SMART (10 mg/kg per day), MS-275 (10 mg/kg per day), combination (SMART + MS-275, 5 mg/kg + 5 mg/kg), and compound <b>15c</b> (10 mg/kg). Tumor growth inhibition (TGI) was calculated at the end of treatment. As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A, treatment with <b>15c</b>, SMART, MS-275, and combination therapy suppressed tumor growth with TGIs of 70, 25, 47, and 53%, respectively. No significant body weight loss or adverse effects was observed (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B) during treatment. Tumor weights in the combination therapy group were lower than those in the monotherapy groups (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C), indicating that combining SMART with MS-275 was favorable for antitumor efficacy. Notably, compound <b>15c</b> demonstrated the highest <i>in vivo</i> antitumor efficacy among the 5 groups with a TGI of 70%. Both the tumor weights (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C) and tumor volumes (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>D) were decreased significantly when compared to SMART or MS-275 monotherapy and combination therapy (SMART + MS-275). Taken together, these results highlighted the advantages of dual tubulin/HDAC3 inhibitors for cancer treatment.</div><figure id="fig11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0012.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> antitumor efficacy study. After administering vehicle, SMART (10 mg/kg per day), MS-275 (10 mg/kg per day), SMART + MS-275 (10 mg/kg per day), and compound 1<b>5c</b> (10 mg/kg per day) for 14 days, mice were sacrificed, and the tumors were weighed. (A) Images of tumor size at 14 days after treatment. (B) Body weight changes of mice during treatment. (C) Tumor weights for each group. **<i>P</i> < 0.05 vs control group. (D) Tumor volume changes for each group. Note: SM: SMART and MS: MS-275.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.12.  Effects on Acetyl-Histone 3 (Ac-H3) Expression Levels in Melanoma Tumor Tissues</h3><div class="NLM_p">After the <i>in vivo</i> study, immunohistochemistry was conducted to analyze the expression of the acetyl-histone 3 (Ac-H3) protein. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, treatment with <b>15c</b>, MS-275, or the combination of MS-375+SMART increased Ac-H3 expression obviously in tumor tissues with positive ratios of 36.7, 27.9, and 16.3%, respectively, whereas no significant change in the expression of Ac-H3 was observed for the control or SMART treatment group.</div><figure id="fig12" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0013.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Immunohistochemistry of Ac-H3 expressions in melanoma tumor tissues. Formalin-fixed paraffin-embedded sections from melanoma tumor tissues were stained with H&E stain. **<i>P</i> < 0.05 vs control group. ImageJ was used to quantify the Ac-H3 positive ratio.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.13.  <i>In Vivo</i> Safety Profiling of <b>15c</b></h3><div class="NLM_p">To assess the <i>in vivo</i> safety profiles of <b>15c</b>, we conducted pathohistological analysis utilizing H&E staining of major organ tissue sections (heart, liver, kidney) collected at the end of the <i>in vivo</i> study. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A, no apparent morphological abnormalities in the kidney and liver of different treatment groups were observed. However, there were morphological changes in the cardiac tissues from the MS-275 treatment group, implying the potential risk of heart damage caused by MS-275.</div><figure id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0014.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <i>In vivo</i> safety profiling. (A) Pathological sections of major tissues (heart, liver, kidney) were obtained from mice bearing melanoma tumors. Organs were stained with hematoxylin and eosin (H&E) and captured the representative images. (B) Evaluation of <i>in vivo</i> cardiotoxicity of <b>15c</b> by ECG and heart rate measurement in C57BL/6 mice. (C) Serum biochemistry analysis of indicators of kidney and liver function in mice of the above animal experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cardiotoxicity, such as arrhythmias, is the common side effect of several major classes of HDAC inhibitors.<a onclick="showRef(event, 'ref76 ref77 ref78 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref76 ref77 ref78 ref79 ref80">(76−80)</a> In clinical trials, electrocardiogram (ECG) abnormalities are often monitored to alert the occurrence of cardiovascular toxicity of drugs. Therefore, the <i>in vivo</i> cardiotoxicity of tested compounds in the above animal experiments was determined by ECG. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B, the HDAC inhibitor MS-275 induced QTc interval shortening and inversion of the S-T wave, indicating a potential cardiovascular risk such as myocardial ischemia. On the other hand, there was no significant difference in the ECG of control, SMART, combination, and <b>15c</b>-treated groups. Additionally, a normal heart rate was observed for <b>15c</b>. Collectively, these results suggest that the tubulin/HDAC3 dual-targeting compound <b>15c</b> has a safe cardiotoxicity profile.</div><div class="NLM_p last">To further investigate the safety profiles of compound <b>15c</b>, we conducted serum biochemistry analysis. As displayed in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C, compound <b>15c</b> had no obvious nephrotoxicity and hepatotoxicity in tested mice compared to the control group, as assessed by the indicators of liver function (e.g., alanine aminotransferase-ALT, albumin-ALB, aspartate aminotransferase-AST, aspartate aminotransferase-AST, alanine aminotransferase-ALT, total bilirubin-TBIL, albumin/globulin-A/G) and kidney function (e.g., globulin-GLO, creatinine-CRE, UREA).</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">5.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this work, we designed, synthesized, and bioevaluated for the first time a series of dual HDAC3/tubulin inhibitors by combining the pharmacophores of the tubulin inhibitor SMART and the HDAC inhibitor MS-275. Among the newly synthesized molecules, compound <b>15c</b> was identified to be the most potent and balanced HDAC3/tubulin dual inhibitor with high HDAC3 activity (IC<sub>50</sub> = 30 nM, biochemical assay) and selectivity (SI of HDAC3 > 1000) as well as potent antiproliferative activity against various cancer cell lines, including colon cancer, melanoma, leukemia, and nonsmall cell lung cancer (IC<sub>50</sub> values in the range of 30–140 nM, MTT assay). Notably, <b>15c</b> was nearly equally potent against the HDAC inhibitor-resistant cancer cell line (YCC3/7) and the corresponding sensitive cell line (YCC11). In addition, <b>15c</b> was able to inhibit B16-F10 cancer cell migration and colony formation. It also induced apoptosis in B16-F10 cells with a significant G2/M cell cycle arrest. Compound <b>15c</b> acted by inhibiting tubulin polymerization <i>in vitro</i> and increasing the level of acetyl-H3 protein in a dose-dependent manner. Importantly, the therapeutic potential of compound <b>15c</b> was validated in an <i>in vivo</i> B16-F10 tumor model in which it exhibited a TGI of 70.0%, which was much more efficacious than that of MS-275 and SMART and even more effective than the combination of MS-275 and SMART. Finally, <b>15c</b> demonstrated a safe cardiotoxicity profile and did not cause nephro- and hepatotoxicity. Although several groups have reported the discovery of novel and potent HDAC/tubulin dual inhibitors as anticancer agents in recent years,<a onclick="showRef(event, 'ref30 ref49 ref50 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref30 ref49 ref50 ref51 ref52 ref53 ref54">(30,49−54)</a> the low or lack of HDAC-isoform selectivity may have hindered their further development. The dual HDAC3/tubulin inhibitors described in this work demonstrated not only high antitumor efficacy but also excellent HDAC3 selectivity (SI > 1000), which can offer advantages over reported HDAC/tubulin dual inhibitors. Taken together, the above analysis suggests that the novel dual HDAC3/tubulin inhibitors would be promising for further development as potential anticancer agents.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">6.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">6.1.  General Methods</h3><div class="NLM_p last">Solvents and reagents were purchased from commercial sources and used without further purification. The reference compound MS-275 was obtained from InvivoChem (Libertyville, IL 60048). All of the reactions were monitored by thin-layer chromatography (TLC) using silica gel GF/UV 254. Column chromatography was carried out using commercially available silica gel (200–300 mesh) under pressure. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on Bruker AV-400 spectrometer, with TMS as an internal standard. High-resolution mass spectrometry (HRMS) was obtained on a Micromass Q-TOF mass spectrometer. The purity of the tested compounds was ≥95%, as estimated by HPLC (SHIMADZU LC-20A, UV detection at 254 nm) analysis on the C18 column (4.6 mm × 150 mm, 5 μm). HPLC conditions: injection volume: 10 μL, flow rate, 1 mL/min with a mobile phase of H<sub>2</sub>O/MeOH; H<sub>2</sub>O/MeOH = 55/45 was initially held for 3 min, followed by a linear gradient from 55/45 to 5/95 = H<sub>2</sub>O/MeOH over 15 min, which was then held for 12 min.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">6.2.  General Procedure for the Preparation of Dual-Target Compounds</h3><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">6.2.1.  Synthesis of SMART</h4><div id="sec6_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34">6.2.1.1.  General Procedure for Intermediate <b>2</b></h5><div class="NLM_p last">To a stirred solution of 3,4,5-trimethoxyaniline <b>1</b> (2.05 g, 11.20 mmol) in THF (20 mL) was added 4 M aqueous HCl (28.00 mL), and the solution was cooled in an ice water bath. A solution of NaNO<sub>2</sub> (926.42 mg, 13.43 mmol) in H<sub>2</sub>O (10.00 mL) was added dropwise. After 20 min, a solution of KI (4.64 g, 28.00 mmol) in H<sub>2</sub>O (10 mL) was added and stirred for 10 min in the ice water bath. Then, the solution was slowly warmed up to room temperature and stirred for 1 h before 1 M aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> was added until the color of the mixture did not change. The phases were separated, and the aqueous phase was extracted with EtOAc (25 mL × 3). The combined organic layers were washed with H<sub>2</sub>O (5 mL × 2) and brine (5 mL × 1), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by column chromatography on silica gel (PE/EtOAc = 40/1-20/1) to provide intermediate <b>2</b> (3.02 g, 92% yield) as a yellow liquid.</div></div><div id="sec6_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35">6.2.1.2.  General Procedure for Intermediate <b>3</b></h5><div class="NLM_p last">To a stirred solution of intermediate <b>2</b> (3.02 g, 10.27 mmol) in DMF (20.00 mL), triethylamine (3.12 g, 30.81 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (360.39 mg, 0.51 mmol), and CuI (195.57 mg, 1.03 mmol) were added to intermediate <b>2</b> solution under a nitrogen atmosphere protect. Finally, a solution of the propargyne (0.49 g, 12.32 mmol) in DMF (4 mL/mmol) was added to the mixture and stirred at 90 °C for 16 h. After cooling, ethyl acetate was added to the crude mixture and filtered with Celite. Then, the solvent was removed <i>in vacuo</i>, and the residue was diluted with H<sub>2</sub>O and extracted with EtOAc (3 × 20 mL). The combined organic layer was then washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i> to provide the crude product, which was directly subjected to silica gel column chromatography and eluted with petroleum PE/EtOAc (25/1, v/v) to give intermediate <b>3</b> as a white power (1.56 g, 74%).</div></div><div id="sec6_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">6.2.1.3.  General Procedure for Intermediate <b>4</b></h5><div class="NLM_p last">To a stirred solution of intermediate <b>3</b> (1.56 g, 7.56 mmol) in dichloromethane (12.00 mL) was added oxidant PhI(OAc)<sub>2</sub> (7.31 g, 22.69 mmol) and catalyst RuCl<sub>3</sub> (156.89 mg, 0.76 mmol) in an ice water bath. Then, water (3.00 mL, dichloromethane: H<sub>2</sub>O = 4:1, v/v) was added. The reaction will be very violent; pay attention to slow down the stirring speed. The solution was slowly warmed up to room temperature and stirred for 2 h. After cooling, dichloromethane was added to the crude mixture and extracted with dichloromethane (3 × 20 mL). The combined organic layer was then washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i> to provide the crude product, which was directly subjected to silica gel column chromatography and eluted with petroleum PE/EtOAc (30/1, v/v) to give intermediate <b>4</b> as a yellow solid (1.15 g, 64%).</div></div><div id="sec6_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">6.2.1.4.  General Procedure for Intermediate <b>5</b></h5><div class="NLM_p last">To a suspension of CuBr<sub>2</sub> (3.23 g, 14.48 mmol) in 30 mL of ethyl acetate was added intermediate <b>4</b> (1.15 g, 4.83 mmol) in 15 mL of chloroform and refluxed overnight. Afterward, the reaction contents were filtered through a silica plug and the filtrate evaporated in a rotary evaporator carefully with contents warmed at room temperature, yielding intermediate <b>5</b> as a clear yellow oil (1.51 g, 98%). The product was sufficiently pure for the following steps.</div></div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">6.3.  General Procedure for SMART</h3><div class="NLM_p last">Intermediate <b>5</b> (1.51 g, 4.73 mmol) was added to a solution of substituted-thiobenzamide <b>6</b> (synthesis from benzamide and Lawesson’s reagent) (5.68 mmol) in ethanol at ambient temperature. The solution was refluxed for 8 h. After confirming that the reaction was complete using TLC analysis, the solution was cooled to room temperature. The solvent was removed under reduced pressure, and the residue was extracted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by silica gel column chromatography to yield the target key intermediate <b>SMART 7a/7b/7c</b> (1.57 g, 89%).</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">6.4.  Synthesis of Dual-Target Compounds <b>10a–i</b> and <b>12a–h</b></h3><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">6.4.1.  General Procedure for Intermediate <b>8</b></h4><div class="NLM_p last">To a solution of intermediate <b>7a</b> (1.00 g, 2.69 mmol) in 10 mL of DMF was added K<sub>2</sub>CO<sub>3</sub> (930.28 mg, 6.73 mmol) at 80 °C. The mixture was stirred at 80 °C for 0.5 h, then the halo-substituted esters (2.96 mmol) were added dropwise to the mixture and stirred for 3 h at 80 °C. After confirming that the reaction was complete using TLC analysis, the solution was cooled to room temperature. The solvent was diluted with H<sub>2</sub>O, and 1 M hydrochloric acid solution, pH = 7, was added until the precipitation occurs. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>8</b> (73% yield).</div></div><div id="sec6_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41">6.4.2.  General Procedure for Intermediate <b>9</b></h4><div class="NLM_p last">To a solution of intermediate <b>8</b> (1.0 mmol, 1.0 equiv) in 30 mL of MeOH was added LiOH solution (2.5 mmol, 2.5 equiv, dissolved in 10 mL of H<sub>2</sub>O) in an ice-bath. The mixture was stirred at room temperature for 2 h until the reaction was complete. The solvent was removed <i>in vacuo</i>, the residue was diluted with H<sub>2</sub>O, and 4 M hydrochloric acid solution, pH = 2, was added. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>9</b> (100% yield).</div></div><div id="sec6_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42">6.4.3.  General Procedure for Target Compounds <b>10a–i</b></h4><div class="NLM_p last">To a solution of <b>9</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, the <i>o</i>-phenylenediamine (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to obtain compound <b>10a–i</b> as a yellow solid (93% yield).</div></div><div id="sec6_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43">6.4.4.  General Procedure for Intermediate <b>11</b></h4><div class="NLM_p last">To a solution of <b>9</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl) hydroxylamine (NH<sub>2</sub>OTHP) (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to obtain intermediate <b>11</b> as a white solid (88% yield).</div></div><div id="sec6_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">6.4.5.  General Procedure for Target Compounds <b>12a–h</b></h4><div class="NLM_p last">The THP-protected intermediate <b>11</b> was dissolved in 4 M HCl in 1,4-dioxane (0.1 mmol/mL dioxane) and left to stir for 4 h. The reaction was monitored by TLC, which indicated a complete conversion. The solution was dried <i>in vacuo</i>, and the crude mixture was purified by chromatography on a silica gel column with dichloromethane/MeOH (40:1) as the eluent to give a white solid (96% yield).</div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">6.5.  Synthesis of Dual-Target Compounds <b>15a–i</b> and <b>17a–i</b></h3><div id="sec6_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">6.5.1.  General Procedure for Intermediate <b>13</b></h4><div class="NLM_p last">To a solution of compound <b>7b</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, carboxylate derivatives were added (1.1 mmol, 1.1 equiv). After stirring for 4 h at room temperature and monitored by TLC, which indicated a complete conversion, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to afford intermediate <b>13</b> as a yellow solid (95% yield).</div></div><div id="sec6_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47">6.5.2.  General Procedure for Intermediate <b>14</b></h4><div class="NLM_p last">To a solution of intermediate <b>13</b> (1.0 mmol, 1.0 equiv) in 30 mL of MeOH was added LiOH solution (2.5 mmol, 2.5 equiv, dissolved in 10 mL of H<sub>2</sub>O) in an ice-bath. The mixture was stirred at room temperature for 2 h until the reaction was complete. The solvent was removed <i>in vacuo</i>, the residue was diluted with H<sub>2</sub>O, and 4 M hydrochloric acid solution, pH = 2, was added. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>14</b> as a white solid (100% yield).</div></div><div id="sec6_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48">6.5.3.  General Procedure for Target Compounds <b>15a–i</b></h4><div class="NLM_p last">To a solution of <b>14</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, <i>o</i>-phenylenediamine (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>15a–i</b> as a yellow solid (91% yield).</div></div><div id="sec6_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49">6.5.4.  General Procedure for Intermediate <b>16</b></h4><div class="NLM_p last">To a solution of <b>14</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl) hydroxylamine (NH<sub>2</sub>OTHP) (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to obtain intermediate <b>16</b> as a white solid (85% yield).</div></div><div id="sec6_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">6.5.5.  General Procedure for Target Compounds <b>17a–i</b></h4><div class="NLM_p last">The THP-protected intermediate <b>16</b> was dissolved in 4 M HCl in 1,4-dioxane (0.1 mmol/mL dioxane) and left to stir for 4 h. The reaction was monitored by TLC, which indicated a complete conversion. The solution was dried <i>in vacuo</i>, and the crude mixture was purified by chromatography on a silica gel column with dichloromethane/MeOH (40:1) as the eluent to give a white solid (97% yield).</div></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">6.6.  Synthesis of Dual-Target Compounds <b>20a–c</b> and <b>22a–c</b></h3><div id="sec6_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">6.6.1.  General Procedure for Intermediate <b>18</b></h4><div class="NLM_p last">A suspension of <b>7b</b> (1.0 mmol, 1.0 equiv), halo-substituted esters (1.2 mmol, 1.2 equiv), potassium iodide (1.5 mmol, 1.5 equiv), and anhydrous potassium carbonate (2.5 mmol, 2.5 equiv) in 20 mL of acetonitrile was refluxed under nitrogen for 15 h. The mixture was cooled and filtered, and the filtrate was dissolved in dichloromethane and extracted with aqueous sodium bicarbonate solution and then with water. The solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered. After the concentration <i>in vacuo</i>, the crude residue was purified by silica gel column chromatography using the solvent system 15% ethyl acetate in hexane as an eluent to give intermediate <b>18</b> (59% yield) as a light yellowish crystal.</div></div><div id="sec6_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">6.6.2.  General Procedure for Intermediate <b>19</b></h4><div class="NLM_p last">To a solution of compound <b>18</b> (1.0 mmol, 1.0 equiv) in 30 mL of MeOH was added LiOH solution (2.5 mmol, 2.5 equiv, dissolved in 10 mL of H<sub>2</sub>O) in an ice-bath. The mixture was stirred at room temperature for 2 h until the reaction was complete. The solvent was removed <i>in vacuo</i>, the residue was diluted with H<sub>2</sub>O, and 4 M hydrochloric acid solution, pH = 2, was added. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>19</b> as a yellow solid (100% yield).</div></div><div id="sec6_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54">6.6.3.  General Procedure for Target Compounds <b>20a–c</b></h4><div class="NLM_p last">To a solution of <b>19</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, <i>o</i>-phenylenediamine (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>20a–c</b> as a yellow solid (93% yield).</div></div><div id="sec6_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55">6.6.4.  General Procedure for Intermediate <b>21</b></h4><div class="NLM_p last">To a solution of <b>19</b> (1.0 mmol, 1.0 equiv) in DMF (15 mL) were added triethylamine (2.5 mmol, 2.5 equiv), HOBt (1.2 mmol, 1.2 equiv), and EDCI (1.2 mmol, 1.2 equiv) and stirred for 10 min. Then, <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl) hydroxylamine (NH<sub>2</sub>OTHP) (1.1 mmol, 1.1 equiv) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to obtain intermediate <b>21</b> as a white solid (87% yield).</div></div><div id="sec6_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56">6.6.5.  General Procedure for Target Compounds <b>22a–c</b></h4><div class="NLM_p last">The THP-protected intermediate <b>21</b> was dissolved in 4 M HCl in 1,4-dioxane (0.1 mmol/mL dioxane) and left to stir for 4 h. The reaction was monitored by TLC, which indicated a complete conversion. The solution was dried <i>in vacuo</i>, and the crude mixture was purified by chromatography on a silica gel column with dichloromethane/MeOH (40:1) as the eluent to give a white solid (91% yield).</div></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">6.7.  Synthesis of Dual-Target Compounds <b>25a</b> and <b>27a</b></h3><div id="sec6_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58">6.7.1.  General Procedure for Intermediate <b>23</b></h4><div class="NLM_p last">To a solution of bromo-substituted <b>SMART 7c</b> (1.00 g, 2.30 mmol) in DMF (10.00 mL), methyl 4-pentynoate (309.81 mg, 2.76 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (80.81 mg, 0.12 mmol), and Et<sub>3</sub>N (582.50 mg, 5.76 mmol) were added under N<sub>2</sub>. The reaction mixture was degassed and stirred under a N<sub>2</sub> atmosphere for 20 min before the addition of CuI (43.85 mg, 0.23 mmol). The reaction mixture was then stirred at 90 °C for 12 h before it was diluted with diethyl ether (10 mL). The content was poured into a separate funnel and washed with 0.1 M HCl (10 mL), H<sub>2</sub>O (10 mL), and brine (10 mL), respectively. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was purified by column chromatography (PE/EtOAc = 20:1) on silica gel to provide a yellow solid intermediate <b>23</b> (762.30 mg, 71% yield).</div></div><div id="sec6_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59">6.7.2.  General Procedure for Intermediate <b>24</b></h4><div class="NLM_p last">To a solution of compound <b>23</b> (762.30 mg, 1.64 mmol) in 30 mL of MeOH was added LiOH solution (98.02 mg, 4.09 mmol, dissolved in 3 mL of H<sub>2</sub>O) in an ice-bath. The mixture was stirred at room temperature for 2 h until the reaction was complete. The solvent was removed <i>in vacuo</i>, the residue was diluted with H<sub>2</sub>O, and 4 M hydrochloric acid solution, pH = 2, was added. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>24</b> as a yellow solid (739.04 mg, 100% yield).</div></div><div id="sec6_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60">6.7.3.  General Procedure for Target Compounds <b>25a</b></h4><div class="NLM_p last">To a solution of <b>24</b> (739.04 mg, 1.64 mmol) in DMF (10 mL) were added triethylamine (414.08 mg, 4.09 mmol), HOBt (265.41 mg, 1.96 mmol), and EDCI (376.53 mg, 1.96 mmol) and stirred for 10 min. Then, <i>o</i>-phenylenediamine (194.71 mg, 1.80 mmol) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>25a</b> as a yellow solid (853.12 mg, 96% yield).</div></div><div id="sec6_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61">6.7.4.  General Procedure for Intermediate <b>26</b></h4><div class="NLM_p last">To a solution of <b>24</b> (739.04 mg, 1.64 mmol) in DMF (10 mL) were added triethylamine (414.08 mg, 4.09 mmol), HOBt (265.41 mg, 1.96 mmol), and EDCI (376.53 mg, 1.96 mmol) and stirred for 10 min. Then, <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl) hydroxylamine (NH<sub>2</sub>OTHP) (210.92 mg, 1.80 mmol) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>26</b> as a yellow solid (806.96 mg, 89% yield).</div></div><div id="sec6_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62">6.7.5.  General Procedure for Target Compounds <b>27a</b></h4><div class="NLM_p last">The THP-protected intermediate <b>26</b> was dissolved in 4 M HCl in 1,4-dioxane (0.1 mmol/mL dioxane) and left to stir for 4 h. The reaction was monitored by TLC, which indicated a complete conversion. The solution was dried <i>in vacuo</i>, and the crude mixture was purified by chromatography on a silica gel column with dichloromethane/MeOH (40:1) as the eluent to give a white solid (643.56 mg, 94% yield).</div></div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">6.8.  Synthesis of Dual-Target Compounds <b>30a</b> and <b>32a</b></h3><div id="sec6_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64">6.8.1.  General Procedure for Intermediate <b>28</b></h4><div class="NLM_p last">Compound <b>7c</b> (1.00 g, 2.30 mmol), methyl acrylate (237.87 mg, 2.76 mmol), Pd(OAc)<sub>2</sub> (25.85 mg, 0.12 mmol), PPh<sub>3</sub> (60.93 mg, 0.23 mmol), and Et<sub>3</sub>N (582.50 mg, 5.76 mmol) were dissolved in DMF (5 mL). The reaction mixture was stirred at 110 °C for 12 h. After that, the reaction mixture was cooled to rt and the reaction mixture was extracted with EtOAc (3 × 10 mL), the combined organic phase was washed with H<sub>2</sub>O (5 × 5 mL) and brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified by column chromatography (PE/EtOAc = 20:1) on silica gel to provide a white oil-liquid <b>28</b> (563.27 mg, 52% yield).</div></div><div id="sec6_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65">6.8.2.  General Procedure for Intermediate <b>29</b></h4><div class="NLM_p last">To a solution of compound <b>28</b> (563.27 mg, 1.28 mmol) in 30 mL of MeOH was added LiOH solution (76.69 mg, 3.20 mmol, dissolved in 3 mL of H<sub>2</sub>O) in an ice-bath. The mixture was stirred at room temperature for 2 h until the reaction was complete. The solvent was removed <i>in vacuo</i>, the residue was diluted with H<sub>2</sub>O, and 4 M hydrochloric acid solution, pH = 2, was added. Then, the mixture was filtered, and the filtered residue was obtained and further dried to yield intermediate <b>29</b> as a white solid (542.45 mg, 100% yield).</div></div><div id="sec6_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66">6.8.3.  General Procedure for Target Compound <b>30a</b></h4><div class="NLM_p last">To a solution of <b>29</b> (542.45 mg, 1.27 mmol) in DMF (10 mL) were added triethylamine (322.55 mg, 3.19 mmol), HOBt (206.74 mg, 1.53 mmol), and EDCI (293.30 mg, 1.53 mmol) and stirred for 10 min. Then, <i>o</i>-phenylenediamine (151.67 mg, 1.40 mmol) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>30a</b> as a yellow solid (598.39 mg, 91% yield).</div></div><div id="sec6_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67">6.8.4.  General Procedure for Intermediate <b>31</b></h4><div class="NLM_p last">To a solution of <b>29</b> (542.45 mg, 1.27 mmol) in DMF (10 mL) were added triethylamine (322.55 mg, 3.19 mmol), HOBt (206.74 mg, 1.53 mmol), and EDCI (293.30 mg, 1.53 mmol) and stirred for 10 min. Then, the <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (NH<sub>2</sub>OTHP) (164.30 mg, 1.40 mmol) was added. After stirring for 4 h at room temperature until the reaction was complete, water was added to the reaction mixture. Then, the mixture was filtered, and the filtered residue was obtained and further dried to provide compound <b>31</b> as a yellow solid (556.81 mg, 83% yield).</div></div><div id="sec6_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68">6.8.5.  General Procedure for Target Compound <b>32a</b></h4><div class="NLM_p">The THP-protected intermediate <b>31</b> (556.81 mg, 1.06 mmol) was dissolved in 4 M HCl in 1,4-dioxane (0.1 mmol/mL dioxane) and left to stir for 4 h. The reaction was monitored by TLC, which indicated a complete conversion. The solution was dried <i>in vacuo</i>, and the crude mixture was purified by chromatography on a silica gel column with dichloromethane/MeOH (40:1) as the eluent to give a white solid (439.16 mg, 94% yield).</div><div id="sec6_8_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69">6.8.5.1.  (2-(4-Hydroxyphenyl)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>7a</b>)</h5><div class="NLM_p last">Yellow solid, yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 8.80 (s, 1H), 8.39 (d, <i>J</i> = 7.2 Hz, 2H), 8.30 (d, <i>J</i> = 9.2 Hz, 2H), 7.61 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 185.01, 165.21, 154.93, 152.95, 148.84, 142.49, 138.31, 132.27, 131.95, 128.02, 125.14, 108.39, 60.65, 56.45. M.p.: 123.0–125.4 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>18</sub>NO<sub>5</sub>S: 372.0827, found: 372.0830.</div></div><div id="sec6_8_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70">6.8.5.2.  (2-(4-Aminophenyl)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>7b</b>)</h5><div class="NLM_p last">Yellow solid, yield: 44%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.40 (s, 1H), 7.70 (d, <i>J</i> = 8.0 Hz, 3H), 7.65 (s, 2H), 6.66 (d, <i>J</i> = 7.9 Hz, 2H), 5.77 (d, <i>J</i> = 14.3 Hz, 2H), 3.87 (s, 8H), 3.80 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.25, 164.75, 154.50, 152.51, 148.39, 142.05, 137.87, 131.83, 131.51, 127.57, 124.70, 107.96, 60.20, 56.01. M.p.: 120.7–122.3 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>S: 371.0987, found: 371.0996.</div></div><div id="sec6_8_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71">6.8.5.3.  (2-(4-Bromophenyl)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>7c</b>)</h5><div class="NLM_p last">Yellow solid, yield: 47%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.67 (s, 1H), 7.98 (d, <i>J</i> = 8.5 Hz, 2H), 7.76 (d, <i>J</i> = 8.5 Hz, 2H), 7.60 (s, 2H), 3.86 (s, 6H), 3.79 (s, 3H) <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.93, 152.52, 143.13, 141.73, 132.47, 131.39, 130.41, 128.34, 123.81, 107.98, 60.25, 56.02. M.p.: 123.7–125.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>17</sub>BrNO<sub>4</sub>S: 433.9983, found: 433.9980.</div></div><div id="sec6_8_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72">6.8.5.4.  <i>N</i>-(2-Aminophenyl)-2-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)acetamide (<b>10a</b>)</h5><div class="NLM_p last">Yellow solid, yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.37 (s, 1H), 8.57 (s, 1H), 8.00 (d, <i>J</i> = 8.5 Hz, 2H), 7.64 (s, 2H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 6.94 (t, <i>J</i> = 7.3 Hz, 1H), 6.74 (d, <i>J</i> = 7.8 Hz, 1H), 6.56 (t, <i>J</i> = 7.5 Hz, 1H), 4.90 (s, 2H), 4.82 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 184.62, 167.15, 153.92, 152.47, 141.90, 131.81, 129.21, 128.08, 127.99, 127.45, 127.30, 127.15, 126.69, 116.10, 107.97, 68.92, 60.21, 55.97. M.p.: 147.1–149.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O<sub>6</sub>S: 520.1464, found: 520.1467. HPLC: <i>t</i><sub>R</sub> 18.6 min, purity 97.2%.</div></div><div id="sec6_8_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73">6.8.5.5.  <i>N</i>-(2-Aminophenyl)-3-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)propanamide (<b>10b</b>)</h5><div class="NLM_p last">Yellow solid, yield: 31%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.11 (s, 1H), 8.53 (d, <i>J</i> = 4.8 Hz, 1H), 7.95 (d, <i>J</i> = 3.6 Hz, 2H), 7.63 (s, 2H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 2H), 6.88 (t, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 7.6 Hz, 1H), 6.52 (t, <i>J</i> = 7.6 Hz, 1H), 4.80 (s, 2H), 4.05 (t, <i>J</i> = 5.6 Hz, 2H), 3.86 (s, 6H), 3.79 (s, 3H), 2.33 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 185.14, 173.60, 171.63, 167.35, 154.28, 152.88, 142.20, 132.20, 127.49, 125.61, 119.74, 116.27, 108.38, 60.63, 56.38, 51.57, 33.63. M.p.: 125.5–127.7 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>S: 534.1621, found: 534.1625. HPLC: <i>t</i><sub>R</sub> 17.7 min, purity 98.2%.</div></div><div id="sec6_8_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74">6.8.5.6.  <i>N</i>-(2-Aminophenyl)-4-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)butanamide (<b>10c</b>)</h5><div class="NLM_p last">Yellow solid, yield: 29%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.16 (s, 1H), 8.56 (s, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.14 (dd, <i>J</i> = 14.8, 8.0 Hz, 3H), 6.89 (s, 1H), 6.71 (d, <i>J</i> = 7.9 Hz, 1H), 6.54 (d, <i>J</i> = 7.2 Hz, 1H), 4.83 (s, 2H), 4.13 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.03 (d, <i>J</i> = 33.5 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.97, 173.37, 152.84, 142.28, 132.19, 129.46, 128.41, 125.79, 115.61, 108.35, 99.93, 60.59, 56.35, 51.73, 30.25, 24.50. M.p.: 124.8–126.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>30</sub>N<sub>3</sub>O<sub>6</sub>S: 548.1771, found: 548.1771. HPLC: <i>t</i><sub>R</sub> 18.0 min, purity 99.0%.</div></div><div id="sec6_8_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75">6.8.5.7.  <i>N</i>-(2-Aminophenyl)-5-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)pentanamide (<b>10d</b>)</h5><div class="NLM_p last">Yellow solid, yield: 28%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.14 (s, 1H), 8.55 (s, 1H), 7.95 (d, <i>J</i> = 8.0 Hz, 2H), 7.64 (s, 2H), 7.13 (dd, <i>J</i> = 17.4, 8.0 Hz, 3H), 6.89 (t, <i>J</i> = 7.3 Hz, 1H), 6.72 (d, <i>J</i> = 7.8 Hz, 1H), 6.54 (t, <i>J</i> = 7.3 Hz, 1H), 4.82 (s, 2H), 4.10 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.40 (s, 2H), 1.79 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.62, 170.96, 167.28, 160.77, 153.90, 152.47, 141.90, 131.82, 129.08, 128.04, 125.74, 125.31, 123.51, 116.18, 115.90, 115.26, 107.97, 67.55, 60.21, 55.97, 35.31, 28.15, 21.88. M.p.: 120.1–121.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>32</sub>N<sub>3</sub>O<sub>6</sub>S: 562.1934, found: 562.1935. HPLC: <i>t</i><sub>R</sub> 17.4 min, purity 96.2%.</div></div><div id="sec6_8_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76">6.8.5.8.  <i>N</i>-(2-Aminophenyl)-6-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)hexanamide (<b>10e</b>)</h5><div class="NLM_p last">Yellow solid, yield: 37%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 8.54 (s, 1H), 7.94 (d, <i>J</i> = 7.8 Hz, 2H), 7.64 (s, 2H), 7.16 (d, <i>J</i> = 7.1 Hz, 1H), 7.08 (s, 3H), 6.88 (d, <i>J</i> = 6.8 Hz, 1H), 6.72 (d, <i>J</i> = 7.4 Hz, 1H), 6.54 (d, <i>J</i> = 6.5 Hz, 1H), 4.82 (s, 2H), 4.05 (d, <i>J</i> = 5.1 Hz, 3H), 3.87 (s, 7H), 3.79 (s, 3H), 2.33 (d, <i>J</i> = 17.3 Hz, 3H), 1.72 (dd, <i>J</i> = 25.7, 8.7 Hz, 5H), 1.58 (d, <i>J</i> = 8.7 Hz, 2H), 1.45 (d, <i>J</i> = 24.3 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.67, 173.41, 171.19, 167.38, 160.89, 154.02, 152.57, 141.99, 131.91, 129.64, 129.28, 129.14, 128.12, 125.80, 125.38, 125.20, 123.67, 116.28, 116.00, 115.32, 114.80, 108.09, 60.31, 56.06, 51.28, 35.79, 33.31, 28.48, 25.15. M.p.: 122.7–124.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>31</sub>H<sub>34</sub>N<sub>3</sub>O<sub>6</sub>S: 576.2090, found: 576.2096. HPLC: <i>t</i><sub>R</sub> 18.2 min, purity 98.8%.</div></div><div id="sec6_8_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77">6.8.5.9.  <i>N</i>-(2-Aminophenyl)-7-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)heptanamide (<b>10f</b>)</h5><div class="NLM_p last">Yellow solid, yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.11 (s, 1H), 8.53 (d, <i>J</i> = 4.8 Hz, 1H), 7.95 (d, <i>J</i> = 3.9 Hz, 2H), 7.63 (s, 2H), 7.14 (d, <i>J</i> = 7.5 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 2H), 6.88 (t, <i>J</i> = 7.4 Hz, 1H), 6.71 (d, <i>J</i> = 7.7 Hz, 1H), 6.53 (t, <i>J</i> = 7.4 Hz, 1H), 4.80 (s, 2H), 4.08–4.01 (m, 2H), 3.86 (s, 6H), 3.79 (s, 3H), 2.33 (s, 2H), 1.74 (s, 3H), 1.67–1.57 (m, 2H), 1.47 (s, 3H), 1.38 (d, <i>J</i> = 21.9 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 184.72, 171.28, 167.37, 162.43, 160.86, 153.94, 152.53, 141.93, 131.88, 129.14, 128.10, 125.78, 125.36, 125.14, 123.62, 116.27, 115.97, 115.31, 108.02, 67.83, 60.28, 56.04, 35.86, 35.74, 30.84, 28.52, 25.29. M.p.: 131.3–133.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>32</sub>H<sub>36</sub>N<sub>3</sub>O<sub>6</sub>S: 590.2247, found: 590.2243. HPLC: <i>t</i><sub>R</sub> 18.4 min, purity 99.1%.</div></div><div id="sec6_8_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78">6.8.5.10.  <i>N</i>-(2-Aminophenyl)-4-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)methyl)benzamide (<b>10g</b>)</h5><div class="NLM_p last">Yellow solid, yield: 31%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.68 (s, 1H), 8.56 (s, 1H), 8.04–7.94 (m, 4H), 7.68–7.56 (m, 4H), 7.48 (dd, <i>J</i> = 36.8, 6.8 Hz, 2H), 7.20 (s, 3H), 6.97 (d, <i>J</i> = 6.5 Hz, 1H), 6.79 (d, <i>J</i> = 7.5 Hz, 1H), 6.60 (s, 1H), 5.27 (d, <i>J</i> = 25.7 Hz, 2H), 4.91 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H).<sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 184.62, 169.87, 167.17, 165.06, 160.33, 160.25, 153.95, 152.49, 143.16, 141.92, 140.05, 137.83, 136.09, 134.20, 131.82, 129.38, 129.21, 128.09, 128.01, 127.56, 127.48, 127.33, 127.17, 126.73, 126.55, 125.60, 123.27, 116.29, 116.15, 115.72, 115.63, 108.00, 69.05, 60.23, 55.98. M.p.: 135.2–138.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>33</sub>H<sub>30</sub>N<sub>3</sub>O<sub>6</sub>S: 596.1777, found: 596.1779. HPLC: <i>t</i><sub>R</sub> 16.1 min, purity 96.9%.</div></div><div id="sec6_8_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79">6.8.5.11.  (<i>E</i>)-<i>N</i>-(2-Aminophenyl)-3-(4-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)methyl)phenyl)acrylamide (<b>10h</b>)</h5><div class="NLM_p last">Yellow solid, yield: 34%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.41 (s, 1H), 8.56 (s, 1H), 7.98 (dd, <i>J</i> = 8.5, 4.4 Hz, 2H), 7.75 (t, <i>J</i> = 8.7 Hz, 1H), 7.70–7.64 (m, 2H), 7.63 (s, 2H), 7.57–7.51 (m, 2H), 7.34 (d, <i>J</i> = 7.7 Hz, 1H), 7.20 (dd, <i>J</i> = 8.3, 5.9 Hz, 2H), 6.95–6.88 (m, 1H), 6.75 (d, <i>J</i> = 7.9 Hz, 1H), 6.66 (d, <i>J</i> = 16.1 Hz, 1H), 6.59 (d, <i>J</i> = 7.6 Hz, 1H), 5.24 (d, <i>J</i> = 5.6 Hz, 2H), 4.94 (s, 2H), 3.87 (s, 6H), 3.79 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.64, 167.18, 163.47, 153.93, 152.48, 141.91, 141.60, 139.11, 138.13, 134.58, 131.82, 129.22, 128.25, 128.09, 127.80, 127.55, 125.80, 124.71, 123.49, 122.59, 117.41, 116.27, 116.01, 115.67, 114.68, 107.98, 60.22, 55.98, 48.73. M.p.: 141.0–143.7 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>35</sub>H<sub>32</sub>N<sub>3</sub>O<sub>6</sub>S: 622.1934, found: 622.1930. HPLC: <i>t</i><sub>R</sub> 17.4 min, purity 98.6%.</div></div><div id="sec6_8_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80">6.8.5.12.  (<i>E</i>)-<i>N</i>-(2-Aminophenyl)-4-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)but-2-enamide (<b>10i</b>)</h5><div class="NLM_p last">Yellow solid, yield: 26%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.16 (s, 1H), 8.60 (s, 1H), 8.04 (s, 2H), 7.63 (s, 2H), 7.21 (d, <i>J</i> = 39.0 Hz, 3H), 6.90 (s, 3H), 6.72 (s, 2H), 6.54 (s, 2H), 5.25 (s, 1H), 4.85 (s, 2H), 3.83 (d, <i>J</i> = 28.4 Hz, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 185.64, 169.16, 167.18, 152.90, 142.42, 132.19, 128.68, 125.84, 123.66, 117.14, 116.52, 116.19, 108.38, 69.61, 60.63, 56.40. M.p.: 130.1–131.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>S: 546.1621, found: 546.1623. HPLC: <i>t</i><sub>R</sub> 17.7 min, purity 98.0%.</div></div><div id="sec6_8_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81">6.8.5.13.  <i>N</i>-Hydroxy-2-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)acetamide (<b>12a</b>)</h5><div class="NLM_p last">White solid, yield: 25%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.46 (s, 1H), 8.79 (s, 1H), 8.53 (s, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.63 (s, 2H), 7.02 (d, <i>J</i> = 8.3 Hz, 2H), 4.54 (s, 2H), 3.86 (s, 6H), 3.79 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.58, 167.31, 153.91, 152.46, 141.88, 131.81, 129.06, 127.83, 125.07, 115.32, 107.96, 60.20, 55.97, 29.00. M.p.: 123.2–124.6 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>21</sub>N<sub>2</sub>O<sub>7</sub>S: 445.0991, found: 445.0993. HPLC: <i>t</i><sub>R</sub> 13.5 min, purity 96.4%.</div></div><div id="sec6_8_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82">6.8.5.14.  <i>N</i>-Hydroxy-3-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)propanamide (<b>12b</b>)</h5><div class="NLM_p last">White solid, yield: 24%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 8.64 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 3H), 4.19 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.35 (d, <i>J</i> = 4.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.63, 171.50, 168.92, 167.17, 153.94, 152.46, 141.89, 131.78, 129.29, 127.13, 119.30, 107.95, 64.27, 60.19, 55.95, 32.14. M.p.: 121.3–123.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>7</sub>S: 459.1148, found: 459.1150. HPLC: <i>t</i><sub>R</sub> 13.2 min, purity 96.6%.</div></div><div id="sec6_8_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83">6.8.5.15.  <i>N</i>-Hydroxy-4-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)butanamide (<b>12c</b>)</h5><div class="NLM_p last">White solid, yield: 28%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 8.72 (s, 1H), 8.55 (s, 1H), 7.96 (d, <i>J</i> = 7.1 Hz, 2H), 7.63 (s, 2H), 7.09 (d, <i>J</i> = 6.9 Hz, 2H), 4.05 (s, 2H), 3.87 (s, 6H), 3.79 (s, 3H), 2.15 (s, 2H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 1184.63, 168.59, 167.26, 160.66, 153.91, 152.48, 141.91, 131.82, 129.64, 129.11, 128.05, 125.22, 115.28, 107.98, 67.15, 60.22, 55.98, 29.02, 28.64. M.p.: 126.4–127.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>7</sub>S: 473.1304, found: 473.1300. HPLC: <i>t</i><sub>R</sub> 14.0 min, purity 99.7%.</div></div><div id="sec6_8_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84">6.8.5.16.  <i>N</i>-Hydroxy-5-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)pentanamide (<b>12d</b>)</h5><div class="NLM_p last">White solid, yield: 26%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 8.71 (s, 1H), 8.54 (s, 1H), 7.94 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (s, 2H), 7.08 (d, <i>J</i> = 8.2 Hz, 3H), 4.04 (s, 2H), 3.87 (s, 6H), 3.79 (s, 3H), 2.04 (d, <i>J</i> = 6.6 Hz, 2H), 1.76–1.64 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.58, 168.95, 167.28, 160.76, 153.94, 152.48, 141.92, 131.82, 129.06, 128.03, 125.15, 115.25, 108.00, 67.44, 60.35, 60.23, 55.98, 31.89, 28.09, 21.74. M.p.: 123.2–125.7 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>27</sub>N<sub>2</sub>O<sub>7</sub>S: 487.1461, found: 486.1469. HPLC: <i>t</i><sub>R</sub> 14.0 min, purity 98.4%.</div></div><div id="sec6_8_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85">6.8.5.17.  <i>N</i>-Hydroxy-6-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)hexanamide (<b>12e</b>)</h5><div class="NLM_p last">White solid, yield: 27%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.91 (s, 1H), 8.47 (s, 1H), 8.24 (s, 1H), 7.82 (d, <i>J</i> = 8.6 Hz, 2H), 7.04 (d, <i>J</i> = 8.7 Hz, 2H), 6.85 (s, 2H), 4.01 (t, <i>J</i> = 6.4 Hz, 2H), 3.74 (d, <i>J</i> = 7.0 Hz, 6H), 3.71 (s, 3H), 2.23 (t, <i>J</i> = 7.2 Hz, 2H), 1.76–1.70 (m, 2H), 1.59–1.52 (m, 2H), 1.46–1.39 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.45, 165.20, 160.44, 152.40, 149.43, 145.61, 138.23, 131.82, 129.70, 127.81, 125.51, 115.16, 105.54, 67.67, 60.15, 55.90, 33.66, 29.04, 28.36, 24.29. M.p.: 126.3–127.8 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>29</sub>N<sub>2</sub>O<sub>7</sub>S: 501.1617, found: 501.1611. HPLC: <i>t</i><sub>R</sub> 14.1 min, purity 97.8%.</div></div><div id="sec6_8_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86">6.8.5.18.  <i>N</i>-Hydroxy-7-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)heptanamide (<b>12f</b>)</h5><div class="NLM_p last">White solid, yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 8.66 (s, 1H), 8.55 (s, 1H), 7.94 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.09 (d, <i>J</i> = 8.4 Hz, 2H), 4.04 (t, <i>J</i> = 5.9 Hz, 2H), 3.87 (s, 6H), 3.81 (d, <i>J</i> = 9.5 Hz, 3H), 1.96 (t, <i>J</i> = 7.1 Hz, 2H), 1.57–1.46 (m, 2H), 1.42 (s, 2H), 1.37–1.26 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.62, 169.12, 167.29, 160.80, 153.91, 152.48, 141.91, 131.83, 129.08, 128.04, 125.10, 115.25, 107.98, 67.76, 60.22, 55.98, 32.20, 28.46, 28.31, 25.19, 25.05. M.p.: 121.3–122.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>31</sub>N<sub>2</sub>O<sub>7</sub>S: 515.1774, found: 515.1778. HPLC: <i>t</i><sub>R</sub> 13.9 min, purity 98.2%.</div></div><div id="sec6_8_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87">6.8.5.19.  <i>N</i>-Hydroxy-4-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenoxy)methyl)benzamide (<b>12g</b>)</h5><div class="NLM_p last">White solid, yield: 32%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 8.82 (s, 1H), 8.61 (s, 1H), 8.34 (d, <i>J</i> = 7.6 Hz, 2H), 8.21 (d, <i>J</i> = 4.4 Hz, 2H), 8.05 (d, <i>J</i> = 8.4 Hz, 2H), 7.94 (d, <i>J</i> = 8.8 Hz, 2H), 7.64 (s, 2H), 5.15 (s, 2H), 3.88 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.10, 154.00, 152.49, 142.21, 141.10, 131.79, 129.18, 127.85, 127.06, 120.62, 107.97, 71.85, 60.22, 55.98.1. M.p.: 121.9–123.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>25</sub>N<sub>2</sub>O<sub>7</sub>S: 521.1304, found: 521.1301. HPLC: <i>t</i><sub>R</sub> 14.0 min, purity 99.1%.</div></div><div id="sec6_8_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88">6.8.5.20.  (<i>E</i>)-<i>N</i>-Hydroxy-3-(4-((4-(4-(3,4,5-trimethoxybenzoyl) thiazol-2-yl) phenoxy) methyl) phenyl) acrylamide (<b>12h</b>)</h5><div class="NLM_p last">White solid, yield: 26%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.48 (s, 1H), 9.06 (s, 1H), 8.56 (s, 1H), 7.98 (d, <i>J</i> = 8.7 Hz, 2H), 7.65–7.55 (m, 4H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 7.42–7.34 (m, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 2H), 6.48 (d, <i>J</i> = 15.9 Hz, 1H), 5.23 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.65, 167.14, 166.25, 159.93, 153.92, 152.48, 142.64, 141.90,131.81, 128.02, 126.46, 126.08, 125.78, 122.24, 116.12, 115.80, 107.96, 67.00, 60.21, 55.98. M.p.: 134.4–136.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>27</sub>N<sub>2</sub>O<sub>7</sub>S: 547.1461, found: 547.1464. HPLC: <i>t</i><sub>R</sub> 15.1 min, purity 97.7%.</div></div><div id="sec6_8_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89">6.8.5.21.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>3</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)malonamide (<b>15a</b>)</h5><div class="NLM_p last">Yellow solid, yield: 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.03 (s, 1H), 10.07 (s, 1H), 8.62 (s, 1H), 8.55 (s, 1H), 8.06 (s, 5H), 7.99 (s, 2H), 7.63 (s, 3H), 7.27 (d, <i>J</i> = 7.2 Hz, 1H), 7.00 (s, 1H), 6.79 (d, <i>J</i> = 7.6 Hz, 1H), 6.63 (d, <i>J</i> = 7.7 Hz, 1H), 5.05 (s, 2H), 3.82 (dd, <i>J</i> = 27.1, 12.8 Hz, 11H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 185.12, 167.37, 159.43, 158.84, 154.45, 152.91, 152.84, 143.12, 142.35, 142.29, 140.46, 132.20, 132.11, 130.12, 128.92, 127.49, 127.38, 126.11, 122.42, 121.28, 116.79, 116.68, 108.39, 60.63, 60.58, 56.40, 56.30, 18.95. M.p.: 127.3–128.8 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>27</sub>N<sub>4</sub>O<sub>6</sub>S: 547.1573, found: 547.1567. HPLC: <i>t</i><sub>R</sub> 13.8 min, purity 99.4%.</div></div><div id="sec6_8_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90">6.8.5.22.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)succinamide (<b>15b</b>)</h5><div class="NLM_p last">Yellow solid, yield: 37%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.30 (s, 1H), 9.20 (s, 1H), 8.67 (s, 2H), 8.56 (s, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 2H), 7.77 (d, <i>J</i> = 7.8 Hz, 2H), 7.13 (d, <i>J</i> = 7.5 Hz, 1H), 6.89 (s, 1H), 6.70 (d, <i>J</i> = 7.7 Hz, 1H), 6.53 (d, <i>J</i> = 7.5 Hz, 1H), 4.86 (s, 2H), 3.87 (s, 6H), 3.79 (s, 3H), 2.81 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 176.75, 166.46, 154.17, 152.50, 141.97, 134.74, 131.96, 131.71, 130.42, 127.93, 126.84, 107.98, 60.22, 56.00, 28.55. M.p.: 125.3–127.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>29</sub>N<sub>4</sub>O<sub>6</sub>S: 561.1730, found: 561.1736. HPLC: <i>t</i><sub>R</sub> 13.5 min, purity 98.7%.</div></div><div id="sec6_8_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91">6.8.5.23.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>5</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)glutaramide (<b>15c</b>)</h5><div class="NLM_p last">Yellow solid, yield: 39%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 9.11 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.79 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.18 (d, <i>J</i> = 7.7 Hz, 1H), 6.89 (t, <i>J</i> = 7.4 Hz, 1H), 6.71 (d, <i>J</i> = 7.8 Hz, 1H), 6.54 (d, <i>J</i> = 7.3 Hz, 1H), 4.83 (s, 2H), 3.87 (s, 7H), 3.80 (s, 3H), 2.42 (dt, <i>J</i> = 14.1, 7.1 Hz, 4H), 2.00–1.86 (m, 2H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.67, 171.35, 167.21, 153.96, 152.48, 141.92, 131.80, 129.32, 127.14, 125.73, 125.39, 123.45, 119.37, 116.11, 115.83, 107.97, 60.22, 55.97, 35.74, 34.91, 21.06. M.p.: 125.3–127.6 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>31</sub>N<sub>4</sub>O<sub>6</sub>S: 575.1886, found: 575.1885. HPLC: <i>t</i><sub>R</sub> 14.3 min, purity 98.3%.</div></div><div id="sec6_8_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92">6.8.5.24.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>6</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)adipamide (<b>15d</b>)</h5><div class="NLM_p last">Yellow solid, yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.10 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 2H), 7.79 (d, <i>J</i> = 5.7 Hz, 2H), 7.63 (s, 2H), 7.15 (s, 1H), 6.89 (s, 1H), 6.72 (s, 1H), 6.53 (s, 1H), 4.82 (s, 2H), 3.87 (s, 7H), 3.80 (s, 3H), 2.41–2.26 (m, 4H), 1.66 (s, 2H), 1.60 (s, 2H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.62, 173.21, 171.56, 170.97, 167.18, 153.95, 152.47, 141.90, 131.78, 129.27, 127.12, 125.70, 125.31, 123.50, 119.32, 116.14, 115.86, 107.96, 60.19, 56.01, 55.96, 51.20, 36.35, 33.02, 25.02, 18.53. M.p.: 132.7–134.3 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>31</sub>H<sub>33</sub>N<sub>4</sub>O<sub>6</sub>S: 589.2043, found: 589.2047. HPLC: <i>t</i><sub>R</sub> 13.1 min, purity 96.8%.</div></div><div id="sec6_8_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93">6.8.5.25.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>7</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)heptanediamide (<b>15e</b>)</h5><div class="NLM_p last">Yellow solid, yield: 37%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.08 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.78 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.15 (d, <i>J</i> = 7.7 Hz, 1H), 6.88 (s, 1H), 6.71 (d, <i>J</i> = 7.8 Hz, 1H), 6.52 (s, 1H), 4.80 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.41–2.29 (m, 4H), 1.64 (dd, <i>J</i> = 14.5, 7.2 Hz, 4H), 1.38 (d, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.66, 171.65, 171.09, 167.19, 153.94, 152.47, 141.85, 141.68, 131.79, 129.29, 127.13, 125.66, 125.26, 123.54, 119.31, 116.13, 115.85, 107.95, 60.20, 55.96, 36.36, 35.61, 25.07, 24.81, 18.53. M.p.: 125.3–127.8 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>32</sub>H<sub>35</sub>N<sub>4</sub>O<sub>6</sub>S: 603.2199, found: 603.2207. HPLC: <i>t</i><sub>R</sub> 15.7 min, purity 98.3%.</div></div><div id="sec6_8_5_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94">6.8.5.26.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>8</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)octanediamide (<b>15f</b>)</h5><div class="NLM_p last">Yellow solid, yield: 32%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.28 (s, 1H), 8.60 (s, 1H), 7.99 (d, <i>J</i> = 7.1 Hz, 2H), 7.85 (d, <i>J</i> = 6.7 Hz, 2H), 7.67 (s, 2H), 7.21 (d, <i>J</i> = 6.6 Hz, 1H), 6.91 (s, 1H), 6.74 (d, <i>J</i> = 7.3 Hz, 1H), 6.56 (s, 1H), 4.90 (s, 2H), 3.91 (s, 6H), 3.83 (s, 3H), 2.38 (d, <i>J</i> = 7.0 Hz, 4H), 2.33 (s, 2H), 1.64 (s, 3H), 1.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.37, 171.75, 167.25, 152.48, 141.80, 131.80, 127.09, 125.21, 119.34, 115.87, 107.98, 60.23, 55.98, 51.17, 38.87, 33.23, 28.47, 24.86, 24.31. M.p.: 128.5–130.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>33</sub>H<sub>37</sub>N<sub>4</sub>O<sub>6</sub>S: 617.2356, found: 617.2359. HPLC: <i>t</i><sub>R</sub> 15.4 min, purity 98.5%.</div></div><div id="sec6_8_5_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95">6.8.5.27.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)terephthalamide (<b>15g</b>)</h5><div class="NLM_p last">Yellow solid, yield: 32%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.66 (s, 1H), 9.82 (d, <i>J</i> = 9.4 Hz, 1H), 8.61 (s, 1H), 8.11 (d, <i>J</i> = 8.6 Hz, 3H), 8.07–7.96 (m, 2H), 7.65 (s, 1H), 7.19 (d, <i>J</i> = 7.4 Hz, 1H), 6.99 (t, <i>J</i> = 6.9 Hz, 1H), 6.80 (d, <i>J</i> = 7.9 Hz, 1H), 6.61 (t, <i>J</i> = 7.2 Hz, 1H), 4.94 (s, 2H), 3.89 (s, 6H), 3.81 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 186.42, 181.51, 171.29, 165.11, 154.42, 152.91, 143.67, 137.41, 132.21, 128.29, 128.12, 127.48, 127.24, 127.08, 123.44, 121.11, 116.63, 116.52, 108.40, 60.64, 56.39. M.p.: 133.1–134.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>33</sub>H<sub>29</sub>N<sub>4</sub>O<sub>6</sub>S: 609.1730, found: 609.1735. HPLC: <i>t</i><sub>R</sub> 18.2 min, purity 96.8%.</div></div><div id="sec6_8_5_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96">6.8.5.28.  <i>N</i><sup>1</sup>-(2-Aminophenyl)-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)fumaramide (<b>15h</b>)</h5><div class="NLM_p last">Yellow solid, yield: 24%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.79 (s, 1H), 9.70 (s, 1H), 8.59 (s, 1H), 8.03 (d, <i>J</i> = 7.6 Hz, 2H), 7.88 (d, <i>J</i> = 7.8 Hz, 2H), 7.63 (s, 2H), 7.36–7.24 (m, 1H), 7.19 (d, <i>J</i> = 14.8 Hz, 1H), 6.94 (s, 1H), 6.76 (s, 1H), 6.59 (d, <i>J</i> = 6.7 Hz, 1H), 5.00 (s, 2H), 3.88 (s, 6H), 3.80 (s, 3H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.67, 167.04, 162.57, 162.00, 154.03, 152.50, 141.93, 141.66, 141.10, 134.68, 133.18, 131.79, 129.53, 127.93, 127.30, 126.24, 124.83, 122.74, 119.81, 116.13, 115.91, 107.98, 60.22, 55.99, 54.89. M.p.: 137.1–138.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>27</sub>N<sub>4</sub>O<sub>6</sub>S: 559.1573, found: 559.1570. HPLC: <i>t</i><sub>R</sub> 17.3 min, purity 97.7%.</div></div><div id="sec6_8_5_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97">6.8.5.29.  <i>N</i><sup>2</sup>-(2-Aminophenyl)-<i>N</i><sup>5</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)thiophene-2,5-dicarboxamide (<b>15i</b>)</h5><div class="NLM_p last">Yellow solid, yield: 23%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 9.08 (s, 1H), 8.57 (s, 2H), 8.31 (s, 1H), 7.96 (d, <i>J</i> = 8.8 Hz, 2H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 6.89 (d, <i>J</i> = 6.8 Hz, 1H), 6.70 (d, <i>J</i> = 7.6 Hz, 1H), 6.54 (t, <i>J</i> =13.2 Hz, 1H), 4.80 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 169.16, 167.37, 154.02, 152.90, 142.42, 141.98, 138.55, 132.19, 128.68, 125.84, 123.66, 117.14, 116.52, 108.38, 60.63, 55.96. M.p.: 135.3–136.8 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>31</sub>H<sub>27</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub>: 615.1294, found: 615.1299. HPLC: <i>t</i><sub>R</sub> 17.3 min, purity 98.1%.</div></div><div id="sec6_8_5_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98">6.8.5.30.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>3</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)malonamide (<b>17a</b>)</h5><div class="NLM_p last">White solid, yield: 20%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 10.26 (s, 1H), 8.68 (s, 1H), 8.39 (s, 1H), 8.15 (d, <i>J</i> = 8.3 Hz, 2H), 7.64 (d, <i>J</i> = 3.9 Hz, 3H), 7.48 (d, <i>J</i> = 8.3 Hz, 2H), 6.66 (d, <i>J</i> = 8.4 Hz, 2H), 3.87 (d, <i>J</i> = 3.0 Hz, 6H), 3.79 (d, <i>J</i> = 2.7 Hz, 3H), 2.81 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.74, 173.32, 171.53, 167.26, 154.00, 152.53, 141.97, 141.66, 131.85, 129.70, 129.38, 127.20, 119.40, 108.01, 99.57, 60.28, 56.02, 36.12. M.p.: 145.7–147.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>7</sub>S: 472.1100, found: 472.1109. HPLC: <i>t</i><sub>R</sub> 16.5 min, purity 97.9%.</div></div><div id="sec6_8_5_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99">6.8.5.31.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)succinamide (<b>17b</b>)</h5><div class="NLM_p last">White solid, yield: 25%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.46 (s, 1H), 10.25 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 2H), 7.63 (s, 2H), 7.48 (d, <i>J</i> = 8.0 Hz, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.81 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.01, 176.66, 166.37, 154.08, 152.41, 141.88, 138.55, 134.36, 131.62, 130.38, 127.85, 126.77, 107.89, 99.45, 60.17, 55.96, 28.51. M.p.: 135.7–136.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>O<sub>7</sub>S: 486.1257, found: 486.1251. HPLC: <i>t</i><sub>R</sub> 16.7 min, purity 98.7%.</div></div><div id="sec6_8_5_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100">6.8.5.32.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>5</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)glutaramide (<b>17c</b>)</h5><div class="NLM_p last">Yellow solid, yield: 20%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 10.19 (s, 1H), 8.57 (s, 1H), 8.39 (s, 1H), 7.97 (d, <i>J</i> = 8.6 Hz, 2H), 7.77 (d, <i>J</i> = 8.6 Hz, 2H), 7.63 (s, 2H), 3.87 (s, 9H), 3.80 (s, 3H), 2.40 (t, <i>J</i> = 7.3 Hz, 2H), 2.29 (t, <i>J</i> = 7.3 Hz, 2H), 1.89–1.75 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.63, 174.13, 171.17, 167.18, 153.96, 152.47, 152.42, 141.90, 141.61, 131.79, 129.29, 127.81, 127.13, 119.34, 113.69, 107.96, 60.20, 55.96, 55.93, 35.45, 32.93, 20.31. M.p.: 144.1–146.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O<sub>7</sub>S: 500.1413, found: 500.1418. HPLC: <i>t</i><sub>R</sub> 16.3 min, purity 95.9%.</div></div><div id="sec6_8_5_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101">6.8.5.33.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>6</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)adipamide (<b>17d</b>)</h5><div class="NLM_p last">Yellow solid, yield: 21%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.36 (s, 1H), 10.18 (s, 1H), 8.67 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.6 Hz, 2H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.34 (d, <i>J</i> = 6.5 Hz, 2H), 1.99 (d, <i>J</i> = 6.9 Hz, 2H), 1.56 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.62, 174.33, 171.47, 167.18, 153.95, 152.46, 141.89, 141.64, 131.78, 129.29, 127.13, 119.31, 107.95, 60.19, 55.95, 36.17, 33.40, 24.54, 24.10. M.p.: 144.6–147.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub>S: 514.1570, found: 514.1577. HPLC: <i>t</i><sub>R</sub> 15.9 min, purity 98.5%.</div></div><div id="sec6_8_5_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102">6.8.5.34.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>7</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)heptanediamide (<b>17e</b>)</h5><div class="NLM_p last">White solid, yield: 29%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.33 (s, 1H), 10.16 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.7 Hz, 2H), 7.77 (d, <i>J</i> = 8.7 Hz, 2H), 7.63 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.34 (t, <i>J</i> = 7.3 Hz, 2H), 1.95 (t, <i>J</i> = 7.3 Hz, 2H), 1.59 (dd, <i>J</i> = 14.9, 7.5 Hz, 2H), 1.55–1.46 (m, 2H), 1.29 (dd, <i>J</i> = 9.3, 5.3 Hz, 2H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.63, 171.59, 169.01, 167.17, 153.93, 152.46, 141.88, 141.66, 131.78, 129.28, 127.12, 127.04, 119.28, 107.94, 60.19, 55.95, 36.31, 32.12, 28.20, 24.89, 24.72. M.p.: 134.2–136.5 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O<sub>7</sub>S: 528.1726, found: 528.1723. HPLC: <i>t</i><sub>R</sub> 16.6 min, purity 97.2%.</div></div><div id="sec6_8_5_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103">6.8.5.35.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>8</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)octanediamide (<b>17f</b>)</h5><div class="NLM_p last">White solid, yield: 28%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 10.16 (s, 1H), 8.64 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 2H), 7.77 (d, <i>J</i> = 8.3 Hz, 2H), 7.63 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.34 (t, <i>J</i> = 7.2 Hz, 2H), 2.04–1.90 (m, 2H), 1.58 (d, <i>J</i> = 6.8 Hz, 2H), 1.53–1.41 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.64, 171.65, 169.07, 167.18, 153.94, 152.46, 141.89, 141.68, 131.78, 129.62, 129.29, 127.12, 127.04, 119.30, 107.95, 60.19, 55.95, 29.05, 29.00, 28.55, 28.37, 26.53, 24.90, 13.92. M.p.: 133.3–135.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>7</sub>S: 542.1883, found: 542.1881. HPLC: <i>t</i><sub>R</sub> 16.1 min, purity 98.5%.</div></div><div id="sec6_8_5_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104">6.8.5.36.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)terephthalamide (<b>17g</b>)</h5><div class="NLM_p last">White solid, yield: 24%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 10.62 (s, 1H), 9.17 (s, 1H), 8.61 (s, 1H), 8.06 (dd, <i>J</i> = 9.7, 7.6 Hz, 4H), 8.00 (d, <i>J</i> = 8.8 Hz, 2H), 7.90 (d, <i>J</i> = 8.3 Hz, 2H), 7.64 (s, 2H), 3.88 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.68, 167.10, 154.00, 152.49, 147.10, 142.21, 141.10, 131.79, 129.18, 127.85, 127.06, 120.62, 107.97, 60.22, 55.98. M.p.: 131.0–132.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>O<sub>7</sub>S: 534.1257, found: 534.1262. HPLC: <i>t</i><sub>R</sub> 16.0 min, purity 99.1%.</div></div><div id="sec6_8_5_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105">6.8.5.37.  <i>N</i><sup>1</sup>-Hydroxy-<i>N</i><sup>4</sup>-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)fumaramide (<b>17h</b>)</h5><div class="NLM_p last">White solid, yield: 24%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 10.72 (s, 1H), 8.81 (s, 1H), 8.60 (s, 1H), 8.02 (d, <i>J</i> = 8.6 Hz, 2H), 7.85 (d, <i>J</i> = 8.6 Hz, 2H), 7.63 (s, 2H), 7.12 (d, <i>J</i> = 15.1 Hz, 1H), 6.86 (d, <i>J</i> = 15.2 Hz, 1H), 3.88 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.64, 171.65, 169.07, 167.18, 153.94, 152.46, 141.89, 141.68, 131.78, 129.62, 129.29, 127.12, 127.04, 119.30, 107.95, 60.19, 55.95. M.p.: 140.1–141.7 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>N<sub>3</sub>O<sub>7</sub>S: 484.1100, found: 484.1105. HPLC: <i>t</i><sub>R</sub> 15.5 min, purity 97.2%.</div></div><div id="sec6_8_5_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106">6.8.5.38.  <i>N</i><sup>2</sup>-Hydroxy-<i>N</i><sup>5</sup>-(4-(4-(3,4,5-trimethoxybenzoyl) thiazol-2-yl) phenyl)thiophene-2,5-dicarboxamide (<b>17i</b>)</h5><div class="NLM_p last">White solid, yield: 25%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.49 (s, 1H), 10.73 (s, 1H), 9.33 (s, 1H), 8.60 (s, 1H), 8.11 (d, <i>J</i> = 3.8 Hz, 1H), 8.04 (d, <i>J</i> = 8.6 Hz, 2H), 7.97 (d, <i>J</i> = 8.6 Hz, 2H), 7.68 (s, 1H), 7.64 (s, 2H), 3.87 (d, <i>J</i> = 5.9 Hz, 6H), 3.79 (d, <i>J</i> = 4.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.65, 167.03, 160.83, 153.98, 152.48, 141.91, 140.92, 131.77, 129.57, 127.94, 127.80, 127.06, 124.91, 120.70, 107.96, 60.21, 55.97. M.p.: 134.1–136.5 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>22</sub>N<sub>3</sub>O<sub>7</sub>S<sub>2</sub>: 540.0821, found: 540.0822. HPLC: <i>t</i><sub>R</sub> 16.1 min, purity 96.6%.</div></div><div id="sec6_8_5_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107">6.8.5.39.  <i>N</i>-(2-Aminophenyl)-2-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)acetamide (<b>20a</b>)</h5><div class="NLM_p last">White solid, yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.65 (s, 2H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 6.91 (t, <i>J</i> = 7.0 Hz, 1H), 6.75 (d, <i>J</i> = 8.6 Hz, 2H), 6.72 (s, 1H), 6.71–6.66 (m, 1H), 6.54 (t, <i>J</i> = 7.2 Hz, 1H), 5.82 (s, 1H), 4.84 (s, 2H), 3.99 (d, <i>J</i> = 5.8 Hz, 2H), 3.87 (s, 6H), 3.80 (d, <i>J</i> = 5.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 183.32, 168.33, 158.38, 158.88, 154.45, 152.91, 152.84, 143.82, 142.35, 140.46, 132.20, 127.49, 127.38, 126.11, 122.42, 121.28, 116.79, 116.68, 108.39, 60.69, 56.39, 18.30. M.p.: 141.8–143.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub>S: 519.1624, found: 519.1633. HPLC: <i>t</i><sub>R</sub> 16.4 min, purity 98.4%.</div></div><div id="sec6_8_5_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108">6.8.5.40.  <i>N</i>-(2-Aminophenyl)-3-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)propanamide (<b>20b</b>)</h5><div class="NLM_p last">White solid, yield: 28%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 8.41 (s, 1H), 7.76 (d, <i>J</i> = 8.6 Hz, 2H), 7.65 (s, 2H), 7.20–7.13 (m, 1H), 6.96–6.84 (m, 1H), 6.72 (t, <i>J</i> = 8.0 Hz, 3H), 6.57–6.49 (m, 1H), 6.44 (s, 1H), 5.75 (s, 1H), 4.85 (s, 2H), 3.87 (s, 6H), 3.79 (s, 3H), 3.43 (dd, <i>J</i> = 12.5, 6.5 Hz, 2H), 2.64 (t, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 177.89, 167.22, 153.12, 152.53, 143.97, 134.78, 132.08, 131.82, 130.42, 127.93, 126.84, 108.28, 60.22, 56.00. M.p.: 134.6–136.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>29</sub>N<sub>4</sub>O<sub>5</sub>S: 533.1780, found: 533.1789. HPLC: <i>t</i><sub>R</sub> 17.3 min, purity 97.8%.</div></div><div id="sec6_8_5_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109">6.8.5.41.  <i>N</i>-(2-Aminophenyl)-7-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)heptanamide (<b>20c</b>)</h5><div class="NLM_p last">White solid, yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.78 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 7.14 (d, <i>J</i> = 7.2 Hz, 1H), 6.93–6.85 (m, 1H), 6.71 (d, <i>J</i> = 7.8 Hz, 1H), 6.54 (d, <i>J</i> = 7.2 Hz, 1H), 5.82 (s, 1H), 4.80 (s, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 3.62 (s, 2H), 2.39–2.23 (m, 4H), 1.61 (s, 3H), 1.10–0.96 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.97, 173.37, 167.25, 152.48, 141.80, 131.80, 127.09, 125.21, 119.34, 115.87, 107.98, 60.23, 55.98, 51.17, 33.23, 28.47, 24.86, 24.31. M.p.: 146.4–148.1 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>32</sub>H<sub>37</sub>N<sub>4</sub>O<sub>5</sub>S: 589.2406, found: 589.2409. HPLC: <i>t</i><sub>R</sub> 17.4 min, purity 96.8%.</div></div><div id="sec6_8_5_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110">6.8.5.42.  <i>N</i>-Hydroxy-2-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)acetamide (<b>22a</b>)</h5><div class="NLM_p last">White solid, yield: 24%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 8.73 (s, 1H), 8.57 (s, 1H), 7.97 (d, <i>J</i> = 8.8 Hz, 2H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.64 (s, 2H), 5.86 (s, 1H), 3.88 (s, 6H), 3.80 (s, 3H), 3.72 (s, 2H), 2.39– 2.23 (m, 4H), 1.61 (s, 3H), 1.10–0.96 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 177.98, 167.22, 153.12, 152.53, 150.90, 143.97, 134.78, 132.08, 131.82, 130.42, 127.93, 126.84, 108.28, 61.23, 57.07, 53.53. M.p.: 120.1–121.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>6</sub>S: 444.1151, found: 444.1156. HPLC: <i>t</i><sub>R</sub> 18.1 min, purity 98.5%.</div></div><div id="sec6_8_5_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111">6.8.5.43.  <i>N</i>-Hydroxy-3-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)propanamide (<b>22b</b>)</h5><div class="NLM_p last">White solid, yield: 18%.<sup>1</sup>H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 8.69 (s, 1H), 8.53 (s, 1H), 7.84 (d, <i>J</i> = 8.8 Hz, 2H), 7.70 (d, <i>J</i> = 8.8 Hz, 2H), 7.54 (s, 2H), 5.83 (s, 1H), 3.87 (s, 6H), 3.75 (s, 3H), 3.72 (s, 2H), 2.62 (dd, <i>J</i> = 4.4 Hz, 4.0 Hz, 2H), 1.61 (s, 3H), 1.10–0.96 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 181.35, 158.39, 154.45, 152.52, 141.12, 132.24, 127.43, 126.17, 122.47, 121.28, 116.46, 108.39, 61.45, 56.38, 52.38, 16.30. M.p.: 132.6–133.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for: C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>6</sub>S: 458.1308, found: 458.1302. HPLC: <i>t</i><sub>R</sub> 18.1 min, purity 95.9%.</div></div><div id="sec6_8_5_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112">6.8.5.44.  <i>N</i>-Hydroxy-7-((4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)amino)heptanamide (<b>22c</b>)</h5><div class="NLM_p last">White solid, yield: 20%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (s, 2H), 5.82 (s, 1H), 3.87 (s, 6H), 3.79 (s, 3H), 3.56 (s, 2H), 2.33 (t, <i>J</i> = 7.2 Hz, 2H), 2.01–1.92 (m, 4H), 1.57 (t, <i>J</i> = 7.2 Hz, 2H), 1.49 (t, <i>J</i> = 6.8 Hz, 2H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.63, 171.50, 168.92, 167.17, 153.94, 152.46, 141.89, 131.78, 129.29, 127.13, 119.30, 107.95, 60.19, 55.95, 36.26, 32.14, 24.77, 21.25. M.p.: 129.7–131.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>6</sub>S: 514.1934, found: 514.1937. HPLC: <i>t</i><sub>R</sub> 18.2 min, purity 97.2%.</div></div><div id="sec6_8_5_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113">6.8.5.45.  <i>N</i>-(2-Aminophenyl)-5-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)pent-4-ynamide (<b>25a</b>)</h5><div class="NLM_p last">White solid, yield: 23%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.28 (s, 1H), 8.65 (s, 1H), 8.00 (d, <i>J</i> = 7.3 Hz, 2H), 7.60 (s, 2H), 7.55 (d, <i>J</i> = 7.7 Hz, 2H), 7.14 (d, <i>J</i> = 7.3 Hz, 1H), 6.90 (d, <i>J</i> = 6.8 Hz, 1H), 6.72 (d, <i>J</i> = 7.5 Hz, 1H), 6.55 (d, <i>J</i> = 6.8 Hz, 1H), 4.84 (s, 2H), 3.86 (s, 6H), 3.79 (s, 3H), 2.77 (s, 2H), 2.64 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.76, 169.53, 166.61, 154.20, 152.57, 142.27, 142.06, 132.36, 131.78, 130.38, 126.61, 126.16, 125.69, 123.18, 116.25, 115.87, 108.05, 60.32, 56.07, 34.71, 15.55. M.p.: 140.2–141.9 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>28</sub>N<sub>3</sub>O<sub>5</sub>S: 542.1671, found: 542.1674. HPLC: <i>t</i><sub>R</sub> 18.2 min, purity 97.9%.</div></div><div id="sec6_8_5_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114">6.8.5.46.  <i>N</i>-Hydroxy-5-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)pent-4-ynamide (<b>27a</b>)</h5><div class="NLM_p last">White solid, yield: 33%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 8.83 (s, 1H), 8.67 (s, 1H), 8.01 (d, <i>J</i> = 6.8 Hz, 2H), 7.61 (s, 2H), 7.54 (d, <i>J</i> = 7.0 Hz, 2H), 3.87 (s, 6H), 3.80 (s, 3H), 2.68 (s, 2H), 2.27 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.62, 172.85, 166.48, 154.13, 152.48, 141.97, 132.25, 131.69, 130.29, 126.52, 125.32, 107.98, 92.36, 80.00, 60.21, 55.98, 32.92, 14.86. M.p.: 133.7–135.2 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub>S: 467.1199, found: 467.1193. HPLC: <i>t</i><sub>R</sub> 17.7 min, purity 98.0%.</div></div><div id="sec6_8_5_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115">6.8.5.47.  (<i>E</i>)-<i>N</i>-(2-Aminophenyl)-3-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)acrylamide (<b>30a</b>)</h5><div class="NLM_p last">White solid, yield: 29%. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 8.68 (s, 1H), 8.11 (d, <i>J</i> = 7.9 Hz, 2H), 7.80 (d, <i>J</i> = 7.9 Hz, 2H), 7.64 (s, 2H), 7.59 (s, 1H), 7.37 (d, <i>J</i> = 7.6 Hz, 1H), 7.02 (d, <i>J</i> = 15.9 Hz, 1H), 6.93 (t, <i>J</i> = 7.2 Hz, 1H), 6.76 (d, <i>J</i> = 7.9 Hz, 1H), 6.59 (t, <i>J</i> = 7.4 Hz, 1H), 4.96 (s, 2H), 3.88 (s, 6H), 3.81 (s, 3H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 184.65, 166.65, 163.24, 154.21, 152.52, 142.00, 141.59, 138.40, 137.22, 133.15, 131.72, 130.35, 128.63, 127.00, 125.88, 124.70, 123.75, 116.16, 108.01, 60.24, 56.02. M.p.: 137.3–138.5 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub>S: 516.1515, found: 516.1518. HPLC: <i>t</i><sub>R</sub> 16.8 min, purity 96.0%.</div></div><div id="sec6_8_5_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116">6.8.5.48.  (<i>E</i>)-<i>N</i>-Hydroxy-3-(4-(4-(3,4,5-trimethoxybenzoyl)thiazol-2-yl)phenyl)acrylamide (<b>32a</b>)</h5><div class="NLM_p last">White solid, yield: 12%.<sup>1</sup>H NMR (400 MHz, DMSO) δ 10.85 (s, 1H), 9.01 (d, J = 92.2 Hz, 1H), 8.66 (s, 1H), 8.06 (d, <i>J</i> = 8.1 Hz, 2H), 7.74 (d, <i>J</i> = 8.1 Hz, 2H), 7.63 (s, 2H), 7.51 (d, <i>J</i> = 15.8 Hz, 1H), 6.58 (d, <i>J</i> = 15.8 Hz, 1H), 3.87 (s, 6H), 3.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 184.68, 166.71, 162.51, 154.23, 152.55, 142.04, 137.32, 137.18, 133.06, 131.75, 130.33, 128.54, 126.96, 120.68, 108.04, 60.29, 56.04. M.p.: 141.7–143.0 °C. HRMS (ESI-Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O<sub>6</sub>S: 441.1042, found: 441.1044. HPLC: <i>t</i><sub>R</sub> 16.8 min, purity 95.3%.</div></div></div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117">6.9.  Biological Assays</h3><div id="sec6_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118">6.9.1.  Cell Culture and Cytotoxicity Assay</h4><div class="NLM_p last">The cancer cell lines were purchased from American Type Culture Collection (ATCC). The cytotoxicity of all compounds was evaluated against the HCT-116 (human colon cancer cell), B16-F10 (mouse melanoma cell), and A549 (human lung cancer cell) cell lines using the standard MTT assay <i>in vitro</i>, Jurkat (human T lymphocyte cell) treating CCK-8 assay. All of the cancer cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). The cells were seeded into 96-well plates at a density of 5000 cells/well. After being incubated overnight, the cells were treated with 100 μL of medium with 0.1% DMSO containing our antitubulin compounds at different concentrations and cultured at 37 °C for another 48 h. The MTT or CCK-8 (0.5 mg/mL in PBS) was added and incubated for another 4 h, and then the absorbance was detected with a microplate reader at a wavelength of 570 nm. The IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Prism. All of the experiments were repeated in at least three independent experiments.</div></div><div id="sec6_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119">6.9.2.  <i>In Vitro</i> HDAC Inhibition Assay</h4><div class="NLM_p last">The HDAC1 (#ab101661), HDAC6 (#ab42632), and HDAC7 (#ab101660) enzymes were purchased from Abcam, HDAC3 (#BML-SE515-0050) was purchased from ENZO Inc, and HDAC8 (#H90-30H-05) was purchased from SignalChem. The reaction mixture contained 25 mM Tris (pH 8.0), 1 mM MgCl<sub>2</sub>, 0.1 mg/mL BSA, 137mM NaCl, 2.7 mM KCl, HDAC (HDAC1: 7.2 ng/well; HDAC3: 3.4 ng/well; HDAC6: 15 ng/well; HDAC7: 1.6 ng/well; HDAC8: 22 ng/well) in a total volume of 40 μL. The test compounds (3-fold dilution, 10 concentrations) were diluted in 10% DMSO, and 5 μL of the dilution was added and preincubated with purified recombinant HDAC at room temperature for 5 min before substrate addition. Finally, the enzyme–substrate (Ac-Leu-Gly-Lys (Ac)-AMC, 10 μM for HDAC1, 3, and 6; Ac-Leu-Gly-Lys (Tfa)-AMC, 2 μM for HDAC7, 8) was added and the plate was incubated at 37 °C for 30 min in a final volume of 50 μL. The reaction was quenched with 50 μL of HDAC assay developer (1 mg/mL trypsin and 2 μM TSA in assay buffer) for 30 min at room temperature. The assay was performed by quantitating the fluorescent product amount in solution following an enzyme reaction. Fluorescence was then analyzed with an excitation of 350–360 nm and an emission wavelength of 450–460 nm at a TECAN microtiter plate reader. The IC<sub>50</sub> values were calculated using nonlinear regression with normalized dose–response fit using Prism GraphPad software. All experiments were independently performed at least three times.</div></div><div id="sec6_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120">6.9.3.  <i>In Vitro</i> Tubulin Polymerization Assay</h4><div class="NLM_p">Pig brain microtubule protein was isolated <i>via</i> three cycles of temperature-dependent assembly/disassembly in 100 mM PIPES (pH 6.5), 1 mM GTP, 1 mM MgSO<sub>4</sub>, 2 mM EGTA, and 1 mM 2-mercaptoethanol. Glycerol and phenylmethylsulfonyl fluoride were added to 4 M and 0.2 mM, respectively, in the first cycle of polymerization. Tubulin was prepared from microtubule protein by phosphocellulose (P11) chromatography and stored at −70 °C.</div><div class="NLM_p last">Tubulin was mixed with different concentrations of a compound in PEM buffer (100 mM PIPES, 1 mM MgCl<sub>2</sub>, and 1 mM EGTA) containing 1 mM GTP and 5% glycerol. Microtubule polymerization was detected using a spectrophotometer at 340 nm at 37 °C. The plateau absorbance values were used for calculations.</div></div><div id="sec6_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121">6.9.4.  Immunofluorescence Staining</h4><div class="NLM_p last">B16-F10 cells were seeded on glass coverslips in 24-well plates and then treated with vehicle control 0.1% DMSO, compound <b>SMART</b> (60 nM), compound <b>15c</b> (60 nM), and compound <b>32a</b> (60 nM) for 6 h. The cells were fixed with 4% paraformaldehyde and then penetrated with PBS containing 0.2% Triton X-100. After blocking for 30 min by adding 100 μL of goat serum albumin at room temperature, the cells were incubated with a monoclonal antibody (anti-β-tubulin) at 37 °C for 1 h. Then, the cells were washed three times with PBS following staining with the fluorescence secondary antibody. Nucleus was labeled with 4,6-diamidino-2-phenylindole (DAPI). The cells were finally visualized using a fluorescence microscope.</div></div><div id="sec6_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122">6.9.5.  Wound-Healing Assay</h4><div class="NLM_p last">B16-F10 cells were seeded and incubated in a six-well plate overnight. Scratches were made in confluent monolayers by a 200 μL pipette tip. Then, wounds were washed twice with media to remove debris and uprooted cells. The cells were treated with <b>SMART</b> (60 nM) and different concentrations (0, 20, 40, 60 nM) of compound <b>15c</b>. Images were obtained using phase-contrast microscopy at 0 and 24 h. The migration distance of cells in the wound area was measured manually.</div></div><div id="sec6_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123">6.9.6.  Colony Formation Assay</h4><div class="NLM_p last">B16-F10 cells (1000 units) were counted and seeded in 6-well plates. After being cultured for 24 h at 37 °C, the medium was replaced with a medium added with compound <b>SMART</b> and <b>15c</b> at the indicated concentrations of 0, 20, 40, and 60 nM. After 24 h treatment, the medium was changed to normal. Cultured for another 10–14 days, the colonies were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% Crystal Violet for 15 min. Following washing with PBS, the colonies were then photographed and quantified using ImageJ.</div></div><div id="sec6_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124">6.9.7.  Analysis of Cancer Cell Apoptosis</h4><div class="NLM_p last">B16-F10 cells were seeded into 6-well plates and cultured overnight. After treating with <b>15c</b> for 48 h, the cells were harvested and suspended in a binding buffer containing Annexin V-FITC and PI and then analyzed with a flow cytometer (BD FACSCanto II).</div></div><div id="sec6_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125">6.9.8.  Cell Cycle Analysis</h4><div class="NLM_p last">B16-F10 cells (1000 units) were seeded into 6-well plates and cultured overnight. The cells were treated with <b>15c</b> (25, 50, 100 nM), <b>SMART</b> (100 nM), and <b>MS-275</b> (100 nM) for 48 h. The collected cells were fixed at 4 °C with 70% ethanol overnight. The fixed cells were washed and resuspended using PBS with RNase A and PI. After being incubated for 30 min in the dark, the samples were analyzed for the DNA content with flow cytometry (BD FACSCanto II).</div></div><div id="sec6_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126">6.9.9.  Western Blot Analysis</h4><div class="NLM_p last">B16-F10 cells were seeded (5 × 10<sup>5</sup> cells/well) into 6-well transparent plates (Corning), exposed to compounds <b>15c</b> at 0.1, 0.5, 1.0, and 2.0 μM for 12 h, and then harvested and washed with PBS three times. Then, the cells were lysed with RIPA Cell Lysis Buffer on ice for 30 min. The cell lysates were centrifuged at 12 000<i>g</i> for 20 min at 4 °C. The supernatant was collected and the BCA Protein Assay was used to determine the protein concentration. Equal amounts of protein (30 μg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then, the proteins were transferred to poly(vinylidene fluoride) membranes and were blocked with 5% BSA for 2 h. The membranes were incubated with the primary antibody overnight at 4 °C and were washed with TBST three times. Then, the mixture was incubated with the secondary antibody for 1.5 h. The membranes were washed with TBST three times. The immunoblots were visualized by Odyssey Infrared Imaging. The antibodies, including acetylated histone 3 (#ab177177), histone 3 (#9715S), and GAPDH (#sc-47724), were purchased from Abcam.</div></div><div id="sec6_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127">6.9.10.  Molecular Modeling</h4><div class="NLM_p last">The molecular modeling studies were performed with Schrodinger Molecular Modeling Suite 2011 (Schrodinger LLC, New York, NY) running on a Dell window workstation. The crystal structures of DAMA-colchicine (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>) and HDAC3 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>) were retrieved from the RCSB Protein Data Bank (<a href="http://www.rcsb.org/pdb" class="extLink">http://www.rcsb.org/pdb</a>). <b>15c</b> was prepared using the Ligprep module, and they were docked into the colchicine/HDAC3 site by the Glide module in the Schrodinger Suite. The best docking complexes were subject to restricted molecular dynamics to release any strains using the Macromodel module with the OPLS-2005 force field. The ligand and its surrounding residues within 20 Å could move freely, while the outer atoms are frozen.</div></div><div id="sec6_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128">6.9.11.  <i>In Vivo</i> Antitumor Evaluation</h4><div class="NLM_p last">The animal experiment was performed with the approval of the National Institutional Animal Care and Ethical Committee of Southern Medical University. C57 mice, 6–8 weeks old, purchased from SPF (Beijing) Biotechnology Co., Ltd., were used to study the inhibition effect of <b>15c</b> on the subcutaneous transplanted model of melanoma cells. Logarithmic growth phase B16-F10 cells (4 × 10<sup>6</sup> per mL) were suspended in PBS before injecting into mice. Tumors were established by inoculating subcutaneously with 200 μL containing 3 × 10<sup>5</sup> cells into each mouse. Mice were divided into control or treatment groups (<i>n</i> = 8) randomly. Test compounds were dissolved in a mixed solvent, including ethanol, polyoxyethylene castor oil, and physiological saline (1.25:1.25:7.5) to produce the desired concentrations. The vehicle control solution was formulated with the solvent only. A total of 200 μL of the drug treatment or vehicle control was administered <i>via</i> i.p. injection once a day for 14 days. Body weight was monitored during the entire experiment period to assess acute toxicity. Tumor volume was measured with a caliper and calculated using the formula <i>a</i> × <i>b</i><sup>2</sup> × 0.5, where <i>a</i> and <i>b</i> represent the larger and smaller diameters, respectively. Mice were sacrificed 14 days after the initiation of the experiment, and the tumors were weighed. Tumor Growth Inhibition value (TGI) was calculated using the formula: TGI(%) = [1 – Wt/Wv] × 100%, where Wt and Wv are the mean tumor weight of the treatment group and vehicle control. The harvested organs (liver, kidney) were fixed in 4% paraformaldehyde, processed into paraffin routinely, stained with hematoxylin and eosin (H&E), and captured using a microscope.</div></div><div id="sec6_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129">6.9.12.  Immunohistochemistry (IHC)</h4><div class="NLM_p last">Formalin-fixed paraffin-embedded tumor sections were submitted to LandM Co., Ltd. to conduct the immunohistochemistry assay. In brief, tumor sections were deparaffinized, rehydrated, and immersed in 3% H<sub>2</sub>O<sub>2</sub> to inactivate endogenous peroxidase. For antigen retrieval, slides were incubated in buffer with pH = 9 at 80 °C overnight. After PBS washing, the slides were blocked with fat-free milk and incubated with primary antibody (Ac-H3) at 4 °C overnight. The secondary antibody (IgG) was added, and then Mayer’s hematoxylin solution was used for counterstaining. For hematoxylin, the tumor sections were incubated in hematoxylin solution and then counterstained with eosin, followed by microscope observation and photography.</div></div><div id="sec6_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130">6.9.13.  <i>I<i>n</i> Vivo</i> Cardiotoxicity by ECG and Blood Cell Analysis</h4><div class="NLM_p last">The animal experiment was performed with the approval of the National Institutional Animal Care and Ethical Committee of Southern Medical University. C57 mice, 6–8 weeks old, purchased from SPF(Beijing) Biotechnology Co., Ltd., were used to study the cardiotoxicity of the tested compounds. The tested compounds were administered <i>via</i> intragastric gavage once a day for 14 days. The instrument used: PowerLab (ADI Instruments Castle Hill, NSW, Australia). Electrodes were inserted into the right forelimb (cathode), left limb (anode), and right hind limb (ground) subcutaneously. The right hind limb serves as the reference electrode. The whole blood was also collected into a heparin sodium anticoagulation tube used for blood cell analysis.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00413" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00413?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00413</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Copies of Compounds <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, HPLC spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">4A69 (HDAC3 PDB) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">4O2B (Tubulin PDB) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_001.pdf">jm1c00413_si_001.pdf (9.2 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_002.csv">jm1c00413_si_002.csv (5.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_003.pdb">jm1c00413_si_003.pdb (447.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_004.pdb">jm1c00413_si_004.pdb (789.91 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00413" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Chen</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5668-6572" title="Orcid link">https://orcid.org/0000-0001-5668-6572</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#670d040f0209555627140a1249020312490409"><span class="__cf_email__" data-cfemail="214b4249444f131061524c540f4445540f424f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaopeng Peng</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingxuan Chen</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Li</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiqiang Sun</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichang Ren</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junli Huang</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Southern Medical University, Guangzhou 510515, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.P. and J.C. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6655-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the scientific research project of high-level talents (No. C1051008) in Southern Medical University of China; the Thousand Youth Talents Program (No. C1080092) from the Organization Department of the CPC Central Committee, China; and the International Science and Technology Cooperation Projects of Guangdong Province (No. G819310411).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations used</td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">histone deacetylase inhibitor</p></td></tr><tr><td class="NLM_term">SMART</td><td class="NLM_def"><p class="first last">4-substituted methoxybenzoyl-aryl-thiazoles</p></td></tr><tr><td class="NLM_term">SAI</td><td class="NLM_def"><p class="first last">substituted-2-aryl imidazoles</p></td></tr><tr><td class="NLM_term">ABP</td><td class="NLM_def"><p class="first last">6-Aryl-2-Benzoyl-Pyridine/Phenyl</p></td></tr><tr><td class="NLM_term">TMP</td><td class="NLM_def"><p class="first last">trimethoxyphenyl</p></td></tr><tr><td class="NLM_term">RI</td><td class="NLM_def"><p class="first last">resistance index</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity index</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i135">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 80 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turecki, G.</span></span> <span> </span><span class="NLM_article-title">Transgenerational epigenetic inheritance: an open discussion</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.2217/epi.15.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2217%2Fepi.15.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26344807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CqsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=781-790&author=C.+Nagyauthor=G.+Turecki&title=Transgenerational+epigenetic+inheritance%3A+an+open+discussion&doi=10.2217%2Fepi.15.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Transgenerational epigenetic inheritance: an open discussion</span></div><div class="casAuthors">Nagy, Corina; Turecki, Gustavo</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">781-790</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Much controversy surrounds the idea of transgenerational epigenetics.  Recent papers argue that epigenetic marks acquired through experience are passed to offspring, but as in much of the field of epigenetics, there is lack of precision in the definitions and perhaps too much eagerness to translate animal research to humans.  Here, we review operational definitions of transgenerational inheritance and the processes of epigenetic programming during early development.  Subsequently, based on this background, we critically examine some recent findings of studies investigating transgenerational inheritance.  Finally, we discuss possible mechanisms that may explain transgenerational inheritance, including transmission of an epigenetic blueprint, which may predispose offspring to specific epigenetic patterning.  Taken together, we conclude that presently, the evidence suggesting that acquired epigenetic marks are passed to the subsequent generation remains limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobZ4pI0dHX4bVg90H21EOLACvtfcHk0lhqDF3DzcsJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CqsbzI&md5=5d13e7d3103659298e2257d615b58c30</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.46%26sid%3Dliteratum%253Aachs%26aulast%3DNagy%26aufirst%3DC.%26aulast%3DTurecki%26aufirst%3DG.%26atitle%3DTransgenerational%2520epigenetic%2520inheritance%253A%2520an%2520open%2520discussion%26jtitle%3DEpigenomics%26date%3D2015%26volume%3D7%26spage%3D781%26epage%3D790%26doi%3D10.2217%2Fepi.15.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefsbol, T. O.</span></span> <span> </span><span class="NLM_article-title">Epigenetic linkage of aging, cancer and nutrition</span>. <i>J. Exp. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1242/jeb.107110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1242%2Fjeb.107110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25568452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2Mros1SltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2015&pages=59-70&author=M.+Danielauthor=T.+O.+Tollefsbol&title=Epigenetic+linkage+of+aging%2C+cancer+and+nutrition&doi=10.1242%2Fjeb.107110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic linkage of aging, cancer and nutrition</span></div><div class="casAuthors">Daniel Michael; Tollefsbol Trygve O</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of experimental biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">59-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic mechanisms play a pivotal role in the expression of genes and can be influenced by both the quality and quantity of diet.  Dietary compounds such as sulforaphane (SFN) found in cruciferous vegetables and epigallocatechin-3-gallate (EGCG) in green tea exhibit the ability to affect various epigenetic mechanisms such as DNA methyltransferase (DNMT) inhibition, histone modifications via histone deacetylase (HDAC), histone acetyltransferase (HAT) inhibition, or noncoding RNA expression.  Regulation of these epigenetic mechanisms has been shown to have notable influences on the formation and progression of various neoplasms.  We have shown that an epigenetic diet can influence both cellular longevity and carcinogenesis through the modulation of certain key genes that encode telomerase and p16.  Caloric restriction (CR) can also play a crucial role in aging and cancer.  Reductions in caloric intake have been shown to increase both the life- and health-span in a variety of animal models.  Moreover, restriction of glucose has been demonstrated to decrease the incidence of age-related diseases such as cancer and diabetes.  A diet rich in compounds such as genistein, SFN and EGCG can positively modulate the epigenome and lead to many health benefits.  Also, reducing the quantity of calories and glucose in the diet can confer an increased health-span, including reduced cancer incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmp55G3JtI_r7NkxioyDXTfW6udTcc2eap-JTypDfnELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mros1SltQ%253D%253D&md5=b2b42a9020dc1375b45f8dadce6ef014</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1242%2Fjeb.107110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjeb.107110%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DM.%26aulast%3DTollefsbol%26aufirst%3DT.%2BO.%26atitle%3DEpigenetic%2520linkage%2520of%2520aging%252C%2520cancer%2520and%2520nutrition%26jtitle%3DJ.%2520Exp.%2520Biol.%26date%3D2015%26volume%3D218%26spage%3D59%26epage%3D70%26doi%3D10.1242%2Fjeb.107110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpaknia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.critrevonc.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29958625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1-18&author=A.+Mohammadiauthor=A.+Sharifiauthor=R.+Pourpakniaauthor=S.+Mohammadianauthor=A.+Sahebkar&title=Manipulating+macrophage+polarization+and+function+using+classical+HDAC+inhibitors%3A+Implications+for+autoimmunity+and+inflammation&doi=10.1016%2Fj.critrevonc.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span></div><div class="casAuthors">Mohammadi Asadollah; Sharifi Atefeh; Pourpaknia Reza; Mohammadian Saeed; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases.  Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury.  However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis.  Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors.  In this review we discuss how post-translational modifications of histones influence the innate and adaptive immunity through macrophage survival, proliferation, polarization and functional responses.  We also discuss how emerging classes of pharmacological agents which developed for use as anti-cancer agents, have been applied as anti-inflammatory drugs to treat macrophage-mediated inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA9U7N2BuEAGLFM_lbR1VmfW6udTcc2eYSLhM-pvo4x7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D&md5=9c7e9610928e1158a2d2b73d95dd3cdc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DSharifi%26aufirst%3DA.%26aulast%3DPourpaknia%26aufirst%3DR.%26aulast%3DMohammadian%26aufirst%3DS.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DManipulating%2520macrophage%2520polarization%2520and%2520function%2520using%2520classical%2520HDAC%2520inhibitors%253A%2520Implications%2520for%2520autoimmunity%2520and%2520inflammation%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D128%26spage%3D1%26epage%3D18%26doi%3D10.1016%2Fj.critrevonc.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges of HDAC inhibitors in cancer therapeutics</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fbs.acr.2018.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29551127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=183-211&author=J.+J.+McClureauthor=X.+Liauthor=C.+J.+Chou&title=Advances+and+challenges+of+HDAC+inhibitors+in+cancer+therapeutics&doi=10.1016%2Fbs.acr.2018.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges of HDAC inhibitors in cancer therapeutics</span></div><div class="casAuthors">McClure, Jesse J.; Li, Xiaoyang; Chou, C. James</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-211</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Since the identification and cloning of human histone deacetylases (HDACs) and the rapid approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma, the field of HDAC biol. has met many initial successes.  However, many challenges remain due to the complexity involved in the lysine posttranslational modifications, epigenetic transcription regulation, and nonepigenetic cellular signaling cascades.  In this chapter, we will: review the discovery of the first HDAC inhibitor and present discussion regarding the future of next-generation HDAC inhibitors, give an overview of different classes of HDACs and their differences in lysine deacylation activity, discuss different classes of HDAC inhibitors and their HDAC isoenzyme preferences, and review HDAC inhibitors' preclin. studies, their clin. trials, their pharmacokinetic challenges, and future direction.  We will also discuss the likely reason for the failure of multiple HDAC inhibitor clin. trials in malignancies other than lymphoma and multiple myeloma.  In addn., the potential mol. mechanism(s) that may play a key role in the efficacy and therapeutic response rate in the clinic and the likely patient population for HDAC therapy will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUDUqssP9cRrVg90H21EOLACvtfcHk0ljmRst9VvZb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3L&md5=f5ccc3247e06654093d0fb2a17acd822</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26atitle%3DAdvances%2520and%2520challenges%2520of%2520HDAC%2520inhibitors%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26spage%3D183%26epage%3D211%26doi%3D10.1016%2Fbs.acr.2018.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0ljmRst9VvZb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">HDAC family: What are the cancer relevant targets?</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0lhCGEwzelA-Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glauben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, B.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors in models of inflammation-related tumorigenesis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.canlet.2008.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=19101082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=154-159&author=R.+Glaubenauthor=E.+Sonnenbergauthor=M.+Zeitzauthor=B.+Siegmund&title=HDAC+inhibitors+in+models+of+inflammation-related+tumorigenesis&doi=10.1016%2Fj.canlet.2008.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in models of inflammation-related tumorigenesis</span></div><div class="casAuthors">Glauben, Rainer; Sonnenberg, Elena; Zeitz, Martin; Siegmund, Britta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-159</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors have been described in detail for their anti-proliferative potency.  Recently, an anti-inflammatory property was characterized in vitro and in vivo.  This dual efficacy of HDAC inhibitors is highly attractive, since chronic inflammations such as ulcerative colitis are assocd. with an increased risk of developing carcinomas.  Addnl., in models of colitis and inflammation-induced tumorigenesis inflammation as well as tumor development was significantly inhibited by HDAC inhibitor treatment.  The mechanisms involved reach beyond the simple regulation of histone acetylation and deacetylation.  The currently known key target structures and mechanisms mediating this dual effect will be discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYsMPyjny5FbVg90H21EOLACvtfcHk0lhCGEwzelA-Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt78%253D&md5=5175ac399b14437c3cf31a396f630046</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGlauben%26aufirst%3DR.%26aulast%3DSonnenberg%26aufirst%3DE.%26aulast%3DZeitz%26aufirst%3DM.%26aulast%3DSiegmund%26aufirst%3DB.%26atitle%3DHDAC%2520inhibitors%2520in%2520models%2520of%2520inflammation-related%2520tumorigenesis%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D154%26epage%3D159%26doi%3D10.1016%2Fj.canlet.2008.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+deacetylases+and+their+inhibitors+in+cancer%2C+neurological+diseases+and+immune+disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lhCGEwzelA-Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520deacetylases%2520and%2520their%2520inhibitors%2520in%2520cancer%252C%2520neurological%2520diseases%2520and%2520immune%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovanella, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, S.</span></span> <span> </span><span class="NLM_article-title">Cytogenetic characterization of two human milk-derived cell line (HBL-100) passages differing in tumorigenicity</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=2334116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADyaK3c3ktVKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=113-117&author=M.+K.+Dhaliwalauthor=B.+C.+Giovanellaauthor=S.+Pathak&title=Cytogenetic+characterization+of+two+human+milk-derived+cell+line+%28HBL-100%29+passages+differing+in+tumorigenicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cytogenetic characterization of two human milk-derived cell line (HBL-100) passages differing in tumorigenicity</span></div><div class="casAuthors">Dhaliwal M K; Giovanella B C; Pathak S</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-7</span>
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    </div><div class="casAbstract">Using the trypsin-Giemsa staining technique, cytogenetic analysis was done to determine the karyotypic characteristics in cells from the early nontumorigenic passage 12 and the late tumorigenic passage 147 of the human breast milk-derived cell line HBL-100.  Acquisition of exclusive marker chromosomes in the late passage of HBL-100 may be responsible for the tumorigenic behavior of these cells in athymic nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHt4A3qNmkZBLDWw4HIq2sfW6udTcc2eZg3XcMpRylw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3ktVKguw%253D%253D&md5=0158e035844bdf71d5820b0599f4b5ad</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDhaliwal%26aufirst%3DM.%2BK.%26aulast%3DGiovanella%26aufirst%3DB.%2BC.%26aulast%3DPathak%26aufirst%3DS.%26atitle%3DCytogenetic%2520characterization%2520of%2520two%2520human%2520milk-derived%2520cell%2520line%2520%2528HBL-100%2529%2520passages%2520differing%2520in%2520tumorigenicity%26jtitle%3DAnticancer%2520Res.%26date%3D1990%26volume%3D10%26spage%3D113%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grabiec, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potempa, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic regulation in bacterial infections: targeting histone deacetylases</span>. <i>Crit. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1080/1040841X.2017.1373063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1080%2F1040841X.2017.1373063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28971711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2018&pages=336-350&author=A.+M.+Grabiecauthor=J.+Potempa&title=Epigenetic+regulation+in+bacterial+infections%3A+targeting+histone+deacetylases&doi=10.1080%2F1040841X.2017.1373063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic regulation in bacterial infections: targeting histone deacetylases</span></div><div class="casAuthors">Grabiec, Aleksander M.; Potempa, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">336-350</span>CODEN:
                <span class="NLM_cas:coden">CRVMAC</span>;
        ISSN:<span class="NLM_cas:issn">1040-841X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Pathogens have developed sophisticated strategies to evade the immune response, among which manipulation of host cellular epigenetic mechanisms plays a prominent role.  In the last decade, modulation of histone acetylation in host cells has emerged as an efficient strategy of bacterial immune evasion.  Virulence factors and metabolic products of pathogenic microorganisms alter expression and activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs) to suppress transcription of host defense genes through epigenetic changes in histone acetylation marks.  This new avenue of pathogen-host interactions is particularly important in light of introduction of HDAC inhibitors into clin. practice.  Considerable effort is currently being applied to better understand the effects of HDAC inhibitors on the quality of immune responses to pathogens and to characterize the therapeutic potential of these compds. in microbial infections.  In this review, we will discuss the recently discovered mechanisms utilized by bacteria to facilitate their survival within infected hosts through subversion of the host acetylation system and the effects of acetylation modulators, including HDAC inhibitors and bromodomain-contg. BET protein inhibitors, on innate immune responses against microbial pathogens.  Integration of these two lines of exptl. evidence provides crit. information on the perspectives of epigenetic therapies targeting protein acetylation in infectious diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWOyBcvPfLQ7Vg90H21EOLACvtfcHk0lhdnhG5y1rBpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsLzM&md5=6d621fdcfc6ea6ae7c56329f86448b56</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F1040841X.2017.1373063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1040841X.2017.1373063%26sid%3Dliteratum%253Aachs%26aulast%3DGrabiec%26aufirst%3DA.%2BM.%26aulast%3DPotempa%26aufirst%3DJ.%26atitle%3DEpigenetic%2520regulation%2520in%2520bacterial%2520infections%253A%2520targeting%2520histone%2520deacetylases%26jtitle%3DCrit.%2520Rev.%2520Microbiol.%26date%3D2018%26volume%3D44%26spage%3D336%26epage%3D350%26doi%3D10.1080%2F1040841X.2017.1373063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic protein families: a new frontier for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+protein+families%3A+a+new+frontier+for+drug+discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0lhdnhG5y1rBpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520protein%2520families%253A%2520a%2520new%2520frontier%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barneda-Zahonero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.molonc.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=22963873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=579-589&author=B.+Barneda-Zahoneroauthor=M.+Parra&title=Histone+deacetylases+and+cancer&doi=10.1016%2Fj.molonc.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Barneda-Zahonero, Bruna; Parra, Maribel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-589</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells.  Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).  Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types.  Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clin. research.  However, the contributions of specific HDACs to a given cancer type remain incompletely understood.  The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the anal. of patient samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOl-qXEsP2IrVg90H21EOLACvtfcHk0lijY0FaB5X_eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK&md5=7c294b40669bf079b1319391ee456642</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarneda-Zahonero%26aufirst%3DB.%26aulast%3DParra%26aufirst%3DM.%26atitle%3DHistone%2520deacetylases%2520and%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2012%26volume%3D6%26spage%3D579%26epage%3D589%26doi%3D10.1016%2Fj.molonc.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woster, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: novel therapeutics targeting epigenetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1021/jm501941q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501941q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=523-524&author=S.+J.+Conwayauthor=P.+M.+Wosterauthor=J.+K.+Shenauthor=G.+Georgauthor=S.+Wang&title=Epigenetics%3A+novel+therapeutics+targeting+epigenetics&doi=10.1021%2Fjm501941q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: Novel Therapeutics Targeting Epigenetics</span></div><div class="casAuthors">Conway, Stuart J.; Woster, Patrick M.; Shen, Jing-Kang; Georg, Gunda; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRBHbQISoP7Vg90H21EOLACvtfcHk0lijY0FaB5X_eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP&md5=589ff3da038c55adece6bcdbd6bbe461</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm501941q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501941q%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DShen%26aufirst%3DJ.%2BK.%26aulast%3DGeorg%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEpigenetics%253A%2520novel%2520therapeutics%2520targeting%2520epigenetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D523%26epage%3D524%26doi%3D10.1021%2Fjm501941q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">An overview of HDAC inhibitors and their synthetic routes</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190227221507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F1568026619666190227221507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30827245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1005-1040&author=X.+Pengauthor=G.+Liaoauthor=P.+Sunauthor=Z.+Yuauthor=J.+Chen&title=An+overview+of+HDAC+inhibitors+and+their+synthetic+routes&doi=10.2174%2F1568026619666190227221507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of HDAC Inhibitors and their Synthetic Routes</span></div><div class="casAuthors">Peng, Xiaopeng; Liao, Guochao; Sun, Pinghua; Yu, Zhiqiang; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1005-1040</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Epigenetics play a key role in the origin, development and metastasis of cancer.  Epigenetic processes include DNA methylation, histone acetylation, histone methylation, and histone phosphorylation, among which, histone acetylation is the most common one that plays important roles in the regulation of normal cellular processes, and is controlled by histone deacetylases (HDACs) and histone acetyltransferases (HATs).  HDACs are involved in the regulation of many key cellular processes, such as DNA damage repair, cell cycle control, autophagy, metab., senescence and chaperone function, and can lead to oncogene activation.  As a result, HDACs are considered to be an excellent target for anti-cancer therapeutics like histone deacetylase inhibitors (HDACi) which have attracted much attention in the last decade.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  The primary purpose of this paper is to summarize recent HDAC inhibitors and the synthetic routes as well as to discuss the direction for the future development of new HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhio1W1VLtLVg90H21EOLACvtfcHk0lhs--GiMiUf1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbjI&md5=f3498cd3fca8678c42e7dac3fd20faa8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190227221507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190227221507%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DAn%2520overview%2520of%2520HDAC%2520inhibitors%2520and%2520their%2520synthetic%2520routes%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1005%26epage%3D1040%26doi%3D10.2174%2F1568026619666190227221507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty years of HDAC inhibitors: 2020 insight and hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+years+of+HDAC+inhibitors%3A+2020+insight+and+hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0lhs--GiMiUf1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520years%2520of%2520HDAC%2520inhibitors%253A%25202020%2520insight%2520and%2520hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+a+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eb1T4zmZpD5y7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520a%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. G.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.7150/ijbs.9067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.7150%2Fijbs.9067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25013383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWntL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=757-770&author=Z.+Liauthor=W.+G.+Zhu&title=Targeting+histone+deacetylases+for+cancer+therapy%3A+from+molecular+mechanisms+to+clinical+implications&doi=10.7150%2Fijbs.9067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications</span></div><div class="casAuthors">Li, Zhiming; Zhu, Wei-Guo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">757-770</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Genetic abnormalities have been conventionally considered as hallmarks of cancer.  However, studies over the past decades have demonstrated that epigenetic regulation also participates in the development of cancer.  The fundamental patterns of epigenetic components, such as DNA methylation and histone modifications, are frequently altered in tumor cells.  Acetylation is one of the best characterized modifications of histones, which is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  HDACs are a group of enzymes which catalyze the removal of the acetyl groups of both histones and non-histone proteins.  HDACs are involved in modulating most key cellular processes, including transcriptional regulation, apoptosis, DNA damage repair, cell cycle control, autophagy, metab., senescence and chaperone function.  Because HDACs have been found to function incorrectly in cancer, various HDAC inhibitors are being investigated to act as cancer chemotherapeutics.  The primary purpose of this paper is to summarize recent studies of the links between HDACs and cancer, and further discuss the underlying mechanisms of anti-tumor activities of HDAC inhibitors and clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAiClMpknHObVg90H21EOLACvtfcHk0li0MuDZj84O7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWntL3O&md5=bd463eb902a1a78f54cab5fe166943fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.7150%2Fijbs.9067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.9067%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DW.%2BG.%26atitle%3DTargeting%2520histone%2520deacetylases%2520for%2520cancer%2520therapy%253A%2520from%2520molecular%2520mechanisms%2520to%2520clinical%2520implications%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2014%26volume%3D10%26spage%3D757%26epage%3D770%26doi%3D10.7150%2Fijbs.9067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomathi Priya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjan, M. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of histone deacetylase as antitumor agents: A critical review</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bioorg.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27239721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=18-42&author=M.+Manalauthor=M.+J.+Chandrasekarauthor=J.+Gomathi+Priyaauthor=M.+J.+Nanjan&title=Inhibitors+of+histone+deacetylase+as+antitumor+agents%3A+A+critical+review&doi=10.1016%2Fj.bioorg.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of histone deacetylase as antitumor agents: A critical review</span></div><div class="casAuthors">Manal, Mohammed; Chandrasekar, M. J. N.; Gomathi Priya, Jeyapal; Nanjan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-42</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (E.C. 3.5.1.98 - HDAC) is an amidohydrolase involved in deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital role in the epigenetic regulation of gene expression.  Due to its aberrant activity and over expression in several forms of cancer, HDAC is considered as a potential anticancer drug target.  HDAC inhibitors alter the acetylation status of histone and nonhistone proteins to regulate various cellular events such as cell survival, differentiation and apoptosis in tumor cells and thus exhibit anticancer activity.  Till date, four drugs, namely Vorinostat (SAHA), Romidepsin (FK-228), Belinostat (PXD-101) and Panobinostat (LBH-589) have been granted FDA approval for cancer and several HDAC inhibitors are currently in various phases of clin. trials, either as monotherapy and/or in combination with existing/novel anticancer agents.  Regardless of this, today scientific efforts have fortified the quest for newer and novel HDAC inhibitors that show isoform selectivity.  This review focuses on the chem. of the mols. of two classes of HDAC inhibitors, namely short chain fatty acids and hydroxamic acids, investigated so far as novel therapeutic agents for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdC7-JmHyErrVg90H21EOLACvtfcHk0li0MuDZj84O7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D&md5=82e5562d9b74dfef2d6077bbceccd505</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DManal%26aufirst%3DM.%26aulast%3DChandrasekar%26aufirst%3DM.%2BJ.%26aulast%3DGomathi%2BPriya%26aufirst%3DJ.%26aulast%3DNanjan%26aufirst%3DM.%2BJ.%26atitle%3DInhibitors%2520of%2520histone%2520deacetylase%2520as%2520antitumor%2520agents%253A%2520A%2520critical%2520review%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D67%26spage%3D18%26epage%3D42%26doi%3D10.1016%2Fj.bioorg.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenehjem, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat for the treatment of multiple myeloma: the evidence to date</span>. <i>J. Blood Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.2147/JBM.S69140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2FJBM.S69140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26504410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=269-276&author=H.+Baileyauthor=D.+D.+Stenehjemauthor=S.+Sharma&title=Panobinostat+for+the+treatment+of+multiple+myeloma%3A+the+evidence+to+date&doi=10.2147%2FJBM.S69140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat for the treatment of multiple myeloma: the evidence to date</span></div><div class="casAuthors">Bailey, Hanna; Stenehjem, David D.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Blood Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">JBMOB7</span>;
        ISSN:<span class="NLM_cas:issn">1179-2736</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow.  Survival of patients diagnosed with myeloma has significantly improved in the last decade, following the approval of novel agents.  Despite great strides achieved in the management of multiple myeloma, it is still considered an incurable disease as the majority of patients relapse after initiation of therapy.  Addnl., the duration of response generally decreases with an increasing no. of therapy lines.  The need to overcome resistance to therapy dictates research into more potent agents and those with novel mechanisms of action.  A therapeutic option for relapsed/refractory myeloma includes histone deacetylase inhibition.  Various histone deacetylase inhibitors, including the newly approved panobinostat, are currently under evaluation in this setting.  Panobinostat for multiple myeloma is used in combination with other potent therapeutic agents, such as proteasome inhibitors and steroids.  Ongoing research evaluating other panobinostat-contg. regimens will provide addnl. insight into its place in myeloma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg66vLqHlQjrVg90H21EOLACvtfcHk0li0MuDZj84O7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D&md5=cdff9d1bd461e6fb06e50c4708097951</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2147%2FJBM.S69140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJBM.S69140%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%26aulast%3DStenehjem%26aufirst%3DD.%2BD.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPanobinostat%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520the%2520evidence%2520to%2520date%26jtitle%3DJ.%2520Blood%2520Med.%26date%3D2015%26spage%3D269%26epage%3D276%26doi%3D10.2147%2FJBM.S69140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.2147/btt.s29965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2Fbtt.s29965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23459471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=47-60&author=K.+Ververisauthor=A.+Hiongauthor=T.+C.+Karagiannisauthor=P.+V.+Licciardi&title=Histone+deacetylase+inhibitors+%28HDACIs%29%3A+multitargeted+anticancer+agents&doi=10.2147%2Fbtt.s29965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span></div><div class="casAuthors">Ververis, Katherine; Hiong, Alison; Karagiannis, Tom C.; Licciardi, Paul V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs.  The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addn. to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth.  The family of HDAC inhibitors is large and diverse.  It includes a range of naturally occurring and synthetic compds. that differ in terms of structure, function, and specificity.  HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells.  HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies.  Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax).  More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma.  Many more clin. trials assessing the effects of various HDAC inhibitors on hematol. and solid malignancies are currently being conducted.  Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood.  Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be crit. for the advancement of these drugs, esp. to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents.  This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy.  Further, we outline the pharmacol. and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compds. in clin. studies to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAm6AJlxdHLVg90H21EOLACvtfcHk0li0MuDZj84O7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D&md5=288f04e51d214cef9edf5bc8a8c3c624</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2Fbtt.s29965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fbtt.s29965%26sid%3Dliteratum%253Aachs%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DHiong%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%253A%2520multitargeted%2520anticancer%2520agents%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D47%26epage%3D60%26doi%3D10.2147%2Fbtt.s29965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0lj3yICaRsWUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lj3yICaRsWUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracker, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politz, O.</span></span> <span> </span><span class="NLM_article-title">MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1388</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.biocel.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=17383217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1388-1405&author=H.+Hess-Stumppauthor=T.+U.+Brackerauthor=D.+Hendersonauthor=O.+Politz&title=MS-275%2C+a+potent+orally+available+inhibitor+of+histone+deacetylases%2D%2Dthe+development+of+an+anticancer+agent&doi=10.1016%2Fj.biocel.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent</span></div><div class="casAuthors">Hess-Stumpp, Holger; Bracker, Tomke Ute; Henderson, David; Politz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1388-1405</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the last few years it was found that beside genetic aberrations, epigenetic changes also play an important role in tumorigenesis.  Acetylation and deacetylation of histones have been found to contribute to a significant extent to epigenetic regulation of gene expression.  Analyses of various tumor models and patient samples revealed that the enzyme class of histone deacetylases is assocd. with many types of cancer and that, for example, over-expression of these enzymes leads to a disturbed balance between acetylation and deacetylation of histones, resulting in differences in the gene expression patterns between normal and cancer cells.  Consequently, this class of enzymes has been considered as a potential target for cancer therapy.  Numerous inhibitors have been identified and several are in clin. development.  Although, with SAHA, one inhibitor has been approved by the FDA for a tumor indication, many open questions remain regarding the mode of action of these inhibitors.  In this review, various aspects of preclin. and clin. research of the HDAC inhibitor MS-275 are described, to provide insight into the development of such a compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD6wh1LDkEpLVg90H21EOLACvtfcHk0lj3yICaRsWUWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWltLc%253D&md5=fdf0094118b83648161b4a457bb2e294</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DBracker%26aufirst%3DT.%2BU.%26aulast%3DHenderson%26aufirst%3DD.%26aulast%3DPolitz%26aufirst%3DO.%26atitle%3DMS-275%252C%2520a%2520potent%2520orally%2520available%2520inhibitor%2520of%2520histone%2520deacetylases--the%2520development%2520of%2520an%2520anticancer%2520agent%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1388%26epage%3D1405%26doi%3D10.1016%2Fj.biocel.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armanious, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradley, M. G.</span></span> <span> </span><span class="NLM_article-title">Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities</span>. <i>Trends Cardiovasc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.tcm.2018.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.tcm.2018.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29910109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=29-39&author=A.+Guhaauthor=M.+Armaniousauthor=M.+G.+Fradley&title=Update+on+cardio-oncology%3A+Novel+cancer+therapeutics+and+associated+cardiotoxicities&doi=10.1016%2Fj.tcm.2018.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities</span></div><div class="casAuthors">Guha, Avirup; Armanious, Merna; Fradley, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cardiovascular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">TCMDEQ</span>;
        ISSN:<span class="NLM_cas:issn">1050-1738</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There have been significant advances in the field of oncol. leading to improved survival as a result of novel targeted and immunotherapies.  Despite these improved outcomes, there is increased recognition of cardiotoxicities assocd. with these therapies that can lead to significant morbidity and mortality.  As such, the field of cardio-oncol. has seen significant growth over the last several years.  In this review, we discuss recent advances in the field of cardio-oncol. and provide a detailed discussion of the cardiovascular complications assocd. with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGaYu9pkctLVg90H21EOLACvtfcHk0lhvYq0cbsDZqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqu7%252FK&md5=cc6454527119684c870e4d3050a5d9db</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tcm.2018.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcm.2018.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DA.%26aulast%3DArmanious%26aufirst%3DM.%26aulast%3DFradley%26aufirst%3DM.%2BG.%26atitle%3DUpdate%2520on%2520cardio-oncology%253A%2520Novel%2520cancer%2520therapeutics%2520and%2520associated%2520cardiotoxicities%26jtitle%3DTrends%2520Cardiovasc.%2520Med.%26date%3D2019%26volume%3D29%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.tcm.2018.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiattarella, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimarco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ijcard.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27362830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2016&pages=396-403&author=G.+G.+Schiattarellaauthor=A.+Sanninoauthor=E.+Toscanoauthor=F.+Cattaneoauthor=B.+Trimarcoauthor=G.+Espositoauthor=C.+Perrino&title=Cardiovascular+effects+of+histone+deacetylase+inhibitors+epigenetic+therapies%3A+Systematic+review+of+62+studies+and+new+hypotheses+for+future+research&doi=10.1016%2Fj.ijcard.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span></div><div class="casAuthors">Schiattarella Gabriele Giacomo; Sannino Anna; Toscano Evelina; Cattaneo Fabio; Trimarco Bruno; Esposito Giovanni; Perrino Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">396-403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHU9cOCIEYRA8IxFYvehhofW6udTcc2eY5UrXuD4t-vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D&md5=f85f4a989a24f78a755011d554434cde</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSchiattarella%26aufirst%3DG.%2BG.%26aulast%3DSannino%26aufirst%3DA.%26aulast%3DToscano%26aufirst%3DE.%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DTrimarco%26aufirst%3DB.%26aulast%3DEsposito%26aufirst%3DG.%26aulast%3DPerrino%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520histone%2520deacetylase%2520inhibitors%2520epigenetic%2520therapies%253A%2520Systematic%2520review%2520of%252062%2520studies%2520and%2520new%2520hypotheses%2520for%2520future%2520research%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D219%26spage%3D396%26epage%3D403%26doi%3D10.1016%2Fj.ijcard.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeoung, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.00486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3389%2Ffcell.2020.00486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32626712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB38noslSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=486&author=M.+Yeonauthor=Y.+Kimauthor=H.+S.+Jungauthor=D.+Jeoung&title=Histone+deacetylase+inhibitors+to+overcome+resistance+to+targeted+and+immuno+therapy+in+metastatic+melanoma&doi=10.3389%2Ffcell.2020.00486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma</span></div><div class="casAuthors">Yeon Minjeong; Jung Hyun Suk; Jeoung Dooil; Kim Youngmi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">486</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma.  A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/AKT/mammalian target of rapamycin (mTOR) in melanoma.  Target-specific agents, such as MAPK inhibitors improve progression-free survival.  However, BRAF(V600E) mutant melanomas treated with BRAF kinase inhibitors develop resistance.  Immune checkpoint molecules, such as programmed death-1 (PD-1) and programmed death ligand-1(PD-L1), induce immune evasion of cancer cells.  MAPK inhibitor resistance results from the increased expression of PD-L1.  Immune checkpoint inhibitors, such as anti-PD-L1 or anti-PD-1, are main players in immune therapies designed to target metastatic melanoma.  However, melanoma patients show low response rate and resistance to these inhibitors develops within 6-8 months of treatment.  Epigenetic reprogramming, such as DNA methylaion and histone modification, regulates the expression of genes involved in cellular proliferation, immune checkpoints and the response to anti-cancer drugs.  Histone deacetylases (HDACs) remove acetyl groups from histone and non-histone proteins and act as transcriptional repressors.  HDACs are often dysregulated in melanomas, and regulate MAPK signaling, cancer progression, and responses to various anti-cancer drugs.  HDACs have been shown to regulate the expression of PD-1/PD-L1 and genes involved in immune evasion.  These reports make HDACs ideal targets for the development of anti-melanoma therapeutics.  We review the mechanisms of resistance to anti-melanoma therapies, including MAPK inhibitors and immune checkpoint inhibitors.  We address the effects of HDAC inhibitors on the response to MAPK inhibitors and immune checkpoint inhibitors in melanoma.  In addition, we discuss current progress in anti-melanoma therapies involving a combination of HDAC inhibitors, immune checkpoint inhibitors, and MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKnSTGbtpJagpJitSxOdIlfW6udTcc2eY5UrXuD4t-vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38noslSgsQ%253D%253D&md5=988560a3bd6c4d97922f83d83301f2b5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.00486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.00486%26sid%3Dliteratum%253Aachs%26aulast%3DYeon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DH.%2BS.%26aulast%3DJeoung%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520to%2520overcome%2520resistance%2520to%2520targeted%2520and%2520immuno%2520therapy%2520in%2520metastatic%2520melanoma%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D486%26doi%3D10.3389%2Ffcell.2020.00486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Role of HDACs in normal and malignant hematopoiesis</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">5</span> <span class="refDoi"> DOI: 10.1186/s12943-019-1127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs12943-019-1127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31910827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&author=P.+Wangauthor=Z.+Wangauthor=J.+Liu&title=Role+of+HDACs+in+normal+and+malignant+hematopoiesis&doi=10.1186%2Fs12943-019-1127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of HDACs in normal and malignant hematopoiesis</span></div><div class="casAuthors">Wang Pan; Wang Zi; Wang Pan; Wang Zi; Liu Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Normal hematopoiesis requires the accurate orchestration of lineage-specific patterns of gene expression at each stage of development, and epigenetic regulators play a vital role.  Disordered epigenetic regulation has emerged as a key mechanism contributing to hematological malignancies.  Histone deacetylases (HDACs) are a series of key transcriptional cofactors that regulate gene expression by deacetylation of lysine residues on histone and nonhistone proteins.  In normal hematopoiesis, HDACs are widely involved in the development of various lineages.  Their functions involve stemness maintenance, lineage commitment determination, cell differentiation and proliferation, etc.  Deregulation of HDACs by abnormal expression or activity and oncogenic HDAC-containing transcriptional complexes are involved in hematological malignancies.  Currently, HDAC family members are attractive targets for drug design, and a variety of HDAC-based combination strategies have been developed for the treatment of hematological malignancies.  Drug resistance and limited therapeutic efficacy are key issues that hinder the clinical applications of HDAC inhibitors (HDACis).  In this review, we summarize the current knowledge of how HDACs and HDAC-containing complexes function in normal hematopoiesis and highlight the etiology of HDACs in hematological malignancies.  Moreover, the implication and drug resistance of HDACis are also discussed.  This review presents an overview of the physiology and pathology of HDACs in the blood system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuj8DxhH9_I9LIORRPd5lbfW6udTcc2eYrjwzE4lG3iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D&md5=96b7cff9ffdde16fca3e2b6e79e51078</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1127-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRole%2520of%2520HDACs%2520in%2520normal%2520and%2520malignant%2520hematopoiesis%26jtitle%3DMol.%2520Cancer%26date%3D2020%26volume%3D19%26doi%3D10.1186%2Fs12943-019-1127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 as a novel therapeutic target in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fleu.2013.231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23913134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=680-689&author=J.+Minamiauthor=R.+Suzukiauthor=R.+Mazitschekauthor=G.+Gorgunauthor=B.+Ghoshauthor=D.+Cirsteaauthor=Y.+Huauthor=N.+Mimuraauthor=H.+Ohguchiauthor=F.+Cottiniauthor=J.+Jakubikovaauthor=N.+C.+Munshiauthor=S.+J.+Haggartyauthor=P.+G.+Richardsonauthor=T.+Hideshimaauthor=K.+C.+Anderson&title=Histone+deacetylase+3+as+a+novel+therapeutic+target+in+multiple+myeloma&doi=10.1038%2Fleu.2013.231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 as a novel therapeutic target in multiple myeloma</span></div><div class="casAuthors">Minami, J.; Suzuki, R.; Mazitschek, R.; Gorgun, G.; Ghosh, B.; Cirstea, D.; Hu, Y.; Mimura, N.; Ohguchi, H.; Cottini, F.; Jakubikova, J.; Munshi, N. C.; Haggarty, S. J.; Richardson, P. G.; Hideshima, T.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-689</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) represent novel mol. targets for the treatment of various types of cancers, including multiple myeloma (MM).  Many HDAC inhibitors have already shown remarkable antitumor activities in the preclin. setting; however, their clin. utility is limited because of unfavorable toxicities assocd. with their broad range HDAC inhibitory effects.  Isoform-selective HDAC inhibition may allow for MM cytotoxicity without attendant side effects.  In this study, we demonstrated that HDAC3 knockdown and a small-mol. HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage.  Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3).  Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth.  Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3.  Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity.  Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM.  Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3gGhcOXmyLVg90H21EOLACvtfcHk0liE4YcipIfI9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7%252FK&md5=4ff22875205c892a7bc8c82e2aa4bdd0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.231%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DJakubikova%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHistone%2520deacetylase%25203%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D680%26epage%3D689%26doi%3D10.1038%2Fleu.2013.231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leus, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wouden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krist, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ourailidou, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleftheriadis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistemaker, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjaltema, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haisma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">45047</span> <span class="refDoi"> DOI: 10.1038/srep45047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fsrep45047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28344354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt12gu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=N.+G.+Leusauthor=T.+van+den+Boschauthor=P.+E.+van+der+Woudenauthor=K.+Kristauthor=M.+E.+Ourailidouauthor=N.+Eleftheriadisauthor=L.+E.+Kistemakerauthor=S.+Bosauthor=R.+A.+Gjaltemaauthor=S.+A.+Mekonnenauthor=R.+Bischoffauthor=R.+Gosensauthor=H.+J.+Haismaauthor=F.+J.+Dekker&title=HDAC1-3+inhibitor+MS-275+enhances+IL10+expression+in+RAW264.7+macrophages+and+reduces+cigarette+smoke-induced+airway+inflammation+in+mice&doi=10.1038%2Fsrep45047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice</span></div><div class="casAuthors">Leus, Niek G. J.; van den Bosch, Thea; van der Wouden, Petra E.; Krist, Kim; Ourailidou, Maria E.; Eleftheriadis, Nikolaos; Kistemaker, Loes E. M.; Bos, Sophie; Gjaltema, Rutger A. F.; Mekonnen, Solomon A.; Bischoff, Rainer; Gosens, Reinoud; Haisma, Hidde J.; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45047</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) constitutes a major health burden.  Studying underlying mol. mechanisms could lead to new therapeutic targets.  Macrophages are orchestrators of COPD, by releasing pro-inflammatory cytokines.  This process relies on transcription factors such as NF-κB, among others.  NF-κB is regulated by lysine acetylation; a post-translational modification installed by histone acetyltransferases and removed by histone deacetylases (HDACs).  We hypothesized that small mol. HDAC inhibitors (HDACi) targeting class I HDACs members that can regulate NF-κB could attenuate inflammatory responses in COPD via modulation of the NF-κB signaling output.  MS-275 is an isoform-selective inhibitor of HDAC1-3.  In precision-cut lung slices and RAW264.7 macrophages, MS-275 upregulated the expression of both pro- and anti-inflammatory genes, implying mixed effects.  Interestingly, anti-inflammatory IL10 expression was upregulated in these model systems.  In the macrophages, this was assocd. with increased NF-κB activity, acetylation, nuclear translocation, and binding to the IL10 promoter.  Importantly, in an in vivo model of cigarette smoke-exposed C57Bl/6 mice, MS-275 robustly attenuated inflammatory expression of KC and neutrophil influx in the lungs.  This study highlights for the first time the potential of isoform-selective HDACi for the treatment of inflammatory lung diseases like COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhkKFUYjVj0rVg90H21EOLACvtfcHk0liE4YcipIfI9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt12gu70%253D&md5=617056d0512dd7842c5f6ed1440f4817</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsrep45047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep45047%26sid%3Dliteratum%253Aachs%26aulast%3DLeus%26aufirst%3DN.%2BG.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BWouden%26aufirst%3DP.%2BE.%26aulast%3DKrist%26aufirst%3DK.%26aulast%3DOurailidou%26aufirst%3DM.%2BE.%26aulast%3DEleftheriadis%26aufirst%3DN.%26aulast%3DKistemaker%26aufirst%3DL.%2BE.%26aulast%3DBos%26aufirst%3DS.%26aulast%3DGjaltema%26aufirst%3DR.%2BA.%26aulast%3DMekonnen%26aufirst%3DS.%2BA.%26aulast%3DBischoff%26aufirst%3DR.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DHaisma%26aufirst%3DH.%2BJ.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DHDAC1-3%2520inhibitor%2520MS-275%2520enhances%2520IL10%2520expression%2520in%2520RAW264.7%2520macrophages%2520and%2520reduces%2520cigarette%2520smoke-induced%2520airway%2520inflammation%2520in%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fsrep45047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0liehvIs1RLqZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3240</span>– <span class="NLM_lpage">3244</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmc.2013.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23602523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3240-3244&author=X.+Zhangauthor=J.+Zhangauthor=L.+Tongauthor=Y.+Luoauthor=M.+Suauthor=Y.+Zangauthor=J.+Liauthor=W.+Luauthor=Y.+Chen&title=The+discovery+of+colchicine-SAHA+hybrids+as+a+new+class+of+antitumor+agents&doi=10.1016%2Fj.bmc.2013.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span></div><div class="casAuthors">Zhang, Xuan; Zhang, Jie; Tong, Linjiang; Luo, Yu; Su, Mingbo; Zang, Yi; Li, Jia; Lu, Wei; Chen, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3240-3244</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of colchicine-SAHA hybrids were designed and synthesized based on the synergistic antitumor effect tubulin inhibitors and histone deacetylases(HDAC) inhibitors.  To the best of our knowledge, this is the first design of mols. that are dual inhibitors of tubulin and HDAC.  Biol. evaluations of these compds. included the inhibitory activity of HDAC, in vitro cell cycle anal. in BEL-7402 cells as well as cytotoxicity in five cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-0eT4cJg3rVg90H21EOLACvtfcHk0liehvIs1RLqZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D&md5=2a3020c5a48b617bd04f5c2cb214df99</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520discovery%2520of%2520colchicine-SAHA%2520hybrids%2520as%2520a%2520new%2520class%2520of%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3240%26epage%3D3244%26doi%3D10.1016%2Fj.bmc.2013.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nervi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codacci-Pisanelli, G.</span></span> <span> </span><span class="NLM_article-title">Epigenetic treatment of solid tumours: a review of clinical trials</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">127</span> <span class="refDoi"> DOI: 10.1186/s13148-015-0157-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs13148-015-0157-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26692909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVOks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=C.+Nerviauthor=E.+De+Marinisauthor=G.+Codacci-Pisanelli&title=Epigenetic+treatment+of+solid+tumours%3A+a+review+of+clinical+trials&doi=10.1186%2Fs13148-015-0157-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic treatment of solid tumours: a review of clinical trials</span></div><div class="casAuthors">Nervi, Clara; De Marinis, Elisabetta; Codacci-Pisanelli, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127/1-127/20</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Epigenetic treatment has been approved by regulatory agencies for haematol. malignancies.  The success obsd. in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumors.  Several agents that interfere with DNA methylation-demethylation and histones acetylation/deacetylation have been studied, and some (such as azacytidine, decitabine, valproic acid and vorinostat) are already in clin. use.  The aim of this review is to provide a brief overview of the mol. events underlying the antitumor effects of epigenetic treatments and to summarise data available on clin. trials that tested the use of epigenetic agents against solid tumors.  We not only list results but also try to indicate how the proper evaluation of this treatment might result in a better selection of effective agents and in a more rapid development.  We divided compds. in demethylating agents and HDAC inhibitors.  For each class, we report the antitumor activity and the toxic side effects.  When available, we describe plasma pharmacokinetics and pharmacodynamic evaluation in tumors and in surrogate tissues (generally white blood cells).  Epigenetic treatment is a reality in haematol. malignancies and deserves adequate attention in solid tumors.  A careful consideration of available clin. data however is required for faster drug development and possibly to re-evaluate some mols. that were perhaps discarded too early.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9w8eD5OdO1LVg90H21EOLACvtfcHk0liehvIs1RLqZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVOks7Y%253D&md5=f473a8d7cf1aad0f3d306eac854d9177</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs13148-015-0157-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-015-0157-2%26sid%3Dliteratum%253Aachs%26aulast%3DNervi%26aufirst%3DC.%26aulast%3DDe%2BMarinis%26aufirst%3DE.%26aulast%3DCodacci-Pisanelli%26aufirst%3DG.%26atitle%3DEpigenetic%2520treatment%2520of%2520solid%2520tumours%253A%2520a%2520review%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Epigenet.%26date%3D2015%26volume%3D7%26doi%3D10.1186%2Fs13148-015-0157-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lg0kOCZS1Iksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lg0kOCZS1Iksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+Comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2eay1uiCPcVTwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520Comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinarivala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Multi-targeting anticancer agents: rational approaches, synthetic routes and structure activity relationship</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.2174/1871520619666190118120708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F1871520619666190118120708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30657048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3cjisl2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=842-874&author=H.+Singhauthor=N.+Kinarivalaauthor=S.+Sharma&title=Multi-targeting+anticancer+agents%3A+rational+approaches%2C+synthetic+routes+and+structure+activity+relationship&doi=10.2174%2F1871520619666190118120708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship</span></div><div class="casAuthors">Singh Harbinder; Sharma Sahil; Kinarivala Nihar; Sharma Sahil</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">842-874</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We live in a world with complex diseases such as cancer which cannot be cured with one-compound one-target based therapeutic paradigm.  This could be due to the involvement of multiple pathogenic mechanisms.  One-compound-various-targets stratagem has become a prevailing research topic in anti-cancer drug discovery.  The simultaneous interruption of two or more targets has improved the therapeutic efficacy as compared to the specific targeted based therapy.  In this review, six types of dual targeting agents along with some interesting strategies used for their design and synthesis are discussed.  Their pharmacology with various types of the molecular interactions within their specific targets has also been described.  This assemblage will reveal the recent trends and insights in front of the scientific community working in dual inhibitors and help them in designing the next generation of multi-targeted anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-MrG1fXAfTsKL0FlyGHDofW6udTcc2eay1uiCPcVTwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjisl2ruw%253D%253D&md5=89985c2b548788939754e7fd3701833f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKinarivala%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DMulti-targeting%2520anticancer%2520agents%253A%2520rational%2520approaches%252C%2520synthetic%2520routes%2520and%2520structure%2520activity%2520relationship%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D842%26epage%3D874%26doi%3D10.2174%2F1871520619666190118120708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lj-Kjjm08lzcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00821-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs10637-019-00821-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31414267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFylurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=755-764&author=J.+Chenauthor=B.+Luoauthor=S.+Wenauthor=R.+Pi&title=Discovery+of+a+novel+rhein-SAHA+hybrid+as+a+multi-targeted+anti-glioblastoma+drug&doi=10.1007%2Fs10637-019-00821-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug</span></div><div class="casAuthors">Chen, Jingkao; Luo, Bingling; Wen, Shijun; Pi, Rongbiao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">755-764</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system (CNS).  Effective treatments remain limited.  Therefore, novel chemotherapy drugs with high efficiency and few adverse effects are urgently needed.  Histone deacetylase (HDAC) and serum and glucocorticoid-regulated protein kinase 1 (SGK1) are targets for the prevention and treatment of GBM.  Rhein has antitumor and SGK1 suppression effects, although its biol. activity is limited by poor bioavailability.  To improve the drug-like properties of rhein, we constructed a novel rhein-hydroxyethyl hydroxamic acid deriv. (SYSUP007), which combined rhein with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA).  In the present study, the human GBM cell lines, T98G, U87 and U251, were used to investigate the anticancer effects of SYSUP007 in-vitro.  We found that SYSUP007 was more effective in inhibiting glioma cell proliferation, invasion and migration in-vitro compared with the effects of rhein and SAHA.  We also confirmed that SYSUP007 increased the expression of Ac-K100 and NDRG1 (targets of HDAC and SGK1).  The present study indicates the potential that SYSUP007, as a novel rhein and SAHA deriv., for development as an anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobTrMbwz2MoLVg90H21EOLACvtfcHk0lj-Kjjm08lzcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFylurjL&md5=111f64d1798fdd48e5b19fcc5a17832f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00821-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00821-4%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DPi%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520rhein-SAHA%2520hybrid%2520as%2520a%2520multi-targeted%2520anti-glioblastoma%2520drug%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D755%26epage%3D764%26doi%3D10.1007%2Fs10637-019-00821-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>, <span class="NLM_elocation-id">112831</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.112831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32961382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&author=X.+Pengauthor=Z.+Sunauthor=P.+Kuangauthor=J.+Chen&title=Recent+progress+on+HDAC+inhibitors+with+dual+targeting+capabilities+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.112831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span></div><div class="casAuthors">Peng, Xiaopeng; Sun, Zhiqiang; Kuang, Peihua; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112831</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-acetyl lysine of histones, allowing histones to wrap DNA more tightly.  HDACs play an essential role in many biol. processes such as gene regulation, transcription, cell proliferation, angiogenesis, migration, differentiation and metastasis.  As a result, HDACs represent an excellent target for anti-cancer drug discovery.  The search for histone deacetylase inhibitors (HDACis) has been intensified in the last decade with numerous HDACis being discovered, and some of them have reached the market.  However, currently available HDACis are mostly non-isoform selective and suffer from several drawbacks such as limited efficacy, drug resistance, and toxicities.  Therefore, isoform-selective HDACis and HDACis with dual targeting capabilities have attracted much attention from academia to industry in the past 5 years, and great advances have been achieved in this area.  In this paper, we summarize recent progress on HDACis with dual targeting capabilities and their potential application to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHs5GEjS8RbVg90H21EOLACvtfcHk0lgqO19zmwqamg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM&md5=d6f340dc0222b3f22a702c963cb1728b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520progress%2520on%2520HDAC%2520inhibitors%2520with%2520dual%2520targeting%2520capabilities%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26doi%3D10.1016%2Fj.ejmech.2020.112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+molecules+simultaneously+inhibiting+p53-murine+double+minute+2+%28MDM2%29+interaction+and+histone+deacetylases+%28HDACs%29%3A+discovery+of+novel+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lgqO19zmwqamg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecules%2520simultaneously%2520inhibiting%2520p53-murine%2520double%2520minute%25202%2520%2528MDM2%2529%2520interaction%2520and%2520histone%2520deacetylases%2520%2528HDACs%2529%253A%2520discovery%2520of%2520novel%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>– <span class="NLM_lpage">7983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0lgez-20eqXrRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Janus Kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+Janus+Kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0lgez-20eqXrRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of Leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+the+combinational+treatment+of+Leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lgez-20eqXrRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520the%2520combinational%2520treatment%2520of%2520Leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilha, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K/HDAC inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4256-4292&author=A.+Thakurauthor=G.+J.+Tawaauthor=M.+J.+Hendersonauthor=C.+Danchikauthor=S.+Liuauthor=P.+Shahauthor=A.+Q.+Wangauthor=G.+Dunnauthor=M.+Kabirauthor=E.+C.+Padilhaauthor=X.+Xuauthor=A.+Simeonovauthor=S.+Kharbandaauthor=R.+Stoneauthor=G.+Grewal&title=Design%2C+synthesis%2C+and+biological+evaluation+of+quinazolin-4-one-based+hydroxamic+acids+as+dual+PI3K%2FHDAC+inhibitors&doi=10.1021%2Facs.jmedchem.0c00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span></div><div class="casAuthors">Thakur, Ashish; Tawa, Gregory J.; Henderson, Mark J.; Danchik, Carina; Liu, Suiyang; Shah, Pranav; Wang, Amy Q.; Dunn, Garrett; Kabir, Md.; Padilha, Elias C.; Xu, Xin; Simeonov, Anton; Kharbanda, Surender; Stone, Richard; Grewal, Gurmit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4256-4292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker.  Several of these dual inhibitors were highly potent (IC50 < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines.  The lead compd. 48c, induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients, while showing no cytotoxicity against normal PBMCs, NIH3T3, and HEK293 cells.  Target engagement of PI3Kδ and HDAC6 by 48c was demonstrated in MV411 cells using the cellular thermal shift assay (CETSA).  Compd. 48c showed good pharmacokinetics properties in mice via i.p. administration and provides a means to examine the biol. effects of inhibiting these two important enzymes with a single mol., either in vitro or in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWWMm2AttIWLVg90H21EOLACvtfcHk0li42rSGMRkyyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D&md5=75f1696a5d5826a46380a85e2a115b59</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DPadilha%26aufirst%3DE.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGrewal%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinazolin-4-one-based%2520hydroxamic%2520acids%2520as%2520dual%2520PI3K%252FHDAC%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4256%26epage%3D4292%26doi%3D10.1021%2Facs.jmedchem.0c00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span> <span> </span><span class="NLM_article-title">Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8977</span>– <span class="NLM_lpage">9002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8977-9002&author=T.+Liuauthor=Y.+Wanauthor=Y.+Xiaoauthor=C.+Xiaauthor=G.+Duan&title=Dual-target+inhibitors+based+on+HDACs%3A+novel+antitumor+agents+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.0c00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy</span></div><div class="casAuthors">Liu, Tingting; Wan, Yichao; Xiao, Yuliang; Xia, Chengcai; Duan, Guiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8977-9002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) play an important role in regulating target gene expression.  They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells.  In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment.  In this review, we discuss the theor. basis for designing HDAC-involved dual-target drugs and provide insight into the structure-activity relationships of these dual-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbD4ktOU4jbVg90H21EOLACvtfcHk0li42rSGMRkyyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D&md5=fa6764d35879c6a8973d57231854f821</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DG.%26atitle%3DDual-target%2520inhibitors%2520based%2520on%2520HDACs%253A%2520novel%2520antitumor%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8977%26epage%3D9002%26doi%3D10.1021%2Facs.jmedchem.0c00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0li42rSGMRkyyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lhab7SE7K158Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">82</span> <span class="refDoi"> DOI: 10.1186/s13045-015-0176-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs13045-015-0176-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26156322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&author=M.+W.+Chaoauthor=M.+J.+Laiauthor=J.+P.+Liouauthor=Y.+L.+Changauthor=J.+C.+Wangauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+synergic+effect+of+vincristine+and+vorinostat+in+leukemia+in+vitro+and+in+vivo&doi=10.1186%2Fs13045-015-0176-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span></div><div class="casAuthors">Chao Min-Wu; Chang Ya-Ling; Teng Che-Ming; Lai Mei-Jung; Liou Jing-Ping; Wang Jing-Chi; Pan Shiow-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy.  The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia.  In order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells.  METHODS:  Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by flow cytometry.  In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence analysis was performed to detect microtubule distribution and morphology.  In vivo effect of the combination was evaluated by a MOLT-4 xenograft model.  Statistical analysis was assessed by Bonferroni's t test.  RESULTS:  Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM.  This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation.  Moreover, the results of vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through HDAC6 inhibition.  CONCLUSION:  These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.  These data suggest that the combination effect of vincristine/SAHA could have an important preclinical basis for future clinical trial testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZWw7KK08a6Zp6t8nS6Nc3fW6udTcc2eafWcS6y3oEWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D&md5=b22f13563067cc55509bc41110bb86ab</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0176-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0176-7%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520synergic%2520effect%2520of%2520vincristine%2520and%2520vorinostat%2520in%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26doi%3D10.1186%2Fs13045-015-0176-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang-Verslues, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span> <span> </span><span class="NLM_article-title">A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3389%2Ffphar.2018.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29593536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKnsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=205&author=Y.+W.+Wuauthor=K.+C.+Hsuauthor=H.+Y.+Leeauthor=T.+C.+Huangauthor=T.+E.+Linauthor=Y.+L.+Chenauthor=T.+Y.+Sungauthor=J.+P.+Liouauthor=W.+W.+Hwang-Versluesauthor=S.+L.+Panauthor=W.+C.+HuangFu&title=A+novel+dual+HDAC6+and+tubulin+inhibitor%2C+MPT0B451%2C+displays+anti-tumor+ability+in+human+cancer+cells+in+vitro+and+in+vivo&doi=10.3389%2Ffphar.2018.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A novel dual hdac6 and tubulin inhibitor, mpt0b451, displays anti-tumor ability in human cancer cells in vitro and in vivo</span></div><div class="casAuthors">Wu, Yi-Wen; Hsu, Kai-Cheng; Lee, Hsueh-Yun; Huang, Tsui-Chin; Lin, Tony E.; Chen, Yi-Ling; Sung, Ting-Yi; Liou, Jing-Ping; Hwang-Verslues, Wendy W.; Pan, Shiow-Lin; Huangfu, Wei-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/16</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The combination cancer therapy is a new strategy to circumvent drug resistance for the treatment of high metastasis and advanced malignancies.  Herein, we developed a synthesized compd. MPT0B451 that display inhibitory effect against histone deacetylase (HDAC) 6 and tubulin assembly.  Our data demonstrated that MPT0B451 significantly inhibited cancer cell growths in HL-60 and PC-3 cells due to inhibition of HDAC activity.  MPT0B451 also markedly increased caspase-mediated apoptosis in these cells.  The cell cycle anal. showed mitotic arrest induced by MPT0B451 with enhanced expression of G2/M transition proteins.  Moreover, mol. docking anal. supported MPT0B451 as a dual HDAC6 and tubulin inhibitor.  Finally, MPT0B451 led to tumor growth inhibition (TGI) in HL-60 and PC-3 xenograft models.  These findings indicated that MPT0B451 has dual inhibition effects for HDAC6 and tubulin, and also contributed to G2/M arrest followed by apoptotic induction.  Together, our results suggested that MPT0B451 may serve as a potent anti-cancer treatment regimen in human prostate cancer and acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3JSrfP91mRrVg90H21EOLACvtfcHk0lhab7SE7K158Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKnsr%252FK&md5=6524b2fd87dc06a6035d9d7ec2d3ace9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DHwang-Verslues%26aufirst%3DW.%2BW.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26atitle%3DA%2520novel%2520dual%2520HDAC6%2520and%2520tubulin%2520inhibitor%252C%2520MPT0B451%252C%2520displays%2520anti-tumor%2520ability%2520in%2520human%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D205%26doi%3D10.3389%2Ffphar.2018.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmcl.2019.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31400938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2638-2645&author=B.+Wangauthor=X.+Chenauthor=J.+Gaoauthor=L.+Suauthor=L.+Zhangauthor=H.+Xuauthor=Y.+Luan&title=Anti-tumor+activity+evaluation+of+novel+tubulin+and+HDAC+dual-targeting+inhibitors&doi=10.1016%2Fj.bmcl.2019.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span></div><div class="casAuthors">Wang, Baolei; Chen, Xuehong; Gao, Jianjun; Su, Li; Zhang, Li; Xu, Hongwei; Luan, Yepeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs.  In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors.  Three compds. inhibited the activities of HDAC and tubulin polymn. simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines.  Compd. 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells.  Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by mol. docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7ecC0j2FibVg90H21EOLACvtfcHk0lj9GBrot6UuaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI&md5=ac1e230b5a2b579f503f87bf6821e887</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520evaluation%2520of%2520novel%2520tubulin%2520and%2520HDAC%2520dual-targeting%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2638%26epage%3D2645%26doi%3D10.1016%2Fj.bmcl.2019.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosch, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothemund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfner, M.</span></span> <span> </span><span class="NLM_article-title">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure(-)activity relations of new inhibitors of HDAC and/or tubulin function</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">383</span>, <span class="refDoi"> DOI: 10.3390/ijms20020383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3390%2Fijms20020383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=383&author=F.+Schmittauthor=L.+C.+Goschauthor=A.+Dittmerauthor=M.+Rothemundauthor=T.+Muellerauthor=R.+Schobertauthor=B.+Biersackauthor=A.+Volkamerauthor=M.+Hopfner&title=Oxazole-bridged+combretastatin+A-4+derivatives+with+tethered+hydroxamic+acids%3A+structure%28-%29activity+relations+of+new+inhibitors+of+HDAC+and%2For+tubulin+function&doi=10.3390%2Fijms20020383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span></div><div class="casAuthors">Schmitt, Florian; Gosch, Lisa Chiara; Dittmer, Alexandra; Rothemund, Matthias; Mueller, Thomas; Schobert, Rainer; Biersack, Bernhard; Volkamer, Andrea; Hoepfner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383/1-383/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">New inhibitors of tubulin polymn. and/or histone deacetylase (HDAC) activity were synthesized by attaching alkyl tethered hydroxamic acid appendages of varying length to oxazole-bridged combretastatin A-4 analogous caps.  While their antiproliferative and microtubule disrupting effect was most pronounced for derivs. with short spacers, HDAC inhibition was strongest for those with longer spacers.  These findings were further supported by computational methods such as structure-based docking expts. exploring the target interactions of the derivs. with varying linkers.  For instance, compds. featuring short four-atom spacers between cap and hydroxamic acid inhibited the growth of various cancer cell lines and human endothelial hybrid cells with IC50 values in the low nanomolar range.  In line with their ability to inhibit the microtubule assembly, four- and five-atom spacered hydroxamic acids caused an accumulation of 518A2 melanoma cells in G2/M phase, whereas a compd. featuring a six-atom spacer and performing best in HDAC inhibition, induced a G1 arrest in these cells.  All these beneficial anticancer activities together with their selectivity for cancer cells over non-malignant cells, point out the great potential of these novel pleiotropic HDAC and tubulin inhibitors as drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnd6vxUZSv1bVg90H21EOLACvtfcHk0lj9GBrot6UuaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE&md5=c1c66ac969fd55fe4bfe78527375d8d3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3390%2Fijms20020383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020383%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DF.%26aulast%3DGosch%26aufirst%3DL.%2BC.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DRothemund%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DT.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DHopfner%26aufirst%3DM.%26atitle%3DOxazole-bridged%2520combretastatin%2520A-4%2520derivatives%2520with%2520tethered%2520hydroxamic%2520acids%253A%2520structure%2528-%2529activity%2520relations%2520of%2520new%2520inhibitors%2520of%2520HDAC%2520and%252For%2520tubulin%2520function%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D383%26doi%3D10.3390%2Fijms20020383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, A. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span> <span> </span><span class="NLM_article-title">Novel HDAC/tubulin dual inhibitor: design, synthesis and docking studies of alpha-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3130</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S256756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2FDDDT.S256756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32848361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVSju7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=3111-3130&author=A.+A.+E.+Mouradauthor=M.+A.+E.+Mouradauthor=P.+G.+Jones&title=Novel+HDAC%2Ftubulin+dual+inhibitor%3A+design%2C+synthesis+and+docking+studies+of+alpha-phthalimido-chalcone+hybrids+as+potential+anticancer+agents+with+apoptosis-inducing+activity&doi=10.2147%2FDDDT.S256756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel HDAC/tubulin dual inhibitor: design, synthesis and docking studies of α-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity</span></div><div class="casAuthors">Mourad, Ahmed A. E.; Mourad, Mai A. E.; Jones, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3111-3130</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: In order to develop novel anticancer HDAC/tubulin dual inhibitors, a novel series of α-phthalimido-substituted chalcones-based hybrids was synthesized and characterized by IR, 1 H NMR, 13C NMR, mass spectroscopy and X-ray anal.  Methods: All the synthesized compds. were evaluated for their in vitro anticancer activity against MCF-7 and HepG2 human cancer cell lines using MTT assay.  To explore the mechanism of action of the synthesized compds., in vitro β-tubulin polymn. and HDAC 1 and 2 inhibitory activity were measured for the most potent anticancer hybrids.  Further, cell cycle anal. was also evaluated.  Results: The trimethoxy deriv. 7j showed the most potent anticancer activity, possessed the most potent β-tubulin polymerase and HDAC 1 and 2 inhibitory activity and efficiently induced cell cycle arrest at both G2/M and preG1phases in the MCF-7 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoafZXAkH3jPLVg90H21EOLACvtfcHk0lj9GBrot6UuaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVSju7vN&md5=848ffc6f73c59d45abbac976067e9be7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S256756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S256756%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DA.%2BA.%2BE.%26aulast%3DMourad%26aufirst%3DM.%2BA.%2BE.%26aulast%3DJones%26aufirst%3DP.%2BG.%26atitle%3DNovel%2520HDAC%252Ftubulin%2520dual%2520inhibitor%253A%2520design%252C%2520synthesis%2520and%2520docking%2520studies%2520of%2520alpha-phthalimido-chalcone%2520hybrids%2520as%2520potential%2520anticancer%2520agents%2520with%2520apoptosis-inducing%2520activity%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2020%26volume%3D14%26spage%3D3111%26epage%3D3130%26doi%3D10.2147%2FDDDT.S256756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aboeldahab, A. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshr, E. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, O. M.</span></span> <span> </span><span class="NLM_article-title">Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2018.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29396364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2ns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=79-92&author=A.+M.+A.+Aboeldahabauthor=E.+A.+M.+Beshrauthor=M.+E.+Shomanauthor=S.+M.+Rabeaauthor=O.+M.+Aly&title=Spirohydantoins+and+1%2C2%2C4-triazole-3-carboxamide+derivatives+as+inhibitors+of+histone+deacetylase%3A+Design%2C+synthesis%2C+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Aboeldahab, Alshimaa M. A.; Beshr, Eman A. M.; Shoman, Mai E.; Rabea, Safwat M.; Aly, Omar M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-92</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two structurally novel series of histone deacetylase inhibitors (HDACIs) namely spirohydantoins I [n = 1, 2, 3, 4, 5, 6] and 1,2,4-triazole-3-carboxamide derivs. II with potential surface recognition moieties like 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione and 1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide resp., were designed, synthesized and evaluated for their anti-proliferative and HDAC inhibitory activities.  Mol. modeling study was performed to assess the potential binding ability of some compds. I [n = 5, 6] and II [n = 1, 5] to HDAC enzyme as well as colchicine binding site of β-tubulin.  Compds. II were evaluated as potential HDAC-tubulin dual inhibitors due to the structural similarities between their (1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide) nucleus and Combretastatin A4.  Among them, compd. I [n = 6] showed a remarkable inhibition of HDAC comparable to SAHA while compd. II [n = 5] behaved as potent HDAC-tubulin dual inhibitor.  It was found that, 2-(1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamido)acetic acid showed remarkable cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0pjDxmJ-a7Vg90H21EOLACvtfcHk0lj9GBrot6UuaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2ns7w%253D&md5=2a18a687e6eec35c8b41c50e4c0144f0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DAboeldahab%26aufirst%3DA.%2BM.%2BA.%26aulast%3DBeshr%26aufirst%3DE.%2BA.%2BM.%26aulast%3DShoman%26aufirst%3DM.%2BE.%26aulast%3DRabea%26aufirst%3DS.%2BM.%26aulast%3DAly%26aufirst%3DO.%2BM.%26atitle%3DSpirohydantoins%2520and%25201%252C2%252C4-triazole-3-carboxamide%2520derivatives%2520as%2520inhibitors%2520of%2520histone%2520deacetylase%253A%2520Design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D79%26epage%3D92%26doi%3D10.1016%2Fj.ejmech.2018.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0ljYMmdthmB1sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0ljYMmdthmB1sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuppens, I. E.</span></span> <span> </span><span class="NLM_article-title">Current state of the art of new tubulin inhibitors in the clinic</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2174/157488406775268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F157488406775268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18666378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=57-70&author=I.+E.+Kuppens&title=Current+state+of+the+art+of+new+tubulin+inhibitors+in+the+clinic&doi=10.2174%2F157488406775268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Current state of the art of new tubulin inhibitors in the clinic</span></div><div class="casAuthors">Kuppens, Isa E. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For years the microtubule stabilizing agents docetaxel and paclitaxel belong to the most successful clin. chemotherapeutic agents.  Several attempts have been made over the years to equal and better these drugs.  Both taxanes are assocd. with the notorious side effect neurotoxicity and are often accompanied with increased drug resistance and cross resistance with other chemotherapeutic agents.  In addn. their high lipophilicity demands use of co-solvents, which are assocd. with less favorable side effects such as hypersensitivity.  To prevent these disadvantages and improve the clin. application of the taxanes several new agents have entered clin. testing.  The agents that are discussed are the drug class of the discodermolides; XAA296A and the epothilones; BMS-247550, BMS-310705, epo906, kos-862 and the agents ABT-751 and D-24851.  Here we present an overview of recently performed clin. studies to det. the current state of the art of the tubulin inhibitors which are intended to enlarge and improve the clin. use of the taxanes docetaxel and paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAXF3Hrb0ubVg90H21EOLACvtfcHk0ljYMmdthmB1sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D&md5=e0ab529443ebf69c924de9d76ccc685d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F157488406775268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488406775268200%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%2BE.%26atitle%3DCurrent%2520state%2520of%2520the%2520art%2520of%2520new%2520tubulin%2520inhibitors%2520in%2520the%2520clinic%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D1%26spage%3D57%26epage%3D70%26doi%3D10.2174%2F157488406775268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgSVuUy0l7oCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lgSVuUy0l7oCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>184</i></span>, <span class="NLM_elocation-id">111732</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2019.111732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31610372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2019&author=L.+Liauthor=D.+Quanauthor=J.+Chenauthor=J.+Dingauthor=J.+Zhaoauthor=L.+Lvauthor=J.+Chen&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-substituted+-2-aryl+imidazoles+targeting+tubulin+polymerization+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2019.111732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</span></div><div class="casAuthors">Li, Ling; Quan, Dongling; Chen, Jingxuan; Ding, Jiahao; Zhao, Jinwu; Lv, Lin; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111732</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-substituted-2-aryl imidazoles I [R = Me, 3-MeC6H4, SO2Ph, etc.], benzoates and benzamides ArC(O)XAr1 [Ar = 3-NH2-4-MeOC6H3, 3-NO2-4-MeOC6H3, 3,4,5-(OMe)3; Ar1 = 3-NH2-4-MeOC6H3, 3-NO2-4-MeOC6H3, 3,4,5-(OMe)3; X = N, O] were designed, synthesized and screened for antiproliferative activity against six human cancer cell lines with IC50 values in nano molar range.  Among them, compd. I [R = 3-NH2-4-MeOC6H3] exhibited the best anticancer activity with an av. IC50 value of ~ 100 nM.  The compd. maintained the mechanism of action by inhibiting tubulin polymn., thus causing cell arrest at G2/M phase and apoptosis.  In vivo efficacy studies indicated that compd. I [R = 3-NH2-4-MeOC6H3] was highly effective in suppressing tumor growth in a MDA-MB-468 xenograft model of nude mouse with a TGI (Tumor Growth Suppression) of 77% at 60 mg/kg without causing significant toxicity.  In addn., compd. I [R = 3-NH2-4-MeOC6H3] displayed significantly better water soly. (36.70 μg/mL) than CA-4 (2.83 μg/mL).  Mol. modeling study indicated that compd. I [R = 3-NH2-4-MeOC6H3] could bind well to the colchicine binding site in tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2doLS6peA77Vg90H21EOLACvtfcHk0lgSVuUy0l7oCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjP&md5=004b1bd25a73ba1a6e2642593d835c83</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111732%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQuan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-substituted%2520-2-aryl%2520imidazoles%2520targeting%2520tubulin%2520polymerization%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D184%26doi%3D10.1016%2Fj.ejmech.2019.111732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7414</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm100884b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100884b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7414-7427&author=J.+Chenauthor=Z.+Wangauthor=C.+M.+Liauthor=Y.+Luauthor=P.+K.+Vaddadyauthor=B.+Meibohmauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazoles+targeting+the+colchicines+binding+site+in+tubulin+as+potential+anticancer+agents&doi=10.1021%2Fjm100884b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span></div><div class="casAuthors">Chen, Jianjun; Wang, Zhao; Li, Chien-Ming; Lu, Yan; Vaddady, Pavan K.; Meibohm, Bernd; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7414-7427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivs. and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART).  The av. IC50 of the most active compd. I ( R = Me) was 15.7 nM.  ABI analogs have substantially improved aq. soly. (48.9 μg/mL for I ( R = NMe2) vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4).  Mechanism of action studies indicate that the anticancer activity of ABI analogs is through inhibition of tubulin polymn. by interacting with the colchicine binding site.  Unlike paclitaxel and colchicine, the ABI compds. were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells.  In vivo results indicated that II was more effective than DTIC in inhibiting melanoma xenograph tumor growth.  Our results suggest that the novel ABI compds. may be developed to effectively treat drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0en8R0EjqRrVg90H21EOLACvtfcHk0liUZFMVCSkiMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O&md5=7eb4d70e1e2bf16dce361a6308ea6f93</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm100884b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100884b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazoles%2520targeting%2520the%2520colchicines%2520binding%2520site%2520in%2520tubulin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7414%26epage%3D7427%26doi%3D10.1021%2Fjm100884b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.1021/jm801449a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801449a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1701-1711&author=Y.+Luauthor=C.+M.+Liauthor=Z.+Wangauthor=C.+R.+Rossauthor=J.+Chenauthor=J.+T.+Daltonauthor=W.+Liauthor=D.+D.+Miller&title=Discovery+of+4-substituted+methoxybenzoyl-aryl-thiazole+as+novel+anticancer+agents%3A+synthesis%2C+biological+evaluation%2C+and+structure-activity+relationships&doi=10.1021%2Fjm801449a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Ross, Charles R., II; Chen, Jianjun; Dalton, James T.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1701-1711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) have been discovered and synthesized as a result of structural modifications of the lead compd. 2-arylthiazolidine-4-carboxylic acid amides (ATCAA).  The antiproliferative activity of the SMART agents against melanoma and prostate cancer cells was improved from μM to low nM range compared with the ATCAA series.  The structure-activity relationship was discussed from modifications of "A", "B", and "C" rings and the linker.  Preliminary mechanism of action studies indicated that these compds. exert their anticancer activity through inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnsk5EK9mVLVg90H21EOLACvtfcHk0liUZFMVCSkiMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D&md5=68261f1589c55ffca6f44c4410c91c9c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm801449a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801449a%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%25204-substituted%2520methoxybenzoyl-aryl-thiazole%2520as%2520novel%2520anticancer%2520agents%253A%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1701%26epage%3D1711%26doi%3D10.1021%2Fjm801449a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>213</i></span>, <span class="NLM_elocation-id">113058</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.113058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=33280898" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2020&author=X.+Yangauthor=B.+Chengauthor=Y.+Xiaoauthor=M.+Xueauthor=T.+Liuauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+CA-4+analogs+as+dual+inhibitors+of+tubulin+polymerization+and+PD-1%2FPD-L1+interaction+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.113058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113058%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520CA-4%2520analogs%2520as%2520dual%2520inhibitors%2520of%2520tubulin%2520polymerization%2520and%2520PD-1%252FPD-L1%2520interaction%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D213%26doi%3D10.1016%2Fj.ejmech.2020.113058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1860</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0lgNMziBztmLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P.</span></span> <span> </span><span class="NLM_article-title">RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fonc.2013.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23584480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1527-1537&author=Y.+Zhuauthor=K.+Dasauthor=J.+Wuauthor=M.+H.+Leeauthor=P.+Tan&title=RNH1+regulation+of+reactive+oxygen+species+contributes+to+histone+deacetylase+inhibitor+resistance+in+gastric+cancer+cells&doi=10.1038%2Fonc.2013.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells</span></div><div class="casAuthors">Zhu, Y.; Das, K.; Wu, J.; Lee, M. H.; Tan, P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1527-1537</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) are a promising class of anticancer epigenetic drugs, however, mol. factors influencing the responses of individual tumors to HDACi therapies remain obscure.  Here, we sought to identify genes assocd. with HDACi resistance in gastric cancer.  Treating a panel of 17 gastric cancer cell lines with multiple HDACi compds. (trichostatin A, SAHA and MS275), we identified two distinct classes of lines exhibiting either HDACi sensitivity or resistance.  Genomic comparisons between the sensitive and resistant classes using two independent microarray platforms identified RNH1, encoding a RNase inhibitor, as a gene highly expressed in HDACi-resistant lines.  Using genetic knockdown and overexpression assays, we show that RNH1 is both necessary and sufficient to induce HDACi resistance, and that RNH1 is likely to mediate this resistance through the dampening of HDACi-induced reactive oxygen species (ROS) in cancer cells.  The discovery of RNH1 as a regulator of HDACi resistance in gastric cancer highlights a functional role for ROS induction in the cellular effects of this important drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0HWhkcLDTP7Vg90H21EOLACvtfcHk0lgNMziBztmLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCnt7w%253D&md5=e20ace66e8c8d4fb846ce20ecb9f9124</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.104%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BH.%26aulast%3DTan%26aufirst%3DP.%26atitle%3DRNH1%2520regulation%2520of%2520reactive%2520oxygen%2520species%2520contributes%2520to%2520histone%2520deacetylase%2520inhibitor%2520resistance%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1527%26epage%3D1537%26doi%3D10.1038%2Fonc.2013.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almenara, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3637</span>– <span class="NLM_lpage">3645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=12839953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVGrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3637-3645&author=R.+R.+Rosatoauthor=J.+A.+Almenaraauthor=S.+Grant&title=The+histone+deacetylase+inhibitor+MS-275+promotes+differentiation+or+apoptosis+in+human+leukemia+cells+through+a+process+regulated+by+generation+of+reactive+oxygen+species+and+induction+of+p21CIP1%2FWAF1+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1</span></div><div class="casAuthors">Rosato, Roberto R.; Almenara, Jorge A.; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3637-3645</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effects of the histone deacetylase (HDAC) inhibitor MS-275 have been examd. in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous leukemia blasts in relation to differentiation and apoptosis.  MS-275 displayed dose-dependent effects in each of the cell lines.  When administered at a low concn. (e.g., 1 μM), MS-275 exhibited potent antiproliferative activity, inducing p21CIP1/WAF1-mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells.  These events were accompanied by an increase in hypophosphorylated retinoblastoma protein and down-regulation of cell cycle-related proteins including cyclin D1.  However, at higher concns. (e.g., 5 μM), MS-275 potently induced cell death, triggering apoptosis in ∼70% of cells at 48 h.  In contrast to other HDAC inhibitors such as apicidin, the extrinsic, receptor-mediated pathway played a minimal role in MS-275 lethality.  However, MS-275 potently induced a very early (e.g., within 2 h) increase in reactive oxygen species (ROS), followed by the loss of mitochondrial membrane potential (Δψm) and cytosolic release of cytochrome c.  These events culminated in activation of the caspase cascade, manifested by poly(ADP-ribose) polymerase, p21CIP1/WAF1, p27KIP, Bcl-2, and retinoblastoma protein degrdn.  MS-275 exposure also resulted in diminished expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP.  Administration of the free radical scavenger L-N-acetylcysteine blocked MS-275-mediated mitochondrial injury and apoptosis, suggesting a primary role for ROS generation in MS-275-assocd. lethality.  Lastly, U937 cells stably expressing a p21CIP1/WAF1 antisense construct were significantly more sensitive to MS-275-mediated apoptosis than controls, but they were impaired in their differentiation response.  Together, these findings demonstrate that MS-275 exerts dose-dependent effects in human leukemia cells, i.e., p21CIP1/WAF1-dependent growth arrest and differentiation at low drug concns. and a marked induction of ROS, mitochondrial damage, caspase activation, and apoptosis at higher concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrswikp6uNn3LVg90H21EOLACvtfcHk0lgNMziBztmLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVGrurc%253D&md5=1e29d94ca64fff3e3f81a6275ca9f820</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosato%26aufirst%3DR.%2BR.%26aulast%3DAlmenara%26aufirst%3DJ.%2BA.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520MS-275%2520promotes%2520differentiation%2520or%2520apoptosis%2520in%2520human%2520leukemia%2520cells%2520through%2520a%2520process%2520regulated%2520by%2520generation%2520of%2520reactive%2520oxygen%2520species%2520and%2520induction%2520of%2520p21CIP1%252FWAF1%25201%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3637%26epage%3D3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>– <span class="NLM_lpage">26943</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0lh4obnC_JUxLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayoub, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou El-Magd, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilli, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nindita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klobukowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuszynski, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of lankacidin group antibiotics is due to microtubule stabilization via a paclitaxel-like mechanism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9532</span>– <span class="NLM_lpage">9540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CgsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9532-9540&author=A.+T.+Ayoubauthor=R.+M.+Abou+El-Magdauthor=J.+Xiaoauthor=C.+W.+Lewisauthor=T.+M.+Tilliauthor=K.+Arakawaauthor=Y.+Ninditaauthor=G.+Chanauthor=L.+Sunauthor=M.+Gloverauthor=M.+Klobukowskiauthor=J.+Tuszynski&title=Antitumor+activity+of+lankacidin+group+antibiotics+is+due+to+microtubule+stabilization+via+a+paclitaxel-like+mechanism&doi=10.1021%2Facs.jmedchem.6b01264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism</span></div><div class="casAuthors">Ayoub, Ahmed Taha; Abou El-Magd, Rabab M.; Xiao, Jack; Lewis, Cody Wayne; Tilli, Tatiana Martins; Arakawa, Kenji; Nindita, Yosi; Chan, Gordon; Sun, Luxin; Glover, Mark; Klobukowski, Mariusz; Tuszynski, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9532-9540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lankacidin group antibiotics show strong antimicrobial activity against various Gram-pos. bacteria.  In addn., they were shown to have considerable antitumor activity against certain cell line models.  For decades, the antitumor activity of lankacidin was assocd. with the mechanism of its antimicrobial action, that is interference with peptide bond formation during protein synthesis.  This, however, was never confirmed exptl.  Due to significant similarity to paclitaxel-like hits in a previous computational virtual screening study, the authors suggested that the cytotoxic effect of lankacidin is due to a paclitaxel-like action.  In this study, the authors tested this hypothesis computationally and exptl. and confirmed that lankacidin is a microtubule stabilizer that enhances tubulin assembly and displaces taxoids from their binding site.  This study serves as a starting point for optimization of lankacidin derivs. for better antitumor activities.  It also highlights the power of computational predictions and their aid in guiding expts. and formulating rigorous hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz6aKpkFbdbVg90H21EOLACvtfcHk0lh4obnC_JUxLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CgsLvE&md5=22cf1a4b8adf7d59e218f46c1f4d446e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01264%26sid%3Dliteratum%253Aachs%26aulast%3DAyoub%26aufirst%3DA.%2BT.%26aulast%3DAbou%2BEl-Magd%26aufirst%3DR.%2BM.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%2BW.%26aulast%3DTilli%26aufirst%3DT.%2BM.%26aulast%3DArakawa%26aufirst%3DK.%26aulast%3DNindita%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DGlover%26aufirst%3DM.%26aulast%3DKlobukowski%26aufirst%3DM.%26aulast%3DTuszynski%26aufirst%3DJ.%26atitle%3DAntitumor%2520activity%2520of%2520lankacidin%2520group%2520antibiotics%2520is%2520due%2520to%2520microtubule%2520stabilization%2520via%2520a%2520paclitaxel-like%2520mechanism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9532%26epage%3D9540%26doi%3D10.1021%2Facs.jmedchem.6b01264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Macrophages: obligate partners for tumor cell migration, invasion, and metastasis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.cell.2006.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=16439202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=263-266&author=J.+Condeelisauthor=J.+W.+Pollard&title=Macrophages%3A+obligate+partners+for+tumor+cell+migration%2C+invasion%2C+and+metastasis&doi=10.1016%2Fj.cell.2006.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages: obligate partners for tumor cell migration, invasion, and metastasis</span></div><div class="casAuthors">Condeelis, John; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-266</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Macrophages within the tumor microenvironment facilitate angiogenesis and extracellular-matrix breakdown and remodeling and promote tumor cell motility.  Recent studies reveal that direct communication between macrophages and tumor cells leads to invasion and egress of tumor cells into the blood vessels (intravasation).  Thus, macrophages are at the center of the invasion microenvironment and are an important drug target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9bPyDvlwK1LVg90H21EOLACvtfcHk0lh4obnC_JUxLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KktLo%253D&md5=ddd258f9109498d4f1c252bfc5bc0a63</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DCondeelis%26aufirst%3DJ.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DMacrophages%253A%2520obligate%2520partners%2520for%2520tumor%2520cell%2520migration%252C%2520invasion%252C%2520and%2520metastasis%26jtitle%3DCell%26date%3D2006%26volume%3D124%26spage%3D263%26epage%3D266%26doi%3D10.1016%2Fj.cell.2006.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>202</i></span>, <span class="NLM_elocation-id">112519</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.112519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32650183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKns7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2020&author=G.+Liauthor=Y.+Wangauthor=L.+Liauthor=Y.+Renauthor=X.+Dengauthor=J.+Liuauthor=W.+Wangauthor=M.+Luoauthor=S.+Liuauthor=J.+Chen&title=Design%2C+synthesis%2C+and+bioevaluation+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+derivatives+as+tubulin+polymerization+inhibitors+targeting+the+colchicine+binding+site+with+potent+anticancer+activities&doi=10.1016%2Fj.ejmech.2020.112519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities</span></div><div class="casAuthors">Li, Gang; Wang, Yuxi; Li, Ling; Ren, Yichang; Deng, Xin; Liu, Jin; Wang, Wei; Luo, Meihua; Liu, Shuwen; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112519</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of pyrazolo[1,5-a]pyrimidine analogs com I [R=5-(1-methyl-1H-indole), 4-Me phenol, 6-indole, etc.,] were designed and synthesized as novel tubulin inhibitors.  Among them, compds. com I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] showed the highest antiproliferative activity against a panel of cancer cell lines with av. IC50 values of 24.8 nM and 28 nM, resp.  The crystal structures of compds. of I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] in complex with tubulin and confirmed their direct binding to the colchicine site was discussed.  Com I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] also effectively inhibited tubulin polymn. in vitro, induced cell cycle arrest in G2/M phase, and inhibited cancer cell migration.  In addn., com I [R= 4-Me phenol] exhibited high metabolic stability in human liver microsomes.  Finally, com I [R= 4-Me phenol] was highly effective in suppressing tumor growth in a B16-F10 mouse melanoma model without apparent toxicity.  In summary, these results suggested that com I [R= 4-Me phenol] represent a promising tubulin inhibitor worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFkS2OTrxB8LVg90H21EOLACvtfcHk0ljRJWYU3saxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKns7rL&md5=758a3585e22a57d244a3656750f7eca3</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112519%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioevaluation%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520derivatives%2520as%2520tubulin%2520polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%2520with%2520potent%2520anticancer%2520activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D202%26doi%3D10.1016%2Fj.ejmech.2020.112519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubieniecka, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F1535-7163.MCT-07-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18566246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1751-1761&author=S.+Liuauthor=H.+Chengauthor=W.+Kwanauthor=J.+M.+Lubienieckaauthor=T.+O.+Nielsen&title=Histone+deacetylase+inhibitors+induce+growth+arrest%2C+apoptosis%2C+and+differentiation+in+clear+cell+sarcoma+models&doi=10.1158%2F1535-7163.MCT-07-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models</span></div><div class="casAuthors">Liu, Shuzhen; Cheng, Hongwei; Kwan, Wanda; Lubieniecka, Joanna M.; Nielsen, Torsten O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1751-1761</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clear cell sarcoma is an aggressive malignancy occurring most commonly in the distal extremities of young adults, characterized by t(12;22)(q13;q12) creating the chimeric fusion oncoprotein EWS-ATF1.  We assessed growth inhibition and differentiation effects of histone deacetylase inhibitors MS-275 and romidepsin (depsipeptide, FK228) on clear cell sarcoma cells and evaluated drug sensitivity among related translocation-assocd. sarcomas and other cell models.  Three clear cell sarcoma cell lines, seven other sarcomas, six nonsarcoma malignant cell lines, and two nonneoplastic mesenchymal cell models were treated with MS-275 or romidepsin.  Growth inhibition was assayed by monolayer 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.  Induction of cell cycle arrest and apoptosis were assessed by propidium iodide/Annexin V flow cytometry in monolayer and spheroid cultures and by immunoblotting anal.  Expression levels of key genes involved in mesenchymal differentiation and of EWS-ATF1 were measured by quant. real-time PCR in clear cell sarcoma cells treated with histone deacetylase inhibitors.  MS-275 and romidepsin inhibited growth in clear cell sarcoma cells by inducing cell cycle arrest and apoptosis in a time- and dose-dependent manner.  Sarcomas showed greater sensitivity than other tumor types, with clear cell sarcomas most sensitive of all, whereas nonmalignant mesenchymal cells were highly resistant.  MS-275 at 1 μmol/L and romidepsin at 1 nmol/L induced histone H3 acetylation, cell cycle arrest, apoptosis, and differentiation in clear cell sarcoma cells within 24 h.  Histone deacetylase inhibitors increased expression of SOX9, MYOD1, and PPARG and decreased EWS-ATF1 expression in clear cell sarcoma cells.  Histone deacetylase inhibitors show promising preclin. activity in multiple clear cell sarcoma models. [Mol Cancer Ther 2008;7(6):1751-61].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-oSfn2ycZtrVg90H21EOLACvtfcHk0ljRJWYU3saxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSkurc%253D&md5=fec236f4fb6e8a9acc2aaf7cf4ae8b05</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0560%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKwan%26aufirst%3DW.%26aulast%3DLubieniecka%26aufirst%3DJ.%2BM.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520induce%2520growth%2520arrest%252C%2520apoptosis%252C%2520and%2520differentiation%2520in%2520clear%2520cell%2520sarcoma%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1751%26epage%3D1761%26doi%3D10.1158%2F1535-7163.MCT-07-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, P.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in hematological malignancies and solid tumors</span>. <i>Arch. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">933</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1007/s12272-015-0571-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs12272-015-0571-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25653088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1aqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=933-949&author=P.+Chun&title=Histone+deacetylase+inhibitors+in+hematological+malignancies+and+solid+tumors&doi=10.1007%2Fs12272-015-0571-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in hematological malignancies and solid tumors</span></div><div class="casAuthors">Chun, Pusoon</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">933-949</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs.  Because aberrant activity and expression of HDACs have been implicated in various cancer types, a wide range of HDAC inhibitors are being investigated as anticancer agents.  Furthermore, due to the demonstrable anticancer activity in both in vitro and in vivo studies, numerous HDAC inhibitors have undergone a rapid phase of clin. development in various cancer types, either as a monotherapy or in combination with other anticancer agents.  Although preclin. trials show that HDAC inhibitors have a variety of biol. effects across multiple pathways, including regulation of gene expression, inducing apoptosis and cell cycle arrest, inhibiting angiogenesis, and regulation of DNA damage and repair, the mechanism by which the clin. activity is mediated remains unclear.  Understanding the mechanisms of anticancer activity of HDAC inhibitors is essential not only for rational drug design for targeted therapies, but for the design of optimized clin. protocols.  This paper describes the links between HDACs and cancer, and the underlying mechanisms of action of HDAC inhibitors against hematol. malignancies and solid tumors.  Further, this review presents the clin. outcomes of vorinostat, romidepsin, and belinostat, which are approved by the United States Food and Drug Administration for the treatment of lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpko6AQ_rOm5LVg90H21EOLACvtfcHk0ljRJWYU3saxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1aqu7g%253D&md5=70eecb629ef6bc43204f30007be749ff</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs12272-015-0571-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-015-0571-1%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520hematological%2520malignancies%2520and%2520solid%2520tumors%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2015%26volume%3D38%26spage%3D933%26epage%3D949%26doi%3D10.1007%2Fs12272-015-0571-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC inhibitors in cancer development and therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">a026831</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+inhibitors+in+cancer+development+and+therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0lilfnRiL115uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520inhibitors%2520in%2520cancer%2520development%2520and%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design, synthesis, and biological evaluation of (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6734</span>– <span class="NLM_lpage">6750</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00706</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00706" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1OqsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6734-6750&author=Q.+Wangauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=D.+Maauthor=S.+W.+Whiteauthor=D.+D.+Millerauthor=W.+Liauthor=W.+Li&title=Structure-guided+design%2C+synthesis%2C+and+biological+evaluation+of+%282-%281H-indol-3-yl%29-1H-imidazol-4-yl%29%283%2C4%2C5-trimethoxyphenyl%29+methanone+%28ABI-231%29+analogues+targeting+the+colchicine+binding+site+in+tubulin&doi=10.1021%2Facs.jmedchem.9b00706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin</span></div><div class="casAuthors">Wang, Qinghui; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Ma, Dejian; White, Stephen W.; Miller, Duane D.; Li, Weimin; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6734-6750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clin. trials for prostate cancer.  Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogs, most notably 10ab (I) and 10bb.  The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved mol. interactions to the colchicine site.  In vitro, biol. studies showed that new ABI-231 analogs disrupt tubulin polymn., promote microtubule fragmentation, and inhibit cancer cell migration.  In vivo, analog 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model.  In addn., pharmacol. screening suggested that 10bb has a low risk of potential off-target function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0inGN_kombVg90H21EOLACvtfcHk0lilfnRiL115uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1OqsLnE&md5=6b10b2d294d209eea9ab6e9ec86282f4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DStructure-guided%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520%25282-%25281H-indol-3-yl%2529-1H-imidazol-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529%2520methanone%2520%2528ABI-231%2529%2520analogues%2520targeting%2520the%2520colchicine%2520binding%2520site%2520in%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6734%26epage%3D6750%26doi%3D10.1021%2Facs.jmedchem.9b00706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0lilfnRiL115uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmc.2019.02.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30819618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1405-1413&author=S.+Liuauthor=K.+Zhangauthor=Q.+Zhuauthor=Q.+Shenauthor=Q.+Zhangauthor=J.+Yuauthor=Y.+Chenauthor=W.+Lu&title=Synthesis+and+biological+evaluation+of+paclitaxel+and+vorinostat+co-prodrugs+for+overcoming+drug+resistance+in+cancer+therapy+in+vitro&doi=10.1016%2Fj.bmc.2019.02.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro</span></div><div class="casAuthors">Liu, Shuangxi; Zhang, Kaili; Zhu, Qiwen; Shen, Qianqian; Zhang, Qiumeng; Yu, Jiahui; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1405-1413</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX) is the first-line treatment drug for breast cancer.  However, drug resistance after a course of treatment and low selectivity restricted its clin. utility sometimes.  In this study, we successfully bound PTX and vorinostat (SAHA) to form co-prodrugs based on the synergistic anticancer effects.  The PTX-SAHA co-prodrugs were conjugated by glycine (1a) and succinic acid (1b) resp. and the former has shown better activity in cytotoxicity, cell cycle arrest and western-blot expts.  Therefore, 1a was further prepd. to nanomicelles with mPEG2000-PLA1750 as the carrier by using thin film method.  PTX-SAHA co-prodrug nanomicelles were spherical with a particle size of 20-100 nm.  In vitro drug release test showed 1a nanomicelles had sustained release effect, which could reduce the resistance of PTX.  In vitro cytotoxicity was evaluated by SRB assay in HCT-116 cells, MCF-7 cells and drug-resistant MCF-7/ADR cells.  The results showed 1a nanomicelles had comparable or even better cytotoxicity than PTX esp. in the MCF-7/ADR cells.  All the results suggested that PTX-SAHA co-prodrug nanomicelles were promising treatment for PTX resistance cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SV8dAcYxGbVg90H21EOLACvtfcHk0liFhfK-9ibLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOmu7o%253D&md5=ea6c9ff2d35fa8de07dd8b3897c782e7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.046%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520paclitaxel%2520and%2520vorinostat%2520co-prodrugs%2520for%2520overcoming%2520drug%2520resistance%2520in%2520cancer%2520therapy%2520in%2520vitro%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1405%26epage%3D1413%26doi%3D10.1016%2Fj.bmc.2019.02.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslehi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bersell, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funck-Brentano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, J. E.</span></span> <span> </span><span class="NLM_article-title">Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.pharmthera.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29698683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFWitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2018&pages=89-103&author=J.+Alexandreauthor=J.+J.+Moslehiauthor=K.+R.+Bersellauthor=C.+Funck-Brentanoauthor=D.+M.+Rodenauthor=J.+E.+Salem&title=Anticancer+drug-induced+cardiac+rhythm+disorders%3A+Current+knowledge+and+basic+underlying+mechanisms&doi=10.1016%2Fj.pharmthera.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms</span></div><div class="casAuthors">Alexandre, Joachim; Molsehi, Javid J.; Bersell, Kevin R.; Funck-Brentano, Christian; Roden, Dan M.; Salem, Joe-Elie</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-103</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases.  Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy.  Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy.Supraventricular tachycardias occur in cancer patients treated with cytotoxic chemotherapy (anthracyclines, gemcitabine, cisplatin and alkylating-agents) or kinase-inhibitors (KIs) such as ibrutinib.  Ventricular arrhythmias, with a subset of them being torsades-de-pointes (TdP) favored by QTc prolongation have been reported: this may be the result of direct hERG-channel inhibition or a more recently-described mechanism of phosphoinositide-3-kinase inhibition.  The major anticancer drugs responsible for QTc prolongation in this context are KIs, arsenic trioxide, anthracyclines, histone deacetylase inhibitors, and selective estrogen receptor modulators.Anticancer drug-induced cardiac rhythm disorders remain an underappreciated complication even by experienced clinicians.  Moreover, the causal relationship of a particular anticancer drug with cardiac arrhythmia occurrence remains challenging due in part to patient comorbidities and complex treatment regimens.  For example, any cancer patient may also be diagnosed with common diseases such as hypertension, diabetes or heart failure which increase an individual's arrhythmia susceptibility.  Further, anticancer drugs are generally usually used in combination, increasing the challenge around establishing causation.Thus, arrhythmias appear to be an underappreciated adverse effect of anticancer agents and the incidence, significance and underlying mechanisms are now being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3CEA1S07ZGbVg90H21EOLACvtfcHk0liFhfK-9ibLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFWitbw%253D&md5=c6fd21efa1c8568866decb2f59c676f3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DMoslehi%26aufirst%3DJ.%2BJ.%26aulast%3DBersell%26aufirst%3DK.%2BR.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DSalem%26aufirst%3DJ.%2BE.%26atitle%3DAnticancer%2520drug-induced%2520cardiac%2520rhythm%2520disorders%253A%2520Current%2520knowledge%2520and%2520basic%2520underlying%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D189%26spage%3D89%26epage%3D103%26doi%3D10.1016%2Fj.pharmthera.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamorano, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez Munoz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboyans, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asteggiano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galderisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenihan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Fernandez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piepoli, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamargo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, T. M.</span></span> <span> </span><span class="NLM_article-title">2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2768</span>– <span class="NLM_lpage">2801</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1093%2Feurheartj%2Fehw211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27567406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2szkslKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2768-2801&author=J.+L.+Zamoranoauthor=P.+Lancellottiauthor=D.+Rodriguez+Munozauthor=V.+Aboyansauthor=R.+Asteggianoauthor=M.+Galderisiauthor=G.+Habibauthor=D.+J.+Lenihanauthor=G.+Y.+H.+Lipauthor=A.+R.+Lyonauthor=T.+Lopez+Fernandezauthor=D.+Mohtyauthor=M.+F.+Piepoliauthor=J.+Tamargoauthor=A.+Torbickiauthor=T.+M.+Suter&title=2016+ESC+position+paper+on+cancer+treatments+and+cardiovascular+toxicity+developed+under+the+auspices+of+the+ESC+committee+for+practice+guidelines%3A+the+task+force+for+cancer+treatments+and+cardiovascular+toxicity+of+the+European+society+of+cardiology+%28ESC%29&doi=10.1093%2Feurheartj%2Fehw211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)</span></div><div class="casAuthors">Zamorano Jose Luis; Lancellotti Patrizio; Rodriguez Munoz Daniel; Aboyans Victor; Asteggiano Riccardo; Galderisi Maurizio; Habib Gilbert; Lenihan Daniel J; Lip Gregory Y H; Lyon Alexander R; Lopez Fernandez Teresa; Mohty Dania; Piepoli Massimo F; Tamargo Juan; Torbicki Adam; Suter Thomas M</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">2768-2801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRUs2uUwIgayA3UY9EwTNrfW6udTcc2ebIsX6iMxsCwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szkslKrsA%253D%253D&md5=d2a90317d321c401601e512d243bbb8f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw211%26sid%3Dliteratum%253Aachs%26aulast%3DZamorano%26aufirst%3DJ.%2BL.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DRodriguez%2BMunoz%26aufirst%3DD.%26aulast%3DAboyans%26aufirst%3DV.%26aulast%3DAsteggiano%26aufirst%3DR.%26aulast%3DGalderisi%26aufirst%3DM.%26aulast%3DHabib%26aufirst%3DG.%26aulast%3DLenihan%26aufirst%3DD.%2BJ.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DLopez%2BFernandez%26aufirst%3DT.%26aulast%3DMohty%26aufirst%3DD.%26aulast%3DPiepoli%26aufirst%3DM.%2BF.%26aulast%3DTamargo%26aufirst%3DJ.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSuter%26aufirst%3DT.%2BM.%26atitle%3D2016%2520ESC%2520position%2520paper%2520on%2520cancer%2520treatments%2520and%2520cardiovascular%2520toxicity%2520developed%2520under%2520the%2520auspices%2520of%2520the%2520ESC%2520committee%2520for%2520practice%2520guidelines%253A%2520the%2520task%2520force%2520for%2520cancer%2520treatments%2520and%2520cardiovascular%2520toxicity%2520of%2520the%2520European%2520society%2520of%2520cardiology%2520%2528ESC%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2768%26epage%3D2801%26doi%3D10.1093%2Feurheartj%2Fehw211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minchella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span> <span> </span><span class="NLM_article-title">QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1007/s11523-014-0325-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs11523-014-0325-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24970120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2cfntVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=27-43&author=M.+Locatelliauthor=C.+Criscitielloauthor=A.+Espositoauthor=I.+Minchellaauthor=A.+Goldhirschauthor=C.+Cipollaauthor=G.+Curigliano&title=QTc+prolongation+induced+by+targeted+biotherapies+used+in+clinical+practice+and+under+investigation%3A+a+comprehensive+review&doi=10.1007%2Fs11523-014-0325-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review</span></div><div class="casAuthors">Locatelli Marzia; Criscitiello Carmen; Esposito Angela; Minchella Ida; Goldhirsch Aron; Cipolla Carlo; Curigliano Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death.  Irrespective of overt clinical toxicities, QTc assessment can influence decision making during the conduct of clinical studies, including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal dose for subsequent development.  Efforts are needed to refine strategies for risk management, avoiding unintended consequences that negatively affect patient access and clinical development of promising new cancer treatments.  In this comprehensive review, we will analyze potential effects on QTc prolongations of targeted agents approved by regulatory agencies and under investigation.  A thoughtful risk management plan was generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies to support a development program essential for oncology agents with cardiac safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlbHMQlebL61VwdslNBF-tfW6udTcc2eYQiTYgPLexLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfntVKrsA%253D%253D&md5=d92b887bac40f28f6db1ba02f51f955f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0325-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0325-x%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DA.%26aulast%3DMinchella%26aufirst%3DI.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DCipolla%26aufirst%3DC.%26aulast%3DCurigliano%26aufirst%3DG.%26atitle%3DQTc%2520prolongation%2520induced%2520by%2520targeted%2520biotherapies%2520used%2520in%2520clinical%2520practice%2520and%2520under%2520investigation%253A%2520a%2520comprehensive%2520review%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D27%26epage%3D43%26doi%3D10.1007%2Fs11523-014-0325-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1185</span>, <span class="refDoi"> DOI: 10.1002/cam4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fcam4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25914207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yqsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1178-1185&author=P.+T.+Sagerauthor=B.+Balserauthor=J.+Wolfsonauthor=J.+Nicholsauthor=R.+Pilotauthor=S.+Jonesauthor=H.+A.+Burris&title=Electrocardiographic+effects+of+class+1+selective+histone+deacetylase+inhibitor+romidepsin&doi=10.1002%2Fcam4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin</span></div><div class="casAuthors">Sager, Philip T.; Balser, Barbara; Wolfson, Julie; Nichols, Jean; Pilot, Richard; Jones, Suzanne; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1178-1185</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy.  The objective of this anal. was to evaluate the potential QTc effects of romidepsin.  Patients with advanced malignancy received 4-h infusions of 14 mg/m2 romidepsin on days 1, 8, and 15 of a 28-day cycle.  In cycle 2, a subset of patients received 1-h infusions of 8-12 mg/m2 romidepsin.  Patients were administered antiemetics before each romidepsin dose and electrolyte supplementation as needed.  ECG readings were performed prior to antiemetic administration, prior to romidepsin administration, and at specified time points over the subsequent 24 h.  Romidepsin exposure and heart rate were also assessed.  In the ECG-evaluable population, 26 patients received romidepsin at 14 mg/m2 over 4 h.  The max. mean increases from the preantiemetic baseline for QTcF and heart rate were 10.1 ms (upper 90% CI, 14.5 ms) and 18.2 beats per min, resp.  No patient in this study had an abs. QTcF value >450 ms and only one patient had an increase from the preantiemetic baseline of >60 ms.  There was a mild redn. in the PR interval and no meaningful changes in the QRS interval.  Despite the use of QT-prolonging antiemetics, treatment with romidepsin did not markedly prolong the QTc interval through 24 h.  Increases in calcd. QTc may have been exaggerated as a consequence of transient increases in heart rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_tT1B5qNJbVg90H21EOLACvtfcHk0ljNh87aHE7vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yqsbvI&md5=2cfb095479d4dafad28703fa66f4773e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcam4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.467%26sid%3Dliteratum%253Aachs%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DBalser%26aufirst%3DB.%26aulast%3DWolfson%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DPilot%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DElectrocardiographic%2520effects%2520of%2520class%25201%2520selective%2520histone%2520deacetylase%2520inhibitor%2520romidepsin%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D1178%26epage%3D1185%26doi%3D10.1002%2Fcam4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nydam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen-Freda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scher, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2224-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs00280-013-2224-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23820963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=537-544&author=D.+E.+Rathkopfauthor=J.+Picusauthor=A.+Hussainauthor=S.+Ellardauthor=K.+N.+Chiauthor=T.+Nydamauthor=E.+Allen-Fredaauthor=K.+K.+Mishraauthor=M.+G.+Porroauthor=H.+I.+Scherauthor=G.+Wilding&title=A+phase+2+study+of+intravenous+panobinostat+in+patients+with+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2224-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer</span></div><div class="casAuthors">Rathkopf, Dana E.; Picus, Joel; Hussain, Arif; Ellard, Susan; Chi, Kim Nguyen; Nydam, Thomas; Allen-Freda, Erin; Mishra, Kaushal Kishor; Porro, Maria Grazia; Scher, Howard I.; Wilding, George</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins assocd. with growth and survival of malignant cells.  This phase 2 study evaluated the efficacy of i.v. (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy.  The primary end point was 24-wk progression-free survival.  Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline.  Methods: IV panobinostat (20 mg/m2) was administered to patients on days 1 and 8 of a 21-day cycle.  Tumor response was assessed by imaging every 12 wk (4 cycles) according to modified response evaluation criteria in solid tumors (Scher et al. in Clin Cancer Res 11:5223-5232, 23), and PSA response was defined as a 50 % decrease from baseline maintained for ≥4 wk.  Safety monitoring was routinely performed and included ECG monitoring.  Results: Of 35 enrolled patients, four (11.4 %) were alive without progression of disease at 24 wk.  PSA was evaluated in 34 (97.1 %) patients: five (14.3 %) patients demonstrated a decrease in PSA but none ≥50 %; one patient (2.9 %) had carcinoembryonic antigen as a marker of his prostate cancer, which declined by 43 %.  Toxicities regardless of relationship to panobinostat included fatigue (62.9 %), thrombocytopenia (45.7 %), nausea (51.4 %), and decreased appetite (37.1 %).  Conclusions: Despite promising preclin. data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clin. activity to pursue further investigation as a single agent in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIfYnqVJ-7Vg90H21EOLACvtfcHk0ljNh87aHE7vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrt7bM&md5=1fbbe53ab514fa6949677e5a7b7918f3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2224-8%26sid%3Dliteratum%253Aachs%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DEllard%26aufirst%3DS.%26aulast%3DChi%26aufirst%3DK.%2BN.%26aulast%3DNydam%26aufirst%3DT.%26aulast%3DAllen-Freda%26aufirst%3DE.%26aulast%3DMishra%26aufirst%3DK.%2BK.%26aulast%3DPorro%26aufirst%3DM.%2BG.%26aulast%3DScher%26aufirst%3DH.%2BI.%26aulast%3DWilding%26aufirst%3DG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520intravenous%2520panobinostat%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D537%26epage%3D544%26doi%3D10.1007%2Fs00280-013-2224-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pharmacophore model of marketed HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of tubulin/HDAC dual inhibitors. (A) Docking analysis of SMART in the colchicine-binding site of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>). (B) 90° clockwise rotation of tubulin in complex with SMART along the <i>x</i>-axis. (C) Design strategy of SMART-based HDAC and Tubulin dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0015.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Novel procedure to SMART analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) i: NaNO<sub>2</sub>, HCl, THF, 0 °C; ii: KI, 92%; (b) CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 90 °C, 74%; (c) RuCl<sub>3</sub>, PhI(OAc)<sub>2</sub>, dichloromethane (DCM)/H<sub>2</sub>O = 4/1, rt, 64%; (d) CuBr<sub>2</sub>, CHCl<sub>3</sub>/ethyl acetate = 1/2, 78 °C, 98%; and (e) EtOH, 87 °C, 89–96%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0016.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>10a–i</b> and <b>12a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 73%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 93%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 88%; and (e) HCl/1,4-doxane, DCM, rt, 96%</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0017.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a–i</b> and <b>17a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) EDCI, HOBt, triethylamine, DMF, rt, 95%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, Triethylamine, DMF, rt, 91%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 85%; and (e) HCl/1,4-dioxane, DCM, rt, 97%</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0018.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>20a–c</b> and <b>22a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) KI, K<sub>2</sub>CO<sub>3</sub>, MeCN, 59%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 93%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 87%; and (e) HCl/1,4-dioxane, DCM, rt, 91%</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0019.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>25a</b> and <b>27a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, DMF, 90 °C, 71%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 96%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 89%; and (e) HCl/1,4-dioxane, DCM, rt, 94%</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0020.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>30a</b> and <b>32a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions: (a) Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, triethylamine, DMF, 110 °C, 52%; (b) LiOH, MeOH/H<sub>2</sub>O, rt, 100%; (c) <i>o</i>-phenylenediamine, EDCI, HOBt, triethylamine, DMF, rt, 91%; (d) NH<sub>2</sub>OTHP, EDCI, HOBt, triethylamine, DMF, rt, 83%; and (e) HCl/1,4-dioxane, DCM, rt, 94%</p></p></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of SMART, MS-275, SMART + MS-275, and <b>15c</b> on the B16-F10 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition profiles of the newly synthesized compounds (1 μM) against HDAC isoforms 1, 3, 6, 7, and 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of tubulin polymerization <i>in vitro</i>. (A, B) Tubulin was exposed to 10 μM of selected compounds: vehicle control (5% dimethyl sulfoxide (DMSO)), colchicine, SMART, <b>10f</b>, <b>12c</b>, <b>15a</b>, <b>15c</b>,<b>15d</b>, <b>15e</b>, <b>15h</b>, <b>20b</b>, <b>30a</b>, and <b>32a</b>. (C) Inhibition of tubulin polymerization by SMART. (D) Inhibition of tubulin polymerization by compound <b>15c</b>. (E) SMART exhibited a dose-dependent inhibition of tubulin polymerization. (F) Compound <b>15c</b> exhibited a dose-dependent inhibition of tubulin polymerization..</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of SMART and compound <b>15c</b> on microtubules. B16-F10 cells were treated with vehicle control 0.1% DMSO (A), compound SMART (100 nM) (B), and compound <b>15c</b> (100 nM) (C) for 6 h. Microtubules were visualized with an anti-β-tubulin antibody (green), and the cell nucleus was visualized with DAPI (blue). Fluorescence images were collected using an LSM 880 laser confocal microscope (Carl Zeiss, Germany).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects on the B16-F10 cells migration and colony formation. (A) Representative images of the wound area in a wound-healing assay. Images were obtained at 0 h and 24 h after treatment with compound <b>15c</b> with 0, 25, 50, and 100 nM and SMART (100 nM). (B) Histograms display the length of the scratches at 0 h and 24 h after treatments with compound <b>15c</b> with 0, 25, 50, and 100 nM and SMART (100 nM) (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control). (C) Histograms display the number of colonies at different concentrations after treatments with compound <b>15c</b> (0, 25, 50, 100 nM) and SMART (0, 25, 50, 100 nM) (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control). (D) Number of colonies was counted after treating B16-F10 cells with the indicated concentrations of compound <b>15c</b> and SMART for 24 h (<i>n</i> = 3, **<i>P</i> < 0.05 versus DMSO control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0009.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell cycle arrest and apoptosis induced by MS-275, SMART, and <b>15c</b>. (A) MS-275, SMART, and <b>15c</b> induced G2/M arrest in B16-F10 cells. B16-F10 cells were incubated with MS-275 (100 nM), SMART (100 nM), or varying concentrations of <b>15c</b> (25, 50, and 100 nM) for 48 h. Cells treated with DMSO were used for comparison. (B) Histograms display the percentage of cell cycle distribution after treatment with <b>15c</b> and reference compounds. (C) Compound <b>15c</b> induced apoptosis in B16-F10 cells. B16-F10 cells were exposed to MS-275, SMART, and the increasing concentrations of compound <b>15c</b> (25, 50, and 100 nM) for 48 h. Cells treated with DMSO were used for comparison. The percentages of cells in each stage of cell apoptosis were quantified by flow cytometry: necrosis cells (upper left quadrant); late apoptotic cells (upper right quadrant); live cells (bottom left quadrant); and early apoptotic cells (bottom right quadrant). (D) Histograms displayed the percentage of cell cycle distribution after treatment with compound <b>15c</b> and reference compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0010.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) B16-F10 cells were treated with dimethyl sulfoxide (DMSO) or compound <b>15c</b> (20, 50, 100, and 200 nM) and MS-275 (1.0 μM) for 12 h. The levels of Ac-H3 and Histone 3 were determined by immunoblotting. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. Data are representative of three independent experiments. (B) ImageJ was used to quantify the Western blot data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0011.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Binding interactions between compound <b>15c</b> and target proteins (HDAC3 and Tubulin): (A) proposed binding mode of <b>15c</b> in the active site of HDAC3 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>); (B) 90° clockwise rotation of the dimeric HDAC3 in complex with <b>15c</b> along the x-axis. (C) Proposed binding mode of <b>15c</b> in the active site of tubulin (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>); (D) 90° clockwise rotation of tubulin in complex with <b>15c</b> along the x-axis. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0012.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> antitumor efficacy study. After administering vehicle, SMART (10 mg/kg per day), MS-275 (10 mg/kg per day), SMART + MS-275 (10 mg/kg per day), and compound 1<b>5c</b> (10 mg/kg per day) for 14 days, mice were sacrificed, and the tumors were weighed. (A) Images of tumor size at 14 days after treatment. (B) Body weight changes of mice during treatment. (C) Tumor weights for each group. **<i>P</i> < 0.05 vs control group. (D) Tumor volume changes for each group. Note: SM: SMART and MS: MS-275.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0013.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Immunohistochemistry of Ac-H3 expressions in melanoma tumor tissues. Formalin-fixed paraffin-embedded sections from melanoma tumor tissues were stained with H&E stain. **<i>P</i> < 0.05 vs control group. ImageJ was used to quantify the Ac-H3 positive ratio.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/medium/jm1c00413_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0014.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <i>In vivo</i> safety profiling. (A) Pathological sections of major tissues (heart, liver, kidney) were obtained from mice bearing melanoma tumors. Organs were stained with hematoxylin and eosin (H&E) and captured the representative images. (B) Evaluation of <i>in vivo</i> cardiotoxicity of <b>15c</b> by ECG and heart rate measurement in C57BL/6 mice. (C) Serum biochemistry analysis of indicators of kidney and liver function in mice of the above animal experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00413/20210616/images/large/jm1c00413_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00413&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i135">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 80 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turecki, G.</span></span> <span> </span><span class="NLM_article-title">Transgenerational epigenetic inheritance: an open discussion</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.2217/epi.15.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2217%2Fepi.15.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26344807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CqsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=781-790&author=C.+Nagyauthor=G.+Turecki&title=Transgenerational+epigenetic+inheritance%3A+an+open+discussion&doi=10.2217%2Fepi.15.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Transgenerational epigenetic inheritance: an open discussion</span></div><div class="casAuthors">Nagy, Corina; Turecki, Gustavo</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">781-790</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Much controversy surrounds the idea of transgenerational epigenetics.  Recent papers argue that epigenetic marks acquired through experience are passed to offspring, but as in much of the field of epigenetics, there is lack of precision in the definitions and perhaps too much eagerness to translate animal research to humans.  Here, we review operational definitions of transgenerational inheritance and the processes of epigenetic programming during early development.  Subsequently, based on this background, we critically examine some recent findings of studies investigating transgenerational inheritance.  Finally, we discuss possible mechanisms that may explain transgenerational inheritance, including transmission of an epigenetic blueprint, which may predispose offspring to specific epigenetic patterning.  Taken together, we conclude that presently, the evidence suggesting that acquired epigenetic marks are passed to the subsequent generation remains limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobZ4pI0dHX4bVg90H21EOLACvtfcHk0lhAkragHCLX7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CqsbzI&md5=5d13e7d3103659298e2257d615b58c30</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.46%26sid%3Dliteratum%253Aachs%26aulast%3DNagy%26aufirst%3DC.%26aulast%3DTurecki%26aufirst%3DG.%26atitle%3DTransgenerational%2520epigenetic%2520inheritance%253A%2520an%2520open%2520discussion%26jtitle%3DEpigenomics%26date%3D2015%26volume%3D7%26spage%3D781%26epage%3D790%26doi%3D10.2217%2Fepi.15.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefsbol, T. O.</span></span> <span> </span><span class="NLM_article-title">Epigenetic linkage of aging, cancer and nutrition</span>. <i>J. Exp. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1242/jeb.107110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1242%2Fjeb.107110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25568452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2Mros1SltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2015&pages=59-70&author=M.+Danielauthor=T.+O.+Tollefsbol&title=Epigenetic+linkage+of+aging%2C+cancer+and+nutrition&doi=10.1242%2Fjeb.107110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic linkage of aging, cancer and nutrition</span></div><div class="casAuthors">Daniel Michael; Tollefsbol Trygve O</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of experimental biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">59-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic mechanisms play a pivotal role in the expression of genes and can be influenced by both the quality and quantity of diet.  Dietary compounds such as sulforaphane (SFN) found in cruciferous vegetables and epigallocatechin-3-gallate (EGCG) in green tea exhibit the ability to affect various epigenetic mechanisms such as DNA methyltransferase (DNMT) inhibition, histone modifications via histone deacetylase (HDAC), histone acetyltransferase (HAT) inhibition, or noncoding RNA expression.  Regulation of these epigenetic mechanisms has been shown to have notable influences on the formation and progression of various neoplasms.  We have shown that an epigenetic diet can influence both cellular longevity and carcinogenesis through the modulation of certain key genes that encode telomerase and p16.  Caloric restriction (CR) can also play a crucial role in aging and cancer.  Reductions in caloric intake have been shown to increase both the life- and health-span in a variety of animal models.  Moreover, restriction of glucose has been demonstrated to decrease the incidence of age-related diseases such as cancer and diabetes.  A diet rich in compounds such as genistein, SFN and EGCG can positively modulate the epigenome and lead to many health benefits.  Also, reducing the quantity of calories and glucose in the diet can confer an increased health-span, including reduced cancer incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmp55G3JtI_r7NkxioyDXTfW6udTcc2eY4ZimzxAP2mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mros1SltQ%253D%253D&md5=b2b42a9020dc1375b45f8dadce6ef014</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1242%2Fjeb.107110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjeb.107110%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DM.%26aulast%3DTollefsbol%26aufirst%3DT.%2BO.%26atitle%3DEpigenetic%2520linkage%2520of%2520aging%252C%2520cancer%2520and%2520nutrition%26jtitle%3DJ.%2520Exp.%2520Biol.%26date%3D2015%26volume%3D218%26spage%3D59%26epage%3D70%26doi%3D10.1242%2Fjeb.107110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpaknia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.critrevonc.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29958625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1-18&author=A.+Mohammadiauthor=A.+Sharifiauthor=R.+Pourpakniaauthor=S.+Mohammadianauthor=A.+Sahebkar&title=Manipulating+macrophage+polarization+and+function+using+classical+HDAC+inhibitors%3A+Implications+for+autoimmunity+and+inflammation&doi=10.1016%2Fj.critrevonc.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span></div><div class="casAuthors">Mohammadi Asadollah; Sharifi Atefeh; Pourpaknia Reza; Mohammadian Saeed; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases.  Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury.  However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis.  Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors.  In this review we discuss how post-translational modifications of histones influence the innate and adaptive immunity through macrophage survival, proliferation, polarization and functional responses.  We also discuss how emerging classes of pharmacological agents which developed for use as anti-cancer agents, have been applied as anti-inflammatory drugs to treat macrophage-mediated inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA9U7N2BuEAGLFM_lbR1VmfW6udTcc2eY4ZimzxAP2mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D&md5=9c7e9610928e1158a2d2b73d95dd3cdc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DSharifi%26aufirst%3DA.%26aulast%3DPourpaknia%26aufirst%3DR.%26aulast%3DMohammadian%26aufirst%3DS.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DManipulating%2520macrophage%2520polarization%2520and%2520function%2520using%2520classical%2520HDAC%2520inhibitors%253A%2520Implications%2520for%2520autoimmunity%2520and%2520inflammation%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D128%26spage%3D1%26epage%3D18%26doi%3D10.1016%2Fj.critrevonc.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges of HDAC inhibitors in cancer therapeutics</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fbs.acr.2018.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29551127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=183-211&author=J.+J.+McClureauthor=X.+Liauthor=C.+J.+Chou&title=Advances+and+challenges+of+HDAC+inhibitors+in+cancer+therapeutics&doi=10.1016%2Fbs.acr.2018.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges of HDAC inhibitors in cancer therapeutics</span></div><div class="casAuthors">McClure, Jesse J.; Li, Xiaoyang; Chou, C. James</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-211</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Since the identification and cloning of human histone deacetylases (HDACs) and the rapid approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma, the field of HDAC biol. has met many initial successes.  However, many challenges remain due to the complexity involved in the lysine posttranslational modifications, epigenetic transcription regulation, and nonepigenetic cellular signaling cascades.  In this chapter, we will: review the discovery of the first HDAC inhibitor and present discussion regarding the future of next-generation HDAC inhibitors, give an overview of different classes of HDACs and their differences in lysine deacylation activity, discuss different classes of HDAC inhibitors and their HDAC isoenzyme preferences, and review HDAC inhibitors' preclin. studies, their clin. trials, their pharmacokinetic challenges, and future direction.  We will also discuss the likely reason for the failure of multiple HDAC inhibitor clin. trials in malignancies other than lymphoma and multiple myeloma.  In addn., the potential mol. mechanism(s) that may play a key role in the efficacy and therapeutic response rate in the clinic and the likely patient population for HDAC therapy will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUDUqssP9cRrVg90H21EOLACvtfcHk0ljDlAg246YUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3L&md5=f5ccc3247e06654093d0fb2a17acd822</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26atitle%3DAdvances%2520and%2520challenges%2520of%2520HDAC%2520inhibitors%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26spage%3D183%26epage%3D211%26doi%3D10.1016%2Fbs.acr.2018.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0ljDlAg246YUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">HDAC family: What are the cancer relevant targets?</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0ljDlAg246YUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glauben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, B.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors in models of inflammation-related tumorigenesis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.canlet.2008.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=19101082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=154-159&author=R.+Glaubenauthor=E.+Sonnenbergauthor=M.+Zeitzauthor=B.+Siegmund&title=HDAC+inhibitors+in+models+of+inflammation-related+tumorigenesis&doi=10.1016%2Fj.canlet.2008.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in models of inflammation-related tumorigenesis</span></div><div class="casAuthors">Glauben, Rainer; Sonnenberg, Elena; Zeitz, Martin; Siegmund, Britta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-159</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors have been described in detail for their anti-proliferative potency.  Recently, an anti-inflammatory property was characterized in vitro and in vivo.  This dual efficacy of HDAC inhibitors is highly attractive, since chronic inflammations such as ulcerative colitis are assocd. with an increased risk of developing carcinomas.  Addnl., in models of colitis and inflammation-induced tumorigenesis inflammation as well as tumor development was significantly inhibited by HDAC inhibitor treatment.  The mechanisms involved reach beyond the simple regulation of histone acetylation and deacetylation.  The currently known key target structures and mechanisms mediating this dual effect will be discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYsMPyjny5FbVg90H21EOLACvtfcHk0ljDlAg246YUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt78%253D&md5=5175ac399b14437c3cf31a396f630046</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGlauben%26aufirst%3DR.%26aulast%3DSonnenberg%26aufirst%3DE.%26aulast%3DZeitz%26aufirst%3DM.%26aulast%3DSiegmund%26aufirst%3DB.%26atitle%3DHDAC%2520inhibitors%2520in%2520models%2520of%2520inflammation-related%2520tumorigenesis%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D154%26epage%3D159%26doi%3D10.1016%2Fj.canlet.2008.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+deacetylases+and+their+inhibitors+in+cancer%2C+neurological+diseases+and+immune+disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lhWXS7qf-qp7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520deacetylases%2520and%2520their%2520inhibitors%2520in%2520cancer%252C%2520neurological%2520diseases%2520and%2520immune%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovanella, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, S.</span></span> <span> </span><span class="NLM_article-title">Cytogenetic characterization of two human milk-derived cell line (HBL-100) passages differing in tumorigenicity</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=2334116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADyaK3c3ktVKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=113-117&author=M.+K.+Dhaliwalauthor=B.+C.+Giovanellaauthor=S.+Pathak&title=Cytogenetic+characterization+of+two+human+milk-derived+cell+line+%28HBL-100%29+passages+differing+in+tumorigenicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cytogenetic characterization of two human milk-derived cell line (HBL-100) passages differing in tumorigenicity</span></div><div class="casAuthors">Dhaliwal M K; Giovanella B C; Pathak S</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-7</span>
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    </div><div class="casAbstract">Using the trypsin-Giemsa staining technique, cytogenetic analysis was done to determine the karyotypic characteristics in cells from the early nontumorigenic passage 12 and the late tumorigenic passage 147 of the human breast milk-derived cell line HBL-100.  Acquisition of exclusive marker chromosomes in the late passage of HBL-100 may be responsible for the tumorigenic behavior of these cells in athymic nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHt4A3qNmkZBLDWw4HIq2sfW6udTcc2eYTdjDHJ7Zmprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3ktVKguw%253D%253D&md5=0158e035844bdf71d5820b0599f4b5ad</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDhaliwal%26aufirst%3DM.%2BK.%26aulast%3DGiovanella%26aufirst%3DB.%2BC.%26aulast%3DPathak%26aufirst%3DS.%26atitle%3DCytogenetic%2520characterization%2520of%2520two%2520human%2520milk-derived%2520cell%2520line%2520%2528HBL-100%2529%2520passages%2520differing%2520in%2520tumorigenicity%26jtitle%3DAnticancer%2520Res.%26date%3D1990%26volume%3D10%26spage%3D113%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grabiec, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potempa, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic regulation in bacterial infections: targeting histone deacetylases</span>. <i>Crit. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1080/1040841X.2017.1373063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1080%2F1040841X.2017.1373063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28971711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2018&pages=336-350&author=A.+M.+Grabiecauthor=J.+Potempa&title=Epigenetic+regulation+in+bacterial+infections%3A+targeting+histone+deacetylases&doi=10.1080%2F1040841X.2017.1373063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic regulation in bacterial infections: targeting histone deacetylases</span></div><div class="casAuthors">Grabiec, Aleksander M.; Potempa, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">336-350</span>CODEN:
                <span class="NLM_cas:coden">CRVMAC</span>;
        ISSN:<span class="NLM_cas:issn">1040-841X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Pathogens have developed sophisticated strategies to evade the immune response, among which manipulation of host cellular epigenetic mechanisms plays a prominent role.  In the last decade, modulation of histone acetylation in host cells has emerged as an efficient strategy of bacterial immune evasion.  Virulence factors and metabolic products of pathogenic microorganisms alter expression and activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs) to suppress transcription of host defense genes through epigenetic changes in histone acetylation marks.  This new avenue of pathogen-host interactions is particularly important in light of introduction of HDAC inhibitors into clin. practice.  Considerable effort is currently being applied to better understand the effects of HDAC inhibitors on the quality of immune responses to pathogens and to characterize the therapeutic potential of these compds. in microbial infections.  In this review, we will discuss the recently discovered mechanisms utilized by bacteria to facilitate their survival within infected hosts through subversion of the host acetylation system and the effects of acetylation modulators, including HDAC inhibitors and bromodomain-contg. BET protein inhibitors, on innate immune responses against microbial pathogens.  Integration of these two lines of exptl. evidence provides crit. information on the perspectives of epigenetic therapies targeting protein acetylation in infectious diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWOyBcvPfLQ7Vg90H21EOLACvtfcHk0lhWXS7qf-qp7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsLzM&md5=6d621fdcfc6ea6ae7c56329f86448b56</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F1040841X.2017.1373063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1040841X.2017.1373063%26sid%3Dliteratum%253Aachs%26aulast%3DGrabiec%26aufirst%3DA.%2BM.%26aulast%3DPotempa%26aufirst%3DJ.%26atitle%3DEpigenetic%2520regulation%2520in%2520bacterial%2520infections%253A%2520targeting%2520histone%2520deacetylases%26jtitle%3DCrit.%2520Rev.%2520Microbiol.%26date%3D2018%26volume%3D44%26spage%3D336%26epage%3D350%26doi%3D10.1080%2F1040841X.2017.1373063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic protein families: a new frontier for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+protein+families%3A+a+new+frontier+for+drug+discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0ljuu8BEX5us6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520protein%2520families%253A%2520a%2520new%2520frontier%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barneda-Zahonero, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.molonc.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=22963873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=579-589&author=B.+Barneda-Zahoneroauthor=M.+Parra&title=Histone+deacetylases+and+cancer&doi=10.1016%2Fj.molonc.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Barneda-Zahonero, Bruna; Parra, Maribel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">579-589</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells.  Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).  Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types.  Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clin. research.  However, the contributions of specific HDACs to a given cancer type remain incompletely understood.  The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the anal. of patient samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOl-qXEsP2IrVg90H21EOLACvtfcHk0ljuu8BEX5us6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12gt7%252FK&md5=7c294b40669bf079b1319391ee456642</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarneda-Zahonero%26aufirst%3DB.%26aulast%3DParra%26aufirst%3DM.%26atitle%3DHistone%2520deacetylases%2520and%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2012%26volume%3D6%26spage%3D579%26epage%3D589%26doi%3D10.1016%2Fj.molonc.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woster, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: novel therapeutics targeting epigenetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1021/jm501941q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501941q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=523-524&author=S.+J.+Conwayauthor=P.+M.+Wosterauthor=J.+K.+Shenauthor=G.+Georgauthor=S.+Wang&title=Epigenetics%3A+novel+therapeutics+targeting+epigenetics&doi=10.1021%2Fjm501941q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: Novel Therapeutics Targeting Epigenetics</span></div><div class="casAuthors">Conway, Stuart J.; Woster, Patrick M.; Shen, Jing-Kang; Georg, Gunda; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRBHbQISoP7Vg90H21EOLACvtfcHk0ljuu8BEX5us6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP&md5=589ff3da038c55adece6bcdbd6bbe461</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm501941q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501941q%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DShen%26aufirst%3DJ.%2BK.%26aulast%3DGeorg%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEpigenetics%253A%2520novel%2520therapeutics%2520targeting%2520epigenetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D523%26epage%3D524%26doi%3D10.1021%2Fjm501941q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">An overview of HDAC inhibitors and their synthetic routes</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190227221507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F1568026619666190227221507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30827245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1005-1040&author=X.+Pengauthor=G.+Liaoauthor=P.+Sunauthor=Z.+Yuauthor=J.+Chen&title=An+overview+of+HDAC+inhibitors+and+their+synthetic+routes&doi=10.2174%2F1568026619666190227221507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of HDAC Inhibitors and their Synthetic Routes</span></div><div class="casAuthors">Peng, Xiaopeng; Liao, Guochao; Sun, Pinghua; Yu, Zhiqiang; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1005-1040</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Epigenetics play a key role in the origin, development and metastasis of cancer.  Epigenetic processes include DNA methylation, histone acetylation, histone methylation, and histone phosphorylation, among which, histone acetylation is the most common one that plays important roles in the regulation of normal cellular processes, and is controlled by histone deacetylases (HDACs) and histone acetyltransferases (HATs).  HDACs are involved in the regulation of many key cellular processes, such as DNA damage repair, cell cycle control, autophagy, metab., senescence and chaperone function, and can lead to oncogene activation.  As a result, HDACs are considered to be an excellent target for anti-cancer therapeutics like histone deacetylase inhibitors (HDACi) which have attracted much attention in the last decade.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  The primary purpose of this paper is to summarize recent HDAC inhibitors and the synthetic routes as well as to discuss the direction for the future development of new HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhio1W1VLtLVg90H21EOLACvtfcHk0ljuu8BEX5us6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbjI&md5=f3498cd3fca8678c42e7dac3fd20faa8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190227221507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190227221507%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DAn%2520overview%2520of%2520HDAC%2520inhibitors%2520and%2520their%2520synthetic%2520routes%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1005%26epage%3D1040%26doi%3D10.2174%2F1568026619666190227221507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty years of HDAC inhibitors: 2020 insight and hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+years+of+HDAC+inhibitors%3A+2020+insight+and+hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0liTd5jR2f-_aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520years%2520of%2520HDAC%2520inhibitors%253A%25202020%2520insight%2520and%2520hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+a+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eYOb69j_EWGLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520a%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. G.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.7150/ijbs.9067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.7150%2Fijbs.9067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25013383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWntL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=757-770&author=Z.+Liauthor=W.+G.+Zhu&title=Targeting+histone+deacetylases+for+cancer+therapy%3A+from+molecular+mechanisms+to+clinical+implications&doi=10.7150%2Fijbs.9067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications</span></div><div class="casAuthors">Li, Zhiming; Zhu, Wei-Guo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">757-770</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Genetic abnormalities have been conventionally considered as hallmarks of cancer.  However, studies over the past decades have demonstrated that epigenetic regulation also participates in the development of cancer.  The fundamental patterns of epigenetic components, such as DNA methylation and histone modifications, are frequently altered in tumor cells.  Acetylation is one of the best characterized modifications of histones, which is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  HDACs are a group of enzymes which catalyze the removal of the acetyl groups of both histones and non-histone proteins.  HDACs are involved in modulating most key cellular processes, including transcriptional regulation, apoptosis, DNA damage repair, cell cycle control, autophagy, metab., senescence and chaperone function.  Because HDACs have been found to function incorrectly in cancer, various HDAC inhibitors are being investigated to act as cancer chemotherapeutics.  The primary purpose of this paper is to summarize recent studies of the links between HDACs and cancer, and further discuss the underlying mechanisms of anti-tumor activities of HDAC inhibitors and clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAiClMpknHObVg90H21EOLACvtfcHk0liTd5jR2f-_aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWntL3O&md5=bd463eb902a1a78f54cab5fe166943fd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.7150%2Fijbs.9067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.9067%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DW.%2BG.%26atitle%3DTargeting%2520histone%2520deacetylases%2520for%2520cancer%2520therapy%253A%2520from%2520molecular%2520mechanisms%2520to%2520clinical%2520implications%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2014%26volume%3D10%26spage%3D757%26epage%3D770%26doi%3D10.7150%2Fijbs.9067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomathi Priya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjan, M. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of histone deacetylase as antitumor agents: A critical review</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bioorg.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27239721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=18-42&author=M.+Manalauthor=M.+J.+Chandrasekarauthor=J.+Gomathi+Priyaauthor=M.+J.+Nanjan&title=Inhibitors+of+histone+deacetylase+as+antitumor+agents%3A+A+critical+review&doi=10.1016%2Fj.bioorg.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of histone deacetylase as antitumor agents: A critical review</span></div><div class="casAuthors">Manal, Mohammed; Chandrasekar, M. J. N.; Gomathi Priya, Jeyapal; Nanjan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-42</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (E.C. 3.5.1.98 - HDAC) is an amidohydrolase involved in deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital role in the epigenetic regulation of gene expression.  Due to its aberrant activity and over expression in several forms of cancer, HDAC is considered as a potential anticancer drug target.  HDAC inhibitors alter the acetylation status of histone and nonhistone proteins to regulate various cellular events such as cell survival, differentiation and apoptosis in tumor cells and thus exhibit anticancer activity.  Till date, four drugs, namely Vorinostat (SAHA), Romidepsin (FK-228), Belinostat (PXD-101) and Panobinostat (LBH-589) have been granted FDA approval for cancer and several HDAC inhibitors are currently in various phases of clin. trials, either as monotherapy and/or in combination with existing/novel anticancer agents.  Regardless of this, today scientific efforts have fortified the quest for newer and novel HDAC inhibitors that show isoform selectivity.  This review focuses on the chem. of the mols. of two classes of HDAC inhibitors, namely short chain fatty acids and hydroxamic acids, investigated so far as novel therapeutic agents for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdC7-JmHyErrVg90H21EOLACvtfcHk0liIg2Bb3X373w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D&md5=82e5562d9b74dfef2d6077bbceccd505</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DManal%26aufirst%3DM.%26aulast%3DChandrasekar%26aufirst%3DM.%2BJ.%26aulast%3DGomathi%2BPriya%26aufirst%3DJ.%26aulast%3DNanjan%26aufirst%3DM.%2BJ.%26atitle%3DInhibitors%2520of%2520histone%2520deacetylase%2520as%2520antitumor%2520agents%253A%2520A%2520critical%2520review%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D67%26spage%3D18%26epage%3D42%26doi%3D10.1016%2Fj.bioorg.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenehjem, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat for the treatment of multiple myeloma: the evidence to date</span>. <i>J. Blood Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.2147/JBM.S69140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2FJBM.S69140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26504410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=269-276&author=H.+Baileyauthor=D.+D.+Stenehjemauthor=S.+Sharma&title=Panobinostat+for+the+treatment+of+multiple+myeloma%3A+the+evidence+to+date&doi=10.2147%2FJBM.S69140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat for the treatment of multiple myeloma: the evidence to date</span></div><div class="casAuthors">Bailey, Hanna; Stenehjem, David D.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Blood Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">JBMOB7</span>;
        ISSN:<span class="NLM_cas:issn">1179-2736</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow.  Survival of patients diagnosed with myeloma has significantly improved in the last decade, following the approval of novel agents.  Despite great strides achieved in the management of multiple myeloma, it is still considered an incurable disease as the majority of patients relapse after initiation of therapy.  Addnl., the duration of response generally decreases with an increasing no. of therapy lines.  The need to overcome resistance to therapy dictates research into more potent agents and those with novel mechanisms of action.  A therapeutic option for relapsed/refractory myeloma includes histone deacetylase inhibition.  Various histone deacetylase inhibitors, including the newly approved panobinostat, are currently under evaluation in this setting.  Panobinostat for multiple myeloma is used in combination with other potent therapeutic agents, such as proteasome inhibitors and steroids.  Ongoing research evaluating other panobinostat-contg. regimens will provide addnl. insight into its place in myeloma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg66vLqHlQjrVg90H21EOLACvtfcHk0liIg2Bb3X373w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D&md5=cdff9d1bd461e6fb06e50c4708097951</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2147%2FJBM.S69140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJBM.S69140%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%26aulast%3DStenehjem%26aufirst%3DD.%2BD.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPanobinostat%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520the%2520evidence%2520to%2520date%26jtitle%3DJ.%2520Blood%2520Med.%26date%3D2015%26spage%3D269%26epage%3D276%26doi%3D10.2147%2FJBM.S69140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.2147/btt.s29965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2Fbtt.s29965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23459471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=47-60&author=K.+Ververisauthor=A.+Hiongauthor=T.+C.+Karagiannisauthor=P.+V.+Licciardi&title=Histone+deacetylase+inhibitors+%28HDACIs%29%3A+multitargeted+anticancer+agents&doi=10.2147%2Fbtt.s29965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span></div><div class="casAuthors">Ververis, Katherine; Hiong, Alison; Karagiannis, Tom C.; Licciardi, Paul V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs.  The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addn. to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth.  The family of HDAC inhibitors is large and diverse.  It includes a range of naturally occurring and synthetic compds. that differ in terms of structure, function, and specificity.  HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells.  HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies.  Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax).  More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma.  Many more clin. trials assessing the effects of various HDAC inhibitors on hematol. and solid malignancies are currently being conducted.  Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood.  Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be crit. for the advancement of these drugs, esp. to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents.  This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy.  Further, we outline the pharmacol. and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compds. in clin. studies to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAm6AJlxdHLVg90H21EOLACvtfcHk0liIg2Bb3X373w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D&md5=288f04e51d214cef9edf5bc8a8c3c624</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2Fbtt.s29965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fbtt.s29965%26sid%3Dliteratum%253Aachs%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DHiong%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%253A%2520multitargeted%2520anticancer%2520agents%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D47%26epage%3D60%26doi%3D10.2147%2Fbtt.s29965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piekarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0liIg2Bb3X373w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lhS6rknXQThJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracker, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politz, O.</span></span> <span> </span><span class="NLM_article-title">MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1388</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.biocel.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=17383217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1388-1405&author=H.+Hess-Stumppauthor=T.+U.+Brackerauthor=D.+Hendersonauthor=O.+Politz&title=MS-275%2C+a+potent+orally+available+inhibitor+of+histone+deacetylases%2D%2Dthe+development+of+an+anticancer+agent&doi=10.1016%2Fj.biocel.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent</span></div><div class="casAuthors">Hess-Stumpp, Holger; Bracker, Tomke Ute; Henderson, David; Politz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1388-1405</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the last few years it was found that beside genetic aberrations, epigenetic changes also play an important role in tumorigenesis.  Acetylation and deacetylation of histones have been found to contribute to a significant extent to epigenetic regulation of gene expression.  Analyses of various tumor models and patient samples revealed that the enzyme class of histone deacetylases is assocd. with many types of cancer and that, for example, over-expression of these enzymes leads to a disturbed balance between acetylation and deacetylation of histones, resulting in differences in the gene expression patterns between normal and cancer cells.  Consequently, this class of enzymes has been considered as a potential target for cancer therapy.  Numerous inhibitors have been identified and several are in clin. development.  Although, with SAHA, one inhibitor has been approved by the FDA for a tumor indication, many open questions remain regarding the mode of action of these inhibitors.  In this review, various aspects of preclin. and clin. research of the HDAC inhibitor MS-275 are described, to provide insight into the development of such a compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD6wh1LDkEpLVg90H21EOLACvtfcHk0lhS6rknXQThJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWltLc%253D&md5=fdf0094118b83648161b4a457bb2e294</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DBracker%26aufirst%3DT.%2BU.%26aulast%3DHenderson%26aufirst%3DD.%26aulast%3DPolitz%26aufirst%3DO.%26atitle%3DMS-275%252C%2520a%2520potent%2520orally%2520available%2520inhibitor%2520of%2520histone%2520deacetylases--the%2520development%2520of%2520an%2520anticancer%2520agent%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1388%26epage%3D1405%26doi%3D10.1016%2Fj.biocel.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armanious, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradley, M. G.</span></span> <span> </span><span class="NLM_article-title">Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities</span>. <i>Trends Cardiovasc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.tcm.2018.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.tcm.2018.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29910109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=29-39&author=A.+Guhaauthor=M.+Armaniousauthor=M.+G.+Fradley&title=Update+on+cardio-oncology%3A+Novel+cancer+therapeutics+and+associated+cardiotoxicities&doi=10.1016%2Fj.tcm.2018.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities</span></div><div class="casAuthors">Guha, Avirup; Armanious, Merna; Fradley, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cardiovascular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">TCMDEQ</span>;
        ISSN:<span class="NLM_cas:issn">1050-1738</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There have been significant advances in the field of oncol. leading to improved survival as a result of novel targeted and immunotherapies.  Despite these improved outcomes, there is increased recognition of cardiotoxicities assocd. with these therapies that can lead to significant morbidity and mortality.  As such, the field of cardio-oncol. has seen significant growth over the last several years.  In this review, we discuss recent advances in the field of cardio-oncol. and provide a detailed discussion of the cardiovascular complications assocd. with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGaYu9pkctLVg90H21EOLACvtfcHk0lhS6rknXQThJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqu7%252FK&md5=cc6454527119684c870e4d3050a5d9db</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tcm.2018.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcm.2018.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DA.%26aulast%3DArmanious%26aufirst%3DM.%26aulast%3DFradley%26aufirst%3DM.%2BG.%26atitle%3DUpdate%2520on%2520cardio-oncology%253A%2520Novel%2520cancer%2520therapeutics%2520and%2520associated%2520cardiotoxicities%26jtitle%3DTrends%2520Cardiovasc.%2520Med.%26date%3D2019%26volume%3D29%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.tcm.2018.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiattarella, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toscano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimarco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>219</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ijcard.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27362830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2016&pages=396-403&author=G.+G.+Schiattarellaauthor=A.+Sanninoauthor=E.+Toscanoauthor=F.+Cattaneoauthor=B.+Trimarcoauthor=G.+Espositoauthor=C.+Perrino&title=Cardiovascular+effects+of+histone+deacetylase+inhibitors+epigenetic+therapies%3A+Systematic+review+of+62+studies+and+new+hypotheses+for+future+research&doi=10.1016%2Fj.ijcard.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research</span></div><div class="casAuthors">Schiattarella Gabriele Giacomo; Sannino Anna; Toscano Evelina; Cattaneo Fabio; Trimarco Bruno; Esposito Giovanni; Perrino Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">396-403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHU9cOCIEYRA8IxFYvehhofW6udTcc2eb7csnXXE36Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltFersg%253D%253D&md5=f85f4a989a24f78a755011d554434cde</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSchiattarella%26aufirst%3DG.%2BG.%26aulast%3DSannino%26aufirst%3DA.%26aulast%3DToscano%26aufirst%3DE.%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DTrimarco%26aufirst%3DB.%26aulast%3DEsposito%26aufirst%3DG.%26aulast%3DPerrino%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520histone%2520deacetylase%2520inhibitors%2520epigenetic%2520therapies%253A%2520Systematic%2520review%2520of%252062%2520studies%2520and%2520new%2520hypotheses%2520for%2520future%2520research%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D219%26spage%3D396%26epage%3D403%26doi%3D10.1016%2Fj.ijcard.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeoung, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.00486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3389%2Ffcell.2020.00486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32626712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB38noslSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=486&author=M.+Yeonauthor=Y.+Kimauthor=H.+S.+Jungauthor=D.+Jeoung&title=Histone+deacetylase+inhibitors+to+overcome+resistance+to+targeted+and+immuno+therapy+in+metastatic+melanoma&doi=10.3389%2Ffcell.2020.00486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma</span></div><div class="casAuthors">Yeon Minjeong; Jung Hyun Suk; Jeoung Dooil; Kim Youngmi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">486</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma.  A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/AKT/mammalian target of rapamycin (mTOR) in melanoma.  Target-specific agents, such as MAPK inhibitors improve progression-free survival.  However, BRAF(V600E) mutant melanomas treated with BRAF kinase inhibitors develop resistance.  Immune checkpoint molecules, such as programmed death-1 (PD-1) and programmed death ligand-1(PD-L1), induce immune evasion of cancer cells.  MAPK inhibitor resistance results from the increased expression of PD-L1.  Immune checkpoint inhibitors, such as anti-PD-L1 or anti-PD-1, are main players in immune therapies designed to target metastatic melanoma.  However, melanoma patients show low response rate and resistance to these inhibitors develops within 6-8 months of treatment.  Epigenetic reprogramming, such as DNA methylaion and histone modification, regulates the expression of genes involved in cellular proliferation, immune checkpoints and the response to anti-cancer drugs.  Histone deacetylases (HDACs) remove acetyl groups from histone and non-histone proteins and act as transcriptional repressors.  HDACs are often dysregulated in melanomas, and regulate MAPK signaling, cancer progression, and responses to various anti-cancer drugs.  HDACs have been shown to regulate the expression of PD-1/PD-L1 and genes involved in immune evasion.  These reports make HDACs ideal targets for the development of anti-melanoma therapeutics.  We review the mechanisms of resistance to anti-melanoma therapies, including MAPK inhibitors and immune checkpoint inhibitors.  We address the effects of HDAC inhibitors on the response to MAPK inhibitors and immune checkpoint inhibitors in melanoma.  In addition, we discuss current progress in anti-melanoma therapies involving a combination of HDAC inhibitors, immune checkpoint inhibitors, and MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKnSTGbtpJagpJitSxOdIlfW6udTcc2eb7csnXXE36Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38noslSgsQ%253D%253D&md5=988560a3bd6c4d97922f83d83301f2b5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.00486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.00486%26sid%3Dliteratum%253Aachs%26aulast%3DYeon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DH.%2BS.%26aulast%3DJeoung%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520to%2520overcome%2520resistance%2520to%2520targeted%2520and%2520immuno%2520therapy%2520in%2520metastatic%2520melanoma%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D486%26doi%3D10.3389%2Ffcell.2020.00486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Role of HDACs in normal and malignant hematopoiesis</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">5</span> <span class="refDoi"> DOI: 10.1186/s12943-019-1127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs12943-019-1127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31910827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&author=P.+Wangauthor=Z.+Wangauthor=J.+Liu&title=Role+of+HDACs+in+normal+and+malignant+hematopoiesis&doi=10.1186%2Fs12943-019-1127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of HDACs in normal and malignant hematopoiesis</span></div><div class="casAuthors">Wang Pan; Wang Zi; Wang Pan; Wang Zi; Liu Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Normal hematopoiesis requires the accurate orchestration of lineage-specific patterns of gene expression at each stage of development, and epigenetic regulators play a vital role.  Disordered epigenetic regulation has emerged as a key mechanism contributing to hematological malignancies.  Histone deacetylases (HDACs) are a series of key transcriptional cofactors that regulate gene expression by deacetylation of lysine residues on histone and nonhistone proteins.  In normal hematopoiesis, HDACs are widely involved in the development of various lineages.  Their functions involve stemness maintenance, lineage commitment determination, cell differentiation and proliferation, etc.  Deregulation of HDACs by abnormal expression or activity and oncogenic HDAC-containing transcriptional complexes are involved in hematological malignancies.  Currently, HDAC family members are attractive targets for drug design, and a variety of HDAC-based combination strategies have been developed for the treatment of hematological malignancies.  Drug resistance and limited therapeutic efficacy are key issues that hinder the clinical applications of HDAC inhibitors (HDACis).  In this review, we summarize the current knowledge of how HDACs and HDAC-containing complexes function in normal hematopoiesis and highlight the etiology of HDACs in hematological malignancies.  Moreover, the implication and drug resistance of HDACis are also discussed.  This review presents an overview of the physiology and pathology of HDACs in the blood system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuj8DxhH9_I9LIORRPd5lbfW6udTcc2eb7csnXXE36Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D&md5=96b7cff9ffdde16fca3e2b6e79e51078</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1127-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRole%2520of%2520HDACs%2520in%2520normal%2520and%2520malignant%2520hematopoiesis%26jtitle%3DMol.%2520Cancer%26date%3D2020%26volume%3D19%26doi%3D10.1186%2Fs12943-019-1127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 3 as a novel therapeutic target in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fleu.2013.231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23913134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=680-689&author=J.+Minamiauthor=R.+Suzukiauthor=R.+Mazitschekauthor=G.+Gorgunauthor=B.+Ghoshauthor=D.+Cirsteaauthor=Y.+Huauthor=N.+Mimuraauthor=H.+Ohguchiauthor=F.+Cottiniauthor=J.+Jakubikovaauthor=N.+C.+Munshiauthor=S.+J.+Haggartyauthor=P.+G.+Richardsonauthor=T.+Hideshimaauthor=K.+C.+Anderson&title=Histone+deacetylase+3+as+a+novel+therapeutic+target+in+multiple+myeloma&doi=10.1038%2Fleu.2013.231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 as a novel therapeutic target in multiple myeloma</span></div><div class="casAuthors">Minami, J.; Suzuki, R.; Mazitschek, R.; Gorgun, G.; Ghosh, B.; Cirstea, D.; Hu, Y.; Mimura, N.; Ohguchi, H.; Cottini, F.; Jakubikova, J.; Munshi, N. C.; Haggarty, S. J.; Richardson, P. G.; Hideshima, T.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-689</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) represent novel mol. targets for the treatment of various types of cancers, including multiple myeloma (MM).  Many HDAC inhibitors have already shown remarkable antitumor activities in the preclin. setting; however, their clin. utility is limited because of unfavorable toxicities assocd. with their broad range HDAC inhibitory effects.  Isoform-selective HDAC inhibition may allow for MM cytotoxicity without attendant side effects.  In this study, we demonstrated that HDAC3 knockdown and a small-mol. HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage.  Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3).  Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth.  Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3.  Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity.  Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM.  Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3gGhcOXmyLVg90H21EOLACvtfcHk0lh7Lm1pSXlNhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7%252FK&md5=4ff22875205c892a7bc8c82e2aa4bdd0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.231%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DJakubikova%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHistone%2520deacetylase%25203%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D680%26epage%3D689%26doi%3D10.1038%2Fleu.2013.231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leus, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wouden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krist, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ourailidou, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleftheriadis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistemaker, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjaltema, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haisma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">45047</span> <span class="refDoi"> DOI: 10.1038/srep45047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fsrep45047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=28344354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt12gu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=N.+G.+Leusauthor=T.+van+den+Boschauthor=P.+E.+van+der+Woudenauthor=K.+Kristauthor=M.+E.+Ourailidouauthor=N.+Eleftheriadisauthor=L.+E.+Kistemakerauthor=S.+Bosauthor=R.+A.+Gjaltemaauthor=S.+A.+Mekonnenauthor=R.+Bischoffauthor=R.+Gosensauthor=H.+J.+Haismaauthor=F.+J.+Dekker&title=HDAC1-3+inhibitor+MS-275+enhances+IL10+expression+in+RAW264.7+macrophages+and+reduces+cigarette+smoke-induced+airway+inflammation+in+mice&doi=10.1038%2Fsrep45047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice</span></div><div class="casAuthors">Leus, Niek G. J.; van den Bosch, Thea; van der Wouden, Petra E.; Krist, Kim; Ourailidou, Maria E.; Eleftheriadis, Nikolaos; Kistemaker, Loes E. M.; Bos, Sophie; Gjaltema, Rutger A. F.; Mekonnen, Solomon A.; Bischoff, Rainer; Gosens, Reinoud; Haisma, Hidde J.; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45047</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) constitutes a major health burden.  Studying underlying mol. mechanisms could lead to new therapeutic targets.  Macrophages are orchestrators of COPD, by releasing pro-inflammatory cytokines.  This process relies on transcription factors such as NF-κB, among others.  NF-κB is regulated by lysine acetylation; a post-translational modification installed by histone acetyltransferases and removed by histone deacetylases (HDACs).  We hypothesized that small mol. HDAC inhibitors (HDACi) targeting class I HDACs members that can regulate NF-κB could attenuate inflammatory responses in COPD via modulation of the NF-κB signaling output.  MS-275 is an isoform-selective inhibitor of HDAC1-3.  In precision-cut lung slices and RAW264.7 macrophages, MS-275 upregulated the expression of both pro- and anti-inflammatory genes, implying mixed effects.  Interestingly, anti-inflammatory IL10 expression was upregulated in these model systems.  In the macrophages, this was assocd. with increased NF-κB activity, acetylation, nuclear translocation, and binding to the IL10 promoter.  Importantly, in an in vivo model of cigarette smoke-exposed C57Bl/6 mice, MS-275 robustly attenuated inflammatory expression of KC and neutrophil influx in the lungs.  This study highlights for the first time the potential of isoform-selective HDACi for the treatment of inflammatory lung diseases like COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhkKFUYjVj0rVg90H21EOLACvtfcHk0lh7Lm1pSXlNhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt12gu70%253D&md5=617056d0512dd7842c5f6ed1440f4817</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsrep45047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep45047%26sid%3Dliteratum%253Aachs%26aulast%3DLeus%26aufirst%3DN.%2BG.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BWouden%26aufirst%3DP.%2BE.%26aulast%3DKrist%26aufirst%3DK.%26aulast%3DOurailidou%26aufirst%3DM.%2BE.%26aulast%3DEleftheriadis%26aufirst%3DN.%26aulast%3DKistemaker%26aufirst%3DL.%2BE.%26aulast%3DBos%26aufirst%3DS.%26aulast%3DGjaltema%26aufirst%3DR.%2BA.%26aulast%3DMekonnen%26aufirst%3DS.%2BA.%26aulast%3DBischoff%26aufirst%3DR.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DHaisma%26aufirst%3DH.%2BJ.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DHDAC1-3%2520inhibitor%2520MS-275%2520enhances%2520IL10%2520expression%2520in%2520RAW264.7%2520macrophages%2520and%2520reduces%2520cigarette%2520smoke-induced%2520airway%2520inflammation%2520in%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fsrep45047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0lh7Lm1pSXlNhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3240</span>– <span class="NLM_lpage">3244</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmc.2013.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23602523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3240-3244&author=X.+Zhangauthor=J.+Zhangauthor=L.+Tongauthor=Y.+Luoauthor=M.+Suauthor=Y.+Zangauthor=J.+Liauthor=W.+Luauthor=Y.+Chen&title=The+discovery+of+colchicine-SAHA+hybrids+as+a+new+class+of+antitumor+agents&doi=10.1016%2Fj.bmc.2013.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span></div><div class="casAuthors">Zhang, Xuan; Zhang, Jie; Tong, Linjiang; Luo, Yu; Su, Mingbo; Zang, Yi; Li, Jia; Lu, Wei; Chen, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3240-3244</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of colchicine-SAHA hybrids were designed and synthesized based on the synergistic antitumor effect tubulin inhibitors and histone deacetylases(HDAC) inhibitors.  To the best of our knowledge, this is the first design of mols. that are dual inhibitors of tubulin and HDAC.  Biol. evaluations of these compds. included the inhibitory activity of HDAC, in vitro cell cycle anal. in BEL-7402 cells as well as cytotoxicity in five cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-0eT4cJg3rVg90H21EOLACvtfcHk0libSoyhzeEI0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D&md5=2a3020c5a48b617bd04f5c2cb214df99</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520discovery%2520of%2520colchicine-SAHA%2520hybrids%2520as%2520a%2520new%2520class%2520of%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3240%26epage%3D3244%26doi%3D10.1016%2Fj.bmc.2013.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nervi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codacci-Pisanelli, G.</span></span> <span> </span><span class="NLM_article-title">Epigenetic treatment of solid tumours: a review of clinical trials</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">127</span> <span class="refDoi"> DOI: 10.1186/s13148-015-0157-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs13148-015-0157-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26692909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVOks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=C.+Nerviauthor=E.+De+Marinisauthor=G.+Codacci-Pisanelli&title=Epigenetic+treatment+of+solid+tumours%3A+a+review+of+clinical+trials&doi=10.1186%2Fs13148-015-0157-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic treatment of solid tumours: a review of clinical trials</span></div><div class="casAuthors">Nervi, Clara; De Marinis, Elisabetta; Codacci-Pisanelli, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127/1-127/20</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Epigenetic treatment has been approved by regulatory agencies for haematol. malignancies.  The success obsd. in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumors.  Several agents that interfere with DNA methylation-demethylation and histones acetylation/deacetylation have been studied, and some (such as azacytidine, decitabine, valproic acid and vorinostat) are already in clin. use.  The aim of this review is to provide a brief overview of the mol. events underlying the antitumor effects of epigenetic treatments and to summarise data available on clin. trials that tested the use of epigenetic agents against solid tumors.  We not only list results but also try to indicate how the proper evaluation of this treatment might result in a better selection of effective agents and in a more rapid development.  We divided compds. in demethylating agents and HDAC inhibitors.  For each class, we report the antitumor activity and the toxic side effects.  When available, we describe plasma pharmacokinetics and pharmacodynamic evaluation in tumors and in surrogate tissues (generally white blood cells).  Epigenetic treatment is a reality in haematol. malignancies and deserves adequate attention in solid tumors.  A careful consideration of available clin. data however is required for faster drug development and possibly to re-evaluate some mols. that were perhaps discarded too early.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9w8eD5OdO1LVg90H21EOLACvtfcHk0libSoyhzeEI0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVOks7Y%253D&md5=f473a8d7cf1aad0f3d306eac854d9177</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs13148-015-0157-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-015-0157-2%26sid%3Dliteratum%253Aachs%26aulast%3DNervi%26aufirst%3DC.%26aulast%3DDe%2BMarinis%26aufirst%3DE.%26aulast%3DCodacci-Pisanelli%26aufirst%3DG.%26atitle%3DEpigenetic%2520treatment%2520of%2520solid%2520tumours%253A%2520a%2520review%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Epigenet.%26date%3D2015%26volume%3D7%26doi%3D10.1186%2Fs13148-015-0157-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0libSoyhzeEI0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhVUrfk9AP04A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+Comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2eYtXdA3mektxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520Comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinarivala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Multi-targeting anticancer agents: rational approaches, synthetic routes and structure activity relationship</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.2174/1871520619666190118120708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F1871520619666190118120708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30657048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BB3cjisl2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=842-874&author=H.+Singhauthor=N.+Kinarivalaauthor=S.+Sharma&title=Multi-targeting+anticancer+agents%3A+rational+approaches%2C+synthetic+routes+and+structure+activity+relationship&doi=10.2174%2F1871520619666190118120708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship</span></div><div class="casAuthors">Singh Harbinder; Sharma Sahil; Kinarivala Nihar; Sharma Sahil</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">842-874</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We live in a world with complex diseases such as cancer which cannot be cured with one-compound one-target based therapeutic paradigm.  This could be due to the involvement of multiple pathogenic mechanisms.  One-compound-various-targets stratagem has become a prevailing research topic in anti-cancer drug discovery.  The simultaneous interruption of two or more targets has improved the therapeutic efficacy as compared to the specific targeted based therapy.  In this review, six types of dual targeting agents along with some interesting strategies used for their design and synthesis are discussed.  Their pharmacology with various types of the molecular interactions within their specific targets has also been described.  This assemblage will reveal the recent trends and insights in front of the scientific community working in dual inhibitors and help them in designing the next generation of multi-targeted anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-MrG1fXAfTsKL0FlyGHDofW6udTcc2eYtXdA3mektxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjisl2ruw%253D%253D&md5=89985c2b548788939754e7fd3701833f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKinarivala%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DMulti-targeting%2520anticancer%2520agents%253A%2520rational%2520approaches%252C%2520synthetic%2520routes%2520and%2520structure%2520activity%2520relationship%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D842%26epage%3D874%26doi%3D10.2174%2F1871520619666190118120708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lhVUrfk9AP04A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00821-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs10637-019-00821-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31414267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFylurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=755-764&author=J.+Chenauthor=B.+Luoauthor=S.+Wenauthor=R.+Pi&title=Discovery+of+a+novel+rhein-SAHA+hybrid+as+a+multi-targeted+anti-glioblastoma+drug&doi=10.1007%2Fs10637-019-00821-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug</span></div><div class="casAuthors">Chen, Jingkao; Luo, Bingling; Wen, Shijun; Pi, Rongbiao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">755-764</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system (CNS).  Effective treatments remain limited.  Therefore, novel chemotherapy drugs with high efficiency and few adverse effects are urgently needed.  Histone deacetylase (HDAC) and serum and glucocorticoid-regulated protein kinase 1 (SGK1) are targets for the prevention and treatment of GBM.  Rhein has antitumor and SGK1 suppression effects, although its biol. activity is limited by poor bioavailability.  To improve the drug-like properties of rhein, we constructed a novel rhein-hydroxyethyl hydroxamic acid deriv. (SYSUP007), which combined rhein with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA).  In the present study, the human GBM cell lines, T98G, U87 and U251, were used to investigate the anticancer effects of SYSUP007 in-vitro.  We found that SYSUP007 was more effective in inhibiting glioma cell proliferation, invasion and migration in-vitro compared with the effects of rhein and SAHA.  We also confirmed that SYSUP007 increased the expression of Ac-K100 and NDRG1 (targets of HDAC and SGK1).  The present study indicates the potential that SYSUP007, as a novel rhein and SAHA deriv., for development as an anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobTrMbwz2MoLVg90H21EOLACvtfcHk0lhKkRi-ReI_gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFylurjL&md5=111f64d1798fdd48e5b19fcc5a17832f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00821-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00821-4%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DPi%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520rhein-SAHA%2520hybrid%2520as%2520a%2520multi-targeted%2520anti-glioblastoma%2520drug%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D755%26epage%3D764%26doi%3D10.1007%2Fs10637-019-00821-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>, <span class="NLM_elocation-id">112831</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.112831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32961382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&author=X.+Pengauthor=Z.+Sunauthor=P.+Kuangauthor=J.+Chen&title=Recent+progress+on+HDAC+inhibitors+with+dual+targeting+capabilities+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.112831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span></div><div class="casAuthors">Peng, Xiaopeng; Sun, Zhiqiang; Kuang, Peihua; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112831</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-acetyl lysine of histones, allowing histones to wrap DNA more tightly.  HDACs play an essential role in many biol. processes such as gene regulation, transcription, cell proliferation, angiogenesis, migration, differentiation and metastasis.  As a result, HDACs represent an excellent target for anti-cancer drug discovery.  The search for histone deacetylase inhibitors (HDACis) has been intensified in the last decade with numerous HDACis being discovered, and some of them have reached the market.  However, currently available HDACis are mostly non-isoform selective and suffer from several drawbacks such as limited efficacy, drug resistance, and toxicities.  Therefore, isoform-selective HDACis and HDACis with dual targeting capabilities have attracted much attention from academia to industry in the past 5 years, and great advances have been achieved in this area.  In this paper, we summarize recent progress on HDACis with dual targeting capabilities and their potential application to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHs5GEjS8RbVg90H21EOLACvtfcHk0lhKkRi-ReI_gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM&md5=d6f340dc0222b3f22a702c963cb1728b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520progress%2520on%2520HDAC%2520inhibitors%2520with%2520dual%2520targeting%2520capabilities%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26doi%3D10.1016%2Fj.ejmech.2020.112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+molecules+simultaneously+inhibiting+p53-murine+double+minute+2+%28MDM2%29+interaction+and+histone+deacetylases+%28HDACs%29%3A+discovery+of+novel+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lhKkRi-ReI_gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecules%2520simultaneously%2520inhibiting%2520p53-murine%2520double%2520minute%25202%2520%2528MDM2%2529%2520interaction%2520and%2520histone%2520deacetylases%2520%2528HDACs%2529%253A%2520discovery%2520of%2520novel%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>– <span class="NLM_lpage">7983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0ljemkiejpZ2BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Janus Kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+Janus+Kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0ljemkiejpZ2BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of Leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+the+combinational+treatment+of+Leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0ljemkiejpZ2BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520the%2520combinational%2520treatment%2520of%2520Leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilha, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K/HDAC inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4256-4292&author=A.+Thakurauthor=G.+J.+Tawaauthor=M.+J.+Hendersonauthor=C.+Danchikauthor=S.+Liuauthor=P.+Shahauthor=A.+Q.+Wangauthor=G.+Dunnauthor=M.+Kabirauthor=E.+C.+Padilhaauthor=X.+Xuauthor=A.+Simeonovauthor=S.+Kharbandaauthor=R.+Stoneauthor=G.+Grewal&title=Design%2C+synthesis%2C+and+biological+evaluation+of+quinazolin-4-one-based+hydroxamic+acids+as+dual+PI3K%2FHDAC+inhibitors&doi=10.1021%2Facs.jmedchem.0c00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span></div><div class="casAuthors">Thakur, Ashish; Tawa, Gregory J.; Henderson, Mark J.; Danchik, Carina; Liu, Suiyang; Shah, Pranav; Wang, Amy Q.; Dunn, Garrett; Kabir, Md.; Padilha, Elias C.; Xu, Xin; Simeonov, Anton; Kharbanda, Surender; Stone, Richard; Grewal, Gurmit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4256-4292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker.  Several of these dual inhibitors were highly potent (IC50 < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines.  The lead compd. 48c, induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients, while showing no cytotoxicity against normal PBMCs, NIH3T3, and HEK293 cells.  Target engagement of PI3Kδ and HDAC6 by 48c was demonstrated in MV411 cells using the cellular thermal shift assay (CETSA).  Compd. 48c showed good pharmacokinetics properties in mice via i.p. administration and provides a means to examine the biol. effects of inhibiting these two important enzymes with a single mol., either in vitro or in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWWMm2AttIWLVg90H21EOLACvtfcHk0lilUISEd2Wm5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D&md5=75f1696a5d5826a46380a85e2a115b59</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DPadilha%26aufirst%3DE.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGrewal%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinazolin-4-one-based%2520hydroxamic%2520acids%2520as%2520dual%2520PI3K%252FHDAC%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4256%26epage%3D4292%26doi%3D10.1021%2Facs.jmedchem.0c00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span> <span> </span><span class="NLM_article-title">Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8977</span>– <span class="NLM_lpage">9002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8977-9002&author=T.+Liuauthor=Y.+Wanauthor=Y.+Xiaoauthor=C.+Xiaauthor=G.+Duan&title=Dual-target+inhibitors+based+on+HDACs%3A+novel+antitumor+agents+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.0c00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy</span></div><div class="casAuthors">Liu, Tingting; Wan, Yichao; Xiao, Yuliang; Xia, Chengcai; Duan, Guiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8977-9002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) play an important role in regulating target gene expression.  They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells.  In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment.  In this review, we discuss the theor. basis for designing HDAC-involved dual-target drugs and provide insight into the structure-activity relationships of these dual-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbD4ktOU4jbVg90H21EOLACvtfcHk0lilUISEd2Wm5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D&md5=fa6764d35879c6a8973d57231854f821</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DG.%26atitle%3DDual-target%2520inhibitors%2520based%2520on%2520HDACs%253A%2520novel%2520antitumor%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8977%26epage%3D9002%26doi%3D10.1021%2Facs.jmedchem.0c00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munger, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepicelli, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3647</span>– <span class="NLM_lpage">3656</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0ljXKb2Gr3415w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0ljXKb2Gr3415w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">82</span> <span class="refDoi"> DOI: 10.1186/s13045-015-0176-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1186%2Fs13045-015-0176-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=26156322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&author=M.+W.+Chaoauthor=M.+J.+Laiauthor=J.+P.+Liouauthor=Y.+L.+Changauthor=J.+C.+Wangauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+synergic+effect+of+vincristine+and+vorinostat+in+leukemia+in+vitro+and+in+vivo&doi=10.1186%2Fs13045-015-0176-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span></div><div class="casAuthors">Chao Min-Wu; Chang Ya-Ling; Teng Che-Ming; Lai Mei-Jung; Liou Jing-Ping; Wang Jing-Chi; Pan Shiow-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy.  The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia.  In order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells.  METHODS:  Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by flow cytometry.  In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence analysis was performed to detect microtubule distribution and morphology.  In vivo effect of the combination was evaluated by a MOLT-4 xenograft model.  Statistical analysis was assessed by Bonferroni's t test.  RESULTS:  Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM.  This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation.  Moreover, the results of vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through HDAC6 inhibition.  CONCLUSION:  These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.  These data suggest that the combination effect of vincristine/SAHA could have an important preclinical basis for future clinical trial testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZWw7KK08a6Zp6t8nS6Nc3fW6udTcc2eaUcHpOx-fw7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D&md5=b22f13563067cc55509bc41110bb86ab</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0176-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0176-7%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520synergic%2520effect%2520of%2520vincristine%2520and%2520vorinostat%2520in%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26doi%3D10.1186%2Fs13045-015-0176-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang-Verslues, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span> <span> </span><span class="NLM_article-title">A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3389%2Ffphar.2018.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29593536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKnsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=205&author=Y.+W.+Wuauthor=K.+C.+Hsuauthor=H.+Y.+Leeauthor=T.+C.+Huangauthor=T.+E.+Linauthor=Y.+L.+Chenauthor=T.+Y.+Sungauthor=J.+P.+Liouauthor=W.+W.+Hwang-Versluesauthor=S.+L.+Panauthor=W.+C.+HuangFu&title=A+novel+dual+HDAC6+and+tubulin+inhibitor%2C+MPT0B451%2C+displays+anti-tumor+ability+in+human+cancer+cells+in+vitro+and+in+vivo&doi=10.3389%2Ffphar.2018.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A novel dual hdac6 and tubulin inhibitor, mpt0b451, displays anti-tumor ability in human cancer cells in vitro and in vivo</span></div><div class="casAuthors">Wu, Yi-Wen; Hsu, Kai-Cheng; Lee, Hsueh-Yun; Huang, Tsui-Chin; Lin, Tony E.; Chen, Yi-Ling; Sung, Ting-Yi; Liou, Jing-Ping; Hwang-Verslues, Wendy W.; Pan, Shiow-Lin; Huangfu, Wei-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/16</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The combination cancer therapy is a new strategy to circumvent drug resistance for the treatment of high metastasis and advanced malignancies.  Herein, we developed a synthesized compd. MPT0B451 that display inhibitory effect against histone deacetylase (HDAC) 6 and tubulin assembly.  Our data demonstrated that MPT0B451 significantly inhibited cancer cell growths in HL-60 and PC-3 cells due to inhibition of HDAC activity.  MPT0B451 also markedly increased caspase-mediated apoptosis in these cells.  The cell cycle anal. showed mitotic arrest induced by MPT0B451 with enhanced expression of G2/M transition proteins.  Moreover, mol. docking anal. supported MPT0B451 as a dual HDAC6 and tubulin inhibitor.  Finally, MPT0B451 led to tumor growth inhibition (TGI) in HL-60 and PC-3 xenograft models.  These findings indicated that MPT0B451 has dual inhibition effects for HDAC6 and tubulin, and also contributed to G2/M arrest followed by apoptotic induction.  Together, our results suggested that MPT0B451 may serve as a potent anti-cancer treatment regimen in human prostate cancer and acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3JSrfP91mRrVg90H21EOLACvtfcHk0limbjAHAPxiIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKnsr%252FK&md5=6524b2fd87dc06a6035d9d7ec2d3ace9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DHwang-Verslues%26aufirst%3DW.%2BW.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26atitle%3DA%2520novel%2520dual%2520HDAC6%2520and%2520tubulin%2520inhibitor%252C%2520MPT0B451%252C%2520displays%2520anti-tumor%2520ability%2520in%2520human%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D205%26doi%3D10.3389%2Ffphar.2018.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmcl.2019.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31400938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2638-2645&author=B.+Wangauthor=X.+Chenauthor=J.+Gaoauthor=L.+Suauthor=L.+Zhangauthor=H.+Xuauthor=Y.+Luan&title=Anti-tumor+activity+evaluation+of+novel+tubulin+and+HDAC+dual-targeting+inhibitors&doi=10.1016%2Fj.bmcl.2019.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span></div><div class="casAuthors">Wang, Baolei; Chen, Xuehong; Gao, Jianjun; Su, Li; Zhang, Li; Xu, Hongwei; Luan, Yepeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs.  In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors.  Three compds. inhibited the activities of HDAC and tubulin polymn. simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines.  Compd. 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells.  Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by mol. docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7ecC0j2FibVg90H21EOLACvtfcHk0limbjAHAPxiIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI&md5=ac1e230b5a2b579f503f87bf6821e887</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520evaluation%2520of%2520novel%2520tubulin%2520and%2520HDAC%2520dual-targeting%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2638%26epage%3D2645%26doi%3D10.1016%2Fj.bmcl.2019.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosch, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothemund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfner, M.</span></span> <span> </span><span class="NLM_article-title">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure(-)activity relations of new inhibitors of HDAC and/or tubulin function</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">383</span>, <span class="refDoi"> DOI: 10.3390/ijms20020383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.3390%2Fijms20020383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=383&author=F.+Schmittauthor=L.+C.+Goschauthor=A.+Dittmerauthor=M.+Rothemundauthor=T.+Muellerauthor=R.+Schobertauthor=B.+Biersackauthor=A.+Volkamerauthor=M.+Hopfner&title=Oxazole-bridged+combretastatin+A-4+derivatives+with+tethered+hydroxamic+acids%3A+structure%28-%29activity+relations+of+new+inhibitors+of+HDAC+and%2For+tubulin+function&doi=10.3390%2Fijms20020383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span></div><div class="casAuthors">Schmitt, Florian; Gosch, Lisa Chiara; Dittmer, Alexandra; Rothemund, Matthias; Mueller, Thomas; Schobert, Rainer; Biersack, Bernhard; Volkamer, Andrea; Hoepfner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383/1-383/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">New inhibitors of tubulin polymn. and/or histone deacetylase (HDAC) activity were synthesized by attaching alkyl tethered hydroxamic acid appendages of varying length to oxazole-bridged combretastatin A-4 analogous caps.  While their antiproliferative and microtubule disrupting effect was most pronounced for derivs. with short spacers, HDAC inhibition was strongest for those with longer spacers.  These findings were further supported by computational methods such as structure-based docking expts. exploring the target interactions of the derivs. with varying linkers.  For instance, compds. featuring short four-atom spacers between cap and hydroxamic acid inhibited the growth of various cancer cell lines and human endothelial hybrid cells with IC50 values in the low nanomolar range.  In line with their ability to inhibit the microtubule assembly, four- and five-atom spacered hydroxamic acids caused an accumulation of 518A2 melanoma cells in G2/M phase, whereas a compd. featuring a six-atom spacer and performing best in HDAC inhibition, induced a G1 arrest in these cells.  All these beneficial anticancer activities together with their selectivity for cancer cells over non-malignant cells, point out the great potential of these novel pleiotropic HDAC and tubulin inhibitors as drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnd6vxUZSv1bVg90H21EOLACvtfcHk0limbjAHAPxiIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE&md5=c1c66ac969fd55fe4bfe78527375d8d3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3390%2Fijms20020383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020383%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DF.%26aulast%3DGosch%26aufirst%3DL.%2BC.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DRothemund%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DT.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DHopfner%26aufirst%3DM.%26atitle%3DOxazole-bridged%2520combretastatin%2520A-4%2520derivatives%2520with%2520tethered%2520hydroxamic%2520acids%253A%2520structure%2528-%2529activity%2520relations%2520of%2520new%2520inhibitors%2520of%2520HDAC%2520and%252For%2520tubulin%2520function%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D383%26doi%3D10.3390%2Fijms20020383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, A. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourad, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span> <span> </span><span class="NLM_article-title">Novel HDAC/tubulin dual inhibitor: design, synthesis and docking studies of alpha-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3130</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S256756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2147%2FDDDT.S256756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32848361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVSju7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=3111-3130&author=A.+A.+E.+Mouradauthor=M.+A.+E.+Mouradauthor=P.+G.+Jones&title=Novel+HDAC%2Ftubulin+dual+inhibitor%3A+design%2C+synthesis+and+docking+studies+of+alpha-phthalimido-chalcone+hybrids+as+potential+anticancer+agents+with+apoptosis-inducing+activity&doi=10.2147%2FDDDT.S256756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel HDAC/tubulin dual inhibitor: design, synthesis and docking studies of α-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity</span></div><div class="casAuthors">Mourad, Ahmed A. E.; Mourad, Mai A. E.; Jones, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3111-3130</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: In order to develop novel anticancer HDAC/tubulin dual inhibitors, a novel series of α-phthalimido-substituted chalcones-based hybrids was synthesized and characterized by IR, 1 H NMR, 13C NMR, mass spectroscopy and X-ray anal.  Methods: All the synthesized compds. were evaluated for their in vitro anticancer activity against MCF-7 and HepG2 human cancer cell lines using MTT assay.  To explore the mechanism of action of the synthesized compds., in vitro β-tubulin polymn. and HDAC 1 and 2 inhibitory activity were measured for the most potent anticancer hybrids.  Further, cell cycle anal. was also evaluated.  Results: The trimethoxy deriv. 7j showed the most potent anticancer activity, possessed the most potent β-tubulin polymerase and HDAC 1 and 2 inhibitory activity and efficiently induced cell cycle arrest at both G2/M and preG1phases in the MCF-7 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoafZXAkH3jPLVg90H21EOLACvtfcHk0ljuHvE0w9RM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVSju7vN&md5=848ffc6f73c59d45abbac976067e9be7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S256756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S256756%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DA.%2BA.%2BE.%26aulast%3DMourad%26aufirst%3DM.%2BA.%2BE.%26aulast%3DJones%26aufirst%3DP.%2BG.%26atitle%3DNovel%2520HDAC%252Ftubulin%2520dual%2520inhibitor%253A%2520design%252C%2520synthesis%2520and%2520docking%2520studies%2520of%2520alpha-phthalimido-chalcone%2520hybrids%2520as%2520potential%2520anticancer%2520agents%2520with%2520apoptosis-inducing%2520activity%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2020%26volume%3D14%26spage%3D3111%26epage%3D3130%26doi%3D10.2147%2FDDDT.S256756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aboeldahab, A. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshr, E. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabea, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, O. M.</span></span> <span> </span><span class="NLM_article-title">Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2018.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29396364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2ns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=79-92&author=A.+M.+A.+Aboeldahabauthor=E.+A.+M.+Beshrauthor=M.+E.+Shomanauthor=S.+M.+Rabeaauthor=O.+M.+Aly&title=Spirohydantoins+and+1%2C2%2C4-triazole-3-carboxamide+derivatives+as+inhibitors+of+histone+deacetylase%3A+Design%2C+synthesis%2C+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Aboeldahab, Alshimaa M. A.; Beshr, Eman A. M.; Shoman, Mai E.; Rabea, Safwat M.; Aly, Omar M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-92</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two structurally novel series of histone deacetylase inhibitors (HDACIs) namely spirohydantoins I [n = 1, 2, 3, 4, 5, 6] and 1,2,4-triazole-3-carboxamide derivs. II with potential surface recognition moieties like 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione and 1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide resp., were designed, synthesized and evaluated for their anti-proliferative and HDAC inhibitory activities.  Mol. modeling study was performed to assess the potential binding ability of some compds. I [n = 5, 6] and II [n = 1, 5] to HDAC enzyme as well as colchicine binding site of β-tubulin.  Compds. II were evaluated as potential HDAC-tubulin dual inhibitors due to the structural similarities between their (1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide) nucleus and Combretastatin A4.  Among them, compd. I [n = 6] showed a remarkable inhibition of HDAC comparable to SAHA while compd. II [n = 5] behaved as potent HDAC-tubulin dual inhibitor.  It was found that, 2-(1-(3-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamido)acetic acid showed remarkable cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0pjDxmJ-a7Vg90H21EOLACvtfcHk0ljuHvE0w9RM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2ns7w%253D&md5=2a18a687e6eec35c8b41c50e4c0144f0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DAboeldahab%26aufirst%3DA.%2BM.%2BA.%26aulast%3DBeshr%26aufirst%3DE.%2BA.%2BM.%26aulast%3DShoman%26aufirst%3DM.%2BE.%26aulast%3DRabea%26aufirst%3DS.%2BM.%26aulast%3DAly%26aufirst%3DO.%2BM.%26atitle%3DSpirohydantoins%2520and%25201%252C2%252C4-triazole-3-carboxamide%2520derivatives%2520as%2520inhibitors%2520of%2520histone%2520deacetylase%253A%2520Design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D79%26epage%3D92%26doi%3D10.1016%2Fj.ejmech.2018.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0ljuHvE0w9RM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0lj3rCjPGwo9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuppens, I. E.</span></span> <span> </span><span class="NLM_article-title">Current state of the art of new tubulin inhibitors in the clinic</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2174/157488406775268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.2174%2F157488406775268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18666378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=57-70&author=I.+E.+Kuppens&title=Current+state+of+the+art+of+new+tubulin+inhibitors+in+the+clinic&doi=10.2174%2F157488406775268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Current state of the art of new tubulin inhibitors in the clinic</span></div><div class="casAuthors">Kuppens, Isa E. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For years the microtubule stabilizing agents docetaxel and paclitaxel belong to the most successful clin. chemotherapeutic agents.  Several attempts have been made over the years to equal and better these drugs.  Both taxanes are assocd. with the notorious side effect neurotoxicity and are often accompanied with increased drug resistance and cross resistance with other chemotherapeutic agents.  In addn. their high lipophilicity demands use of co-solvents, which are assocd. with less favorable side effects such as hypersensitivity.  To prevent these disadvantages and improve the clin. application of the taxanes several new agents have entered clin. testing.  The agents that are discussed are the drug class of the discodermolides; XAA296A and the epothilones; BMS-247550, BMS-310705, epo906, kos-862 and the agents ABT-751 and D-24851.  Here we present an overview of recently performed clin. studies to det. the current state of the art of the tubulin inhibitors which are intended to enlarge and improve the clin. use of the taxanes docetaxel and paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAXF3Hrb0ubVg90H21EOLACvtfcHk0lj3rCjPGwo9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D&md5=e0ab529443ebf69c924de9d76ccc685d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F157488406775268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488406775268200%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%2BE.%26atitle%3DCurrent%2520state%2520of%2520the%2520art%2520of%2520new%2520tubulin%2520inhibitors%2520in%2520the%2520clinic%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D1%26spage%3D57%26epage%3D70%26doi%3D10.2174%2F157488406775268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lj3rCjPGwo9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lj3rCjPGwo9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>184</i></span>, <span class="NLM_elocation-id">111732</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2019.111732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=31610372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2019&author=L.+Liauthor=D.+Quanauthor=J.+Chenauthor=J.+Dingauthor=J.+Zhaoauthor=L.+Lvauthor=J.+Chen&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-substituted+-2-aryl+imidazoles+targeting+tubulin+polymerization+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2019.111732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</span></div><div class="casAuthors">Li, Ling; Quan, Dongling; Chen, Jingxuan; Ding, Jiahao; Zhao, Jinwu; Lv, Lin; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111732</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-substituted-2-aryl imidazoles I [R = Me, 3-MeC6H4, SO2Ph, etc.], benzoates and benzamides ArC(O)XAr1 [Ar = 3-NH2-4-MeOC6H3, 3-NO2-4-MeOC6H3, 3,4,5-(OMe)3; Ar1 = 3-NH2-4-MeOC6H3, 3-NO2-4-MeOC6H3, 3,4,5-(OMe)3; X = N, O] were designed, synthesized and screened for antiproliferative activity against six human cancer cell lines with IC50 values in nano molar range.  Among them, compd. I [R = 3-NH2-4-MeOC6H3] exhibited the best anticancer activity with an av. IC50 value of ~ 100 nM.  The compd. maintained the mechanism of action by inhibiting tubulin polymn., thus causing cell arrest at G2/M phase and apoptosis.  In vivo efficacy studies indicated that compd. I [R = 3-NH2-4-MeOC6H3] was highly effective in suppressing tumor growth in a MDA-MB-468 xenograft model of nude mouse with a TGI (Tumor Growth Suppression) of 77% at 60 mg/kg without causing significant toxicity.  In addn., compd. I [R = 3-NH2-4-MeOC6H3] displayed significantly better water soly. (36.70 μg/mL) than CA-4 (2.83 μg/mL).  Mol. modeling study indicated that compd. I [R = 3-NH2-4-MeOC6H3] could bind well to the colchicine binding site in tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2doLS6peA77Vg90H21EOLACvtfcHk0lgivmhJgqF-Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjP&md5=004b1bd25a73ba1a6e2642593d835c83</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111732%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQuan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-substituted%2520-2-aryl%2520imidazoles%2520targeting%2520tubulin%2520polymerization%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D184%26doi%3D10.1016%2Fj.ejmech.2019.111732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7414</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm100884b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100884b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7414-7427&author=J.+Chenauthor=Z.+Wangauthor=C.+M.+Liauthor=Y.+Luauthor=P.+K.+Vaddadyauthor=B.+Meibohmauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazoles+targeting+the+colchicines+binding+site+in+tubulin+as+potential+anticancer+agents&doi=10.1021%2Fjm100884b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span></div><div class="casAuthors">Chen, Jianjun; Wang, Zhao; Li, Chien-Ming; Lu, Yan; Vaddady, Pavan K.; Meibohm, Bernd; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7414-7427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivs. and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART).  The av. IC50 of the most active compd. I ( R = Me) was 15.7 nM.  ABI analogs have substantially improved aq. soly. (48.9 μg/mL for I ( R = NMe2) vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4).  Mechanism of action studies indicate that the anticancer activity of ABI analogs is through inhibition of tubulin polymn. by interacting with the colchicine binding site.  Unlike paclitaxel and colchicine, the ABI compds. were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells.  In vivo results indicated that II was more effective than DTIC in inhibiting melanoma xenograph tumor growth.  Our results suggest that the novel ABI compds. may be developed to effectively treat drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0en8R0EjqRrVg90H21EOLACvtfcHk0lgivmhJgqF-Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O&md5=7eb4d70e1e2bf16dce361a6308ea6f93</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm100884b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100884b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazoles%2520targeting%2520the%2520colchicines%2520binding%2520site%2520in%2520tubulin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7414%26epage%3D7427%26doi%3D10.1021%2Fjm100884b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.1021/jm801449a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801449a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1701-1711&author=Y.+Luauthor=C.+M.+Liauthor=Z.+Wangauthor=C.+R.+Rossauthor=J.+Chenauthor=J.+T.+Daltonauthor=W.+Liauthor=D.+D.+Miller&title=Discovery+of+4-substituted+methoxybenzoyl-aryl-thiazole+as+novel+anticancer+agents%3A+synthesis%2C+biological+evaluation%2C+and+structure-activity+relationships&doi=10.1021%2Fjm801449a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Ross, Charles R., II; Chen, Jianjun; Dalton, James T.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1701-1711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) have been discovered and synthesized as a result of structural modifications of the lead compd. 2-arylthiazolidine-4-carboxylic acid amides (ATCAA).  The antiproliferative activity of the SMART agents against melanoma and prostate cancer cells was improved from μM to low nM range compared with the ATCAA series.  The structure-activity relationship was discussed from modifications of "A", "B", and "C" rings and the linker.  Preliminary mechanism of action studies indicated that these compds. exert their anticancer activity through inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnsk5EK9mVLVg90H21EOLACvtfcHk0lgivmhJgqF-Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D&md5=68261f1589c55ffca6f44c4410c91c9c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm801449a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801449a%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%25204-substituted%2520methoxybenzoyl-aryl-thiazole%2520as%2520novel%2520anticancer%2520agents%253A%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1701%26epage%3D1711%26doi%3D10.1021%2Fjm801449a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>213</i></span>, <span class="NLM_elocation-id">113058</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.113058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=33280898" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2020&author=X.+Yangauthor=B.+Chengauthor=Y.+Xiaoauthor=M.+Xueauthor=T.+Liuauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+CA-4+analogs+as+dual+inhibitors+of+tubulin+polymerization+and+PD-1%2FPD-L1+interaction+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.113058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113058%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520CA-4%2520analogs%2520as%2520dual%2520inhibitors%2520of%2520tubulin%2520polymerization%2520and%2520PD-1%252FPD-L1%2520interaction%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D213%26doi%3D10.1016%2Fj.ejmech.2020.113058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1860</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0likpPpOmXEIoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P.</span></span> <span> </span><span class="NLM_article-title">RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1038/onc.2013.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1038%2Fonc.2013.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23584480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1527-1537&author=Y.+Zhuauthor=K.+Dasauthor=J.+Wuauthor=M.+H.+Leeauthor=P.+Tan&title=RNH1+regulation+of+reactive+oxygen+species+contributes+to+histone+deacetylase+inhibitor+resistance+in+gastric+cancer+cells&doi=10.1038%2Fonc.2013.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells</span></div><div class="casAuthors">Zhu, Y.; Das, K.; Wu, J.; Lee, M. H.; Tan, P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1527-1537</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) are a promising class of anticancer epigenetic drugs, however, mol. factors influencing the responses of individual tumors to HDACi therapies remain obscure.  Here, we sought to identify genes assocd. with HDACi resistance in gastric cancer.  Treating a panel of 17 gastric cancer cell lines with multiple HDACi compds. (trichostatin A, SAHA and MS275), we identified two distinct classes of lines exhibiting either HDACi sensitivity or resistance.  Genomic comparisons between the sensitive and resistant classes using two independent microarray platforms identified RNH1, encoding a RNase inhibitor, as a gene highly expressed in HDACi-resistant lines.  Using genetic knockdown and overexpression assays, we show that RNH1 is both necessary and sufficient to induce HDACi resistance, and that RNH1 is likely to mediate this resistance through the dampening of HDACi-induced reactive oxygen species (ROS) in cancer cells.  The discovery of RNH1 as a regulator of HDACi resistance in gastric cancer highlights a functional role for ROS induction in the cellular effects of this important drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0HWhkcLDTP7Vg90H21EOLACvtfcHk0likpPpOmXEIoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCnt7w%253D&md5=e20ace66e8c8d4fb846ce20ecb9f9124</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.104%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BH.%26aulast%3DTan%26aufirst%3DP.%26atitle%3DRNH1%2520regulation%2520of%2520reactive%2520oxygen%2520species%2520contributes%2520to%2520histone%2520deacetylase%2520inhibitor%2520resistance%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1527%26epage%3D1537%26doi%3D10.1038%2Fonc.2013.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almenara, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3637</span>– <span class="NLM_lpage">3645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=12839953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVGrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3637-3645&author=R.+R.+Rosatoauthor=J.+A.+Almenaraauthor=S.+Grant&title=The+histone+deacetylase+inhibitor+MS-275+promotes+differentiation+or+apoptosis+in+human+leukemia+cells+through+a+process+regulated+by+generation+of+reactive+oxygen+species+and+induction+of+p21CIP1%2FWAF1+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1</span></div><div class="casAuthors">Rosato, Roberto R.; Almenara, Jorge A.; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3637-3645</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effects of the histone deacetylase (HDAC) inhibitor MS-275 have been examd. in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous leukemia blasts in relation to differentiation and apoptosis.  MS-275 displayed dose-dependent effects in each of the cell lines.  When administered at a low concn. (e.g., 1 μM), MS-275 exhibited potent antiproliferative activity, inducing p21CIP1/WAF1-mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells.  These events were accompanied by an increase in hypophosphorylated retinoblastoma protein and down-regulation of cell cycle-related proteins including cyclin D1.  However, at higher concns. (e.g., 5 μM), MS-275 potently induced cell death, triggering apoptosis in ∼70% of cells at 48 h.  In contrast to other HDAC inhibitors such as apicidin, the extrinsic, receptor-mediated pathway played a minimal role in MS-275 lethality.  However, MS-275 potently induced a very early (e.g., within 2 h) increase in reactive oxygen species (ROS), followed by the loss of mitochondrial membrane potential (Δψm) and cytosolic release of cytochrome c.  These events culminated in activation of the caspase cascade, manifested by poly(ADP-ribose) polymerase, p21CIP1/WAF1, p27KIP, Bcl-2, and retinoblastoma protein degrdn.  MS-275 exposure also resulted in diminished expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP.  Administration of the free radical scavenger L-N-acetylcysteine blocked MS-275-mediated mitochondrial injury and apoptosis, suggesting a primary role for ROS generation in MS-275-assocd. lethality.  Lastly, U937 cells stably expressing a p21CIP1/WAF1 antisense construct were significantly more sensitive to MS-275-mediated apoptosis than controls, but they were impaired in their differentiation response.  Together, these findings demonstrate that MS-275 exerts dose-dependent effects in human leukemia cells, i.e., p21CIP1/WAF1-dependent growth arrest and differentiation at low drug concns. and a marked induction of ROS, mitochondrial damage, caspase activation, and apoptosis at higher concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrswikp6uNn3LVg90H21EOLACvtfcHk0lipMy5DjvY9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVGrurc%253D&md5=1e29d94ca64fff3e3f81a6275ca9f820</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosato%26aufirst%3DR.%2BR.%26aulast%3DAlmenara%26aufirst%3DJ.%2BA.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520MS-275%2520promotes%2520differentiation%2520or%2520apoptosis%2520in%2520human%2520leukemia%2520cells%2520through%2520a%2520process%2520regulated%2520by%2520generation%2520of%2520reactive%2520oxygen%2520species%2520and%2520induction%2520of%2520p21CIP1%252FWAF1%25201%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3637%26epage%3D3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>– <span class="NLM_lpage">26943</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0lipMy5DjvY9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayoub, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou El-Magd, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilli, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nindita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klobukowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuszynski, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of lankacidin group antibiotics is due to microtubule stabilization via a paclitaxel-like mechanism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9532</span>– <span class="NLM_lpage">9540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01264</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CgsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9532-9540&author=A.+T.+Ayoubauthor=R.+M.+Abou+El-Magdauthor=J.+Xiaoauthor=C.+W.+Lewisauthor=T.+M.+Tilliauthor=K.+Arakawaauthor=Y.+Ninditaauthor=G.+Chanauthor=L.+Sunauthor=M.+Gloverauthor=M.+Klobukowskiauthor=J.+Tuszynski&title=Antitumor+activity+of+lankacidin+group+antibiotics+is+due+to+microtubule+stabilization+via+a+paclitaxel-like+mechanism&doi=10.1021%2Facs.jmedchem.6b01264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism</span></div><div class="casAuthors">Ayoub, Ahmed Taha; Abou El-Magd, Rabab M.; Xiao, Jack; Lewis, Cody Wayne; Tilli, Tatiana Martins; Arakawa, Kenji; Nindita, Yosi; Chan, Gordon; Sun, Luxin; Glover, Mark; Klobukowski, Mariusz; Tuszynski, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9532-9540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lankacidin group antibiotics show strong antimicrobial activity against various Gram-pos. bacteria.  In addn., they were shown to have considerable antitumor activity against certain cell line models.  For decades, the antitumor activity of lankacidin was assocd. with the mechanism of its antimicrobial action, that is interference with peptide bond formation during protein synthesis.  This, however, was never confirmed exptl.  Due to significant similarity to paclitaxel-like hits in a previous computational virtual screening study, the authors suggested that the cytotoxic effect of lankacidin is due to a paclitaxel-like action.  In this study, the authors tested this hypothesis computationally and exptl. and confirmed that lankacidin is a microtubule stabilizer that enhances tubulin assembly and displaces taxoids from their binding site.  This study serves as a starting point for optimization of lankacidin derivs. for better antitumor activities.  It also highlights the power of computational predictions and their aid in guiding expts. and formulating rigorous hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz6aKpkFbdbVg90H21EOLACvtfcHk0lipMy5DjvY9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CgsLvE&md5=22cf1a4b8adf7d59e218f46c1f4d446e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01264%26sid%3Dliteratum%253Aachs%26aulast%3DAyoub%26aufirst%3DA.%2BT.%26aulast%3DAbou%2BEl-Magd%26aufirst%3DR.%2BM.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%2BW.%26aulast%3DTilli%26aufirst%3DT.%2BM.%26aulast%3DArakawa%26aufirst%3DK.%26aulast%3DNindita%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DGlover%26aufirst%3DM.%26aulast%3DKlobukowski%26aufirst%3DM.%26aulast%3DTuszynski%26aufirst%3DJ.%26atitle%3DAntitumor%2520activity%2520of%2520lankacidin%2520group%2520antibiotics%2520is%2520due%2520to%2520microtubule%2520stabilization%2520via%2520a%2520paclitaxel-like%2520mechanism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9532%26epage%3D9540%26doi%3D10.1021%2Facs.jmedchem.6b01264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Macrophages: obligate partners for tumor cell migration, invasion, and metastasis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.cell.2006.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=16439202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=263-266&author=J.+Condeelisauthor=J.+W.+Pollard&title=Macrophages%3A+obligate+partners+for+tumor+cell+migration%2C+invasion%2C+and+metastasis&doi=10.1016%2Fj.cell.2006.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages: obligate partners for tumor cell migration, invasion, and metastasis</span></div><div class="casAuthors">Condeelis, John; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-266</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Macrophages within the tumor microenvironment facilitate angiogenesis and extracellular-matrix breakdown and remodeling and promote tumor cell motility.  Recent studies reveal that direct communication between macrophages and tumor cells leads to invasion and egress of tumor cells into the blood vessels (intravasation).  Thus, macrophages are at the center of the invasion microenvironment and are an important drug target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9bPyDvlwK1LVg90H21EOLACvtfcHk0ljXrjU4AShEkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KktLo%253D&md5=ddd258f9109498d4f1c252bfc5bc0a63</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DCondeelis%26aufirst%3DJ.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DMacrophages%253A%2520obligate%2520partners%2520for%2520tumor%2520cell%2520migration%252C%2520invasion%252C%2520and%2520metastasis%26jtitle%3DCell%26date%3D2006%26volume%3D124%26spage%3D263%26epage%3D266%26doi%3D10.1016%2Fj.cell.2006.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>202</i></span>, <span class="NLM_elocation-id">112519</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.ejmech.2020.112519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=32650183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKns7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2020&author=G.+Liauthor=Y.+Wangauthor=L.+Liauthor=Y.+Renauthor=X.+Dengauthor=J.+Liuauthor=W.+Wangauthor=M.+Luoauthor=S.+Liuauthor=J.+Chen&title=Design%2C+synthesis%2C+and+bioevaluation+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+derivatives+as+tubulin+polymerization+inhibitors+targeting+the+colchicine+binding+site+with+potent+anticancer+activities&doi=10.1016%2Fj.ejmech.2020.112519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities</span></div><div class="casAuthors">Li, Gang; Wang, Yuxi; Li, Ling; Ren, Yichang; Deng, Xin; Liu, Jin; Wang, Wei; Luo, Meihua; Liu, Shuwen; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112519</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of pyrazolo[1,5-a]pyrimidine analogs com I [R=5-(1-methyl-1H-indole), 4-Me phenol, 6-indole, etc.,] were designed and synthesized as novel tubulin inhibitors.  Among them, compds. com I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] showed the highest antiproliferative activity against a panel of cancer cell lines with av. IC50 values of 24.8 nM and 28 nM, resp.  The crystal structures of compds. of I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] in complex with tubulin and confirmed their direct binding to the colchicine site was discussed.  Com I [R=5-(1-methyl-1H-indole) and R= 4-Me phenol] also effectively inhibited tubulin polymn. in vitro, induced cell cycle arrest in G2/M phase, and inhibited cancer cell migration.  In addn., com I [R= 4-Me phenol] exhibited high metabolic stability in human liver microsomes.  Finally, com I [R= 4-Me phenol] was highly effective in suppressing tumor growth in a B16-F10 mouse melanoma model without apparent toxicity.  In summary, these results suggested that com I [R= 4-Me phenol] represent a promising tubulin inhibitor worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFkS2OTrxB8LVg90H21EOLACvtfcHk0ljXrjU4AShEkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKns7rL&md5=758a3585e22a57d244a3656750f7eca3</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112519%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioevaluation%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520derivatives%2520as%2520tubulin%2520polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%2520with%2520potent%2520anticancer%2520activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D202%26doi%3D10.1016%2Fj.ejmech.2020.112519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubieniecka, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1158%2F1535-7163.MCT-07-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=18566246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1751-1761&author=S.+Liuauthor=H.+Chengauthor=W.+Kwanauthor=J.+M.+Lubienieckaauthor=T.+O.+Nielsen&title=Histone+deacetylase+inhibitors+induce+growth+arrest%2C+apoptosis%2C+and+differentiation+in+clear+cell+sarcoma+models&doi=10.1158%2F1535-7163.MCT-07-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models</span></div><div class="casAuthors">Liu, Shuzhen; Cheng, Hongwei; Kwan, Wanda; Lubieniecka, Joanna M.; Nielsen, Torsten O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1751-1761</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clear cell sarcoma is an aggressive malignancy occurring most commonly in the distal extremities of young adults, characterized by t(12;22)(q13;q12) creating the chimeric fusion oncoprotein EWS-ATF1.  We assessed growth inhibition and differentiation effects of histone deacetylase inhibitors MS-275 and romidepsin (depsipeptide, FK228) on clear cell sarcoma cells and evaluated drug sensitivity among related translocation-assocd. sarcomas and other cell models.  Three clear cell sarcoma cell lines, seven other sarcomas, six nonsarcoma malignant cell lines, and two nonneoplastic mesenchymal cell models were treated with MS-275 or romidepsin.  Growth inhibition was assayed by monolayer 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.  Induction of cell cycle arrest and apoptosis were assessed by propidium iodide/Annexin V flow cytometry in monolayer and spheroid cultures and by immunoblotting anal.  Expression levels of key genes involved in mesenchymal differentiation and of EWS-ATF1 were measured by quant. real-time PCR in clear cell sarcoma cells treated with histone deacetylase inhibitors.  MS-275 and romidepsin inhibited growth in clear cell sarcoma cells by inducing cell cycle arrest and apoptosis in a time- and dose-dependent manner.  Sarcomas showed greater sensitivity than other tumor types, with clear cell sarcomas most sensitive of all, whereas nonmalignant mesenchymal cells were highly resistant.  MS-275 at 1 μmol/L and romidepsin at 1 nmol/L induced histone H3 acetylation, cell cycle arrest, apoptosis, and differentiation in clear cell sarcoma cells within 24 h.  Histone deacetylase inhibitors increased expression of SOX9, MYOD1, and PPARG and decreased EWS-ATF1 expression in clear cell sarcoma cells.  Histone deacetylase inhibitors show promising preclin. activity in multiple clear cell sarcoma models. [Mol Cancer Ther 2008;7(6):1751-61].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-oSfn2ycZtrVg90H21EOLACvtfcHk0ljXrjU4AShEkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSkurc%253D&md5=fec236f4fb6e8a9acc2aaf7cf4ae8b05</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0560%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKwan%26aufirst%3DW.%26aulast%3DLubieniecka%26aufirst%3DJ.%2BM.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520induce%2520growth%2520arrest%252C%2520apoptosis%252C%2520and%2520differentiation%2520in%2520clear%2520cell%2520sarcoma%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1751%26epage%3D1761%26doi%3D10.1158%2F1535-7163.MCT-07-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, P.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in hematological malignancies and solid tumors</span>. <i>Arch. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">933</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1007/s12272-015-0571-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs12272-015-0571-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25653088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1aqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=933-949&author=P.+Chun&title=Histone+deacetylase+inhibitors+in+hematological+malignancies+and+solid+tumors&doi=10.1007%2Fs12272-015-0571-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in hematological malignancies and solid tumors</span></div><div class="casAuthors">Chun, Pusoon</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">933-949</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs.  Because aberrant activity and expression of HDACs have been implicated in various cancer types, a wide range of HDAC inhibitors are being investigated as anticancer agents.  Furthermore, due to the demonstrable anticancer activity in both in vitro and in vivo studies, numerous HDAC inhibitors have undergone a rapid phase of clin. development in various cancer types, either as a monotherapy or in combination with other anticancer agents.  Although preclin. trials show that HDAC inhibitors have a variety of biol. effects across multiple pathways, including regulation of gene expression, inducing apoptosis and cell cycle arrest, inhibiting angiogenesis, and regulation of DNA damage and repair, the mechanism by which the clin. activity is mediated remains unclear.  Understanding the mechanisms of anticancer activity of HDAC inhibitors is essential not only for rational drug design for targeted therapies, but for the design of optimized clin. protocols.  This paper describes the links between HDACs and cancer, and the underlying mechanisms of action of HDAC inhibitors against hematol. malignancies and solid tumors.  Further, this review presents the clin. outcomes of vorinostat, romidepsin, and belinostat, which are approved by the United States Food and Drug Administration for the treatment of lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpko6AQ_rOm5LVg90H21EOLACvtfcHk0lisrT8v6Z6Wuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1aqu7g%253D&md5=70eecb629ef6bc43204f30007be749ff</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs12272-015-0571-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-015-0571-1%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520hematological%2520malignancies%2520and%2520solid%2520tumors%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2015%26volume%3D38%26spage%3D933%26epage%3D949%26doi%3D10.1007%2Fs12272-015-0571-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC inhibitors in cancer development and therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">a026831</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+inhibitors+in+cancer+development+and+therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0lisrT8v6Z6Wuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520inhibitors%2520in%2520cancer%2520development%2520and%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design, synthesis, and biological evaluation of (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6734</span>– <span class="NLM_lpage">6750</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00706</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00706" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1OqsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6734-6750&author=Q.+Wangauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=D.+Maauthor=S.+W.+Whiteauthor=D.+D.+Millerauthor=W.+Liauthor=W.+Li&title=Structure-guided+design%2C+synthesis%2C+and+biological+evaluation+of+%282-%281H-indol-3-yl%29-1H-imidazol-4-yl%29%283%2C4%2C5-trimethoxyphenyl%29+methanone+%28ABI-231%29+analogues+targeting+the+colchicine+binding+site+in+tubulin&doi=10.1021%2Facs.jmedchem.9b00706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin</span></div><div class="casAuthors">Wang, Qinghui; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Ma, Dejian; White, Stephen W.; Miller, Duane D.; Li, Weimin; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6734-6750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clin. trials for prostate cancer.  Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogs, most notably 10ab (I) and 10bb.  The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved mol. interactions to the colchicine site.  In vitro, biol. studies showed that new ABI-231 analogs disrupt tubulin polymn., promote microtubule fragmentation, and inhibit cancer cell migration.  In vivo, analog 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model.  In addn., pharmacol. screening suggested that 10bb has a low risk of potential off-target function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0inGN_kombVg90H21EOLACvtfcHk0lisrT8v6Z6Wuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1OqsLnE&md5=6b10b2d294d209eea9ab6e9ec86282f4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DStructure-guided%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520%25282-%25281H-indol-3-yl%2529-1H-imidazol-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529%2520methanone%2520%2528ABI-231%2529%2520analogues%2520targeting%2520the%2520colchicine%2520binding%2520site%2520in%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6734%26epage%3D6750%26doi%3D10.1021%2Facs.jmedchem.9b00706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0lhIxO3NV9NrUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1405</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.bmc.2019.02.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=30819618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1405-1413&author=S.+Liuauthor=K.+Zhangauthor=Q.+Zhuauthor=Q.+Shenauthor=Q.+Zhangauthor=J.+Yuauthor=Y.+Chenauthor=W.+Lu&title=Synthesis+and+biological+evaluation+of+paclitaxel+and+vorinostat+co-prodrugs+for+overcoming+drug+resistance+in+cancer+therapy+in+vitro&doi=10.1016%2Fj.bmc.2019.02.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro</span></div><div class="casAuthors">Liu, Shuangxi; Zhang, Kaili; Zhu, Qiwen; Shen, Qianqian; Zhang, Qiumeng; Yu, Jiahui; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1405-1413</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX) is the first-line treatment drug for breast cancer.  However, drug resistance after a course of treatment and low selectivity restricted its clin. utility sometimes.  In this study, we successfully bound PTX and vorinostat (SAHA) to form co-prodrugs based on the synergistic anticancer effects.  The PTX-SAHA co-prodrugs were conjugated by glycine (1a) and succinic acid (1b) resp. and the former has shown better activity in cytotoxicity, cell cycle arrest and western-blot expts.  Therefore, 1a was further prepd. to nanomicelles with mPEG2000-PLA1750 as the carrier by using thin film method.  PTX-SAHA co-prodrug nanomicelles were spherical with a particle size of 20-100 nm.  In vitro drug release test showed 1a nanomicelles had sustained release effect, which could reduce the resistance of PTX.  In vitro cytotoxicity was evaluated by SRB assay in HCT-116 cells, MCF-7 cells and drug-resistant MCF-7/ADR cells.  The results showed 1a nanomicelles had comparable or even better cytotoxicity than PTX esp. in the MCF-7/ADR cells.  All the results suggested that PTX-SAHA co-prodrug nanomicelles were promising treatment for PTX resistance cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SV8dAcYxGbVg90H21EOLACvtfcHk0lj8q9tfsn_yIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOmu7o%253D&md5=ea6c9ff2d35fa8de07dd8b3897c782e7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.046%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520paclitaxel%2520and%2520vorinostat%2520co-prodrugs%2520for%2520overcoming%2520drug%2520resistance%2520in%2520cancer%2520therapy%2520in%2520vitro%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1405%26epage%3D1413%26doi%3D10.1016%2Fj.bmc.2019.02.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslehi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bersell, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funck-Brentano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, J. E.</span></span> <span> </span><span class="NLM_article-title">Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1016%2Fj.pharmthera.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=29698683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFWitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2018&pages=89-103&author=J.+Alexandreauthor=J.+J.+Moslehiauthor=K.+R.+Bersellauthor=C.+Funck-Brentanoauthor=D.+M.+Rodenauthor=J.+E.+Salem&title=Anticancer+drug-induced+cardiac+rhythm+disorders%3A+Current+knowledge+and+basic+underlying+mechanisms&doi=10.1016%2Fj.pharmthera.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms</span></div><div class="casAuthors">Alexandre, Joachim; Molsehi, Javid J.; Bersell, Kevin R.; Funck-Brentano, Christian; Roden, Dan M.; Salem, Joe-Elie</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-103</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases.  Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy.  Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy.Supraventricular tachycardias occur in cancer patients treated with cytotoxic chemotherapy (anthracyclines, gemcitabine, cisplatin and alkylating-agents) or kinase-inhibitors (KIs) such as ibrutinib.  Ventricular arrhythmias, with a subset of them being torsades-de-pointes (TdP) favored by QTc prolongation have been reported: this may be the result of direct hERG-channel inhibition or a more recently-described mechanism of phosphoinositide-3-kinase inhibition.  The major anticancer drugs responsible for QTc prolongation in this context are KIs, arsenic trioxide, anthracyclines, histone deacetylase inhibitors, and selective estrogen receptor modulators.Anticancer drug-induced cardiac rhythm disorders remain an underappreciated complication even by experienced clinicians.  Moreover, the causal relationship of a particular anticancer drug with cardiac arrhythmia occurrence remains challenging due in part to patient comorbidities and complex treatment regimens.  For example, any cancer patient may also be diagnosed with common diseases such as hypertension, diabetes or heart failure which increase an individual's arrhythmia susceptibility.  Further, anticancer drugs are generally usually used in combination, increasing the challenge around establishing causation.Thus, arrhythmias appear to be an underappreciated adverse effect of anticancer agents and the incidence, significance and underlying mechanisms are now being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3CEA1S07ZGbVg90H21EOLACvtfcHk0lj8q9tfsn_yIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFWitbw%253D&md5=c6fd21efa1c8568866decb2f59c676f3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DMoslehi%26aufirst%3DJ.%2BJ.%26aulast%3DBersell%26aufirst%3DK.%2BR.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DSalem%26aufirst%3DJ.%2BE.%26atitle%3DAnticancer%2520drug-induced%2520cardiac%2520rhythm%2520disorders%253A%2520Current%2520knowledge%2520and%2520basic%2520underlying%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D189%26spage%3D89%26epage%3D103%26doi%3D10.1016%2Fj.pharmthera.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamorano, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez Munoz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboyans, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asteggiano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galderisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenihan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Fernandez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piepoli, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamargo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, T. M.</span></span> <span> </span><span class="NLM_article-title">2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2768</span>– <span class="NLM_lpage">2801</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1093%2Feurheartj%2Fehw211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=27567406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2szkslKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2768-2801&author=J.+L.+Zamoranoauthor=P.+Lancellottiauthor=D.+Rodriguez+Munozauthor=V.+Aboyansauthor=R.+Asteggianoauthor=M.+Galderisiauthor=G.+Habibauthor=D.+J.+Lenihanauthor=G.+Y.+H.+Lipauthor=A.+R.+Lyonauthor=T.+Lopez+Fernandezauthor=D.+Mohtyauthor=M.+F.+Piepoliauthor=J.+Tamargoauthor=A.+Torbickiauthor=T.+M.+Suter&title=2016+ESC+position+paper+on+cancer+treatments+and+cardiovascular+toxicity+developed+under+the+auspices+of+the+ESC+committee+for+practice+guidelines%3A+the+task+force+for+cancer+treatments+and+cardiovascular+toxicity+of+the+European+society+of+cardiology+%28ESC%29&doi=10.1093%2Feurheartj%2Fehw211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)</span></div><div class="casAuthors">Zamorano Jose Luis; Lancellotti Patrizio; Rodriguez Munoz Daniel; Aboyans Victor; Asteggiano Riccardo; Galderisi Maurizio; Habib Gilbert; Lenihan Daniel J; Lip Gregory Y H; Lyon Alexander R; Lopez Fernandez Teresa; Mohty Dania; Piepoli Massimo F; Tamargo Juan; Torbicki Adam; Suter Thomas M</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">2768-2801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRUs2uUwIgayA3UY9EwTNrfW6udTcc2eaJk72pgwpEALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szkslKrsA%253D%253D&md5=d2a90317d321c401601e512d243bbb8f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw211%26sid%3Dliteratum%253Aachs%26aulast%3DZamorano%26aufirst%3DJ.%2BL.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DRodriguez%2BMunoz%26aufirst%3DD.%26aulast%3DAboyans%26aufirst%3DV.%26aulast%3DAsteggiano%26aufirst%3DR.%26aulast%3DGalderisi%26aufirst%3DM.%26aulast%3DHabib%26aufirst%3DG.%26aulast%3DLenihan%26aufirst%3DD.%2BJ.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DLopez%2BFernandez%26aufirst%3DT.%26aulast%3DMohty%26aufirst%3DD.%26aulast%3DPiepoli%26aufirst%3DM.%2BF.%26aulast%3DTamargo%26aufirst%3DJ.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSuter%26aufirst%3DT.%2BM.%26atitle%3D2016%2520ESC%2520position%2520paper%2520on%2520cancer%2520treatments%2520and%2520cardiovascular%2520toxicity%2520developed%2520under%2520the%2520auspices%2520of%2520the%2520ESC%2520committee%2520for%2520practice%2520guidelines%253A%2520the%2520task%2520force%2520for%2520cancer%2520treatments%2520and%2520cardiovascular%2520toxicity%2520of%2520the%2520European%2520society%2520of%2520cardiology%2520%2528ESC%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2768%26epage%3D2801%26doi%3D10.1093%2Feurheartj%2Fehw211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minchella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span> <span> </span><span class="NLM_article-title">QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1007/s11523-014-0325-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs11523-014-0325-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=24970120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A280%3ADC%252BC2cfntVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=27-43&author=M.+Locatelliauthor=C.+Criscitielloauthor=A.+Espositoauthor=I.+Minchellaauthor=A.+Goldhirschauthor=C.+Cipollaauthor=G.+Curigliano&title=QTc+prolongation+induced+by+targeted+biotherapies+used+in+clinical+practice+and+under+investigation%3A+a+comprehensive+review&doi=10.1007%2Fs11523-014-0325-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review</span></div><div class="casAuthors">Locatelli Marzia; Criscitiello Carmen; Esposito Angela; Minchella Ida; Goldhirsch Aron; Cipolla Carlo; Curigliano Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death.  Irrespective of overt clinical toxicities, QTc assessment can influence decision making during the conduct of clinical studies, including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal dose for subsequent development.  Efforts are needed to refine strategies for risk management, avoiding unintended consequences that negatively affect patient access and clinical development of promising new cancer treatments.  In this comprehensive review, we will analyze potential effects on QTc prolongations of targeted agents approved by regulatory agencies and under investigation.  A thoughtful risk management plan was generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies to support a development program essential for oncology agents with cardiac safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlbHMQlebL61VwdslNBF-tfW6udTcc2eaJk72pgwpEALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfntVKrsA%253D%253D&md5=d92b887bac40f28f6db1ba02f51f955f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0325-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0325-x%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DA.%26aulast%3DMinchella%26aufirst%3DI.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DCipolla%26aufirst%3DC.%26aulast%3DCurigliano%26aufirst%3DG.%26atitle%3DQTc%2520prolongation%2520induced%2520by%2520targeted%2520biotherapies%2520used%2520in%2520clinical%2520practice%2520and%2520under%2520investigation%253A%2520a%2520comprehensive%2520review%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D27%26epage%3D43%26doi%3D10.1007%2Fs11523-014-0325-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sager, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1185</span>, <span class="refDoi"> DOI: 10.1002/cam4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1002%2Fcam4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=25914207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yqsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1178-1185&author=P.+T.+Sagerauthor=B.+Balserauthor=J.+Wolfsonauthor=J.+Nicholsauthor=R.+Pilotauthor=S.+Jonesauthor=H.+A.+Burris&title=Electrocardiographic+effects+of+class+1+selective+histone+deacetylase+inhibitor+romidepsin&doi=10.1002%2Fcam4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin</span></div><div class="casAuthors">Sager, Philip T.; Balser, Barbara; Wolfson, Julie; Nichols, Jean; Pilot, Richard; Jones, Suzanne; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1178-1185</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy.  The objective of this anal. was to evaluate the potential QTc effects of romidepsin.  Patients with advanced malignancy received 4-h infusions of 14 mg/m2 romidepsin on days 1, 8, and 15 of a 28-day cycle.  In cycle 2, a subset of patients received 1-h infusions of 8-12 mg/m2 romidepsin.  Patients were administered antiemetics before each romidepsin dose and electrolyte supplementation as needed.  ECG readings were performed prior to antiemetic administration, prior to romidepsin administration, and at specified time points over the subsequent 24 h.  Romidepsin exposure and heart rate were also assessed.  In the ECG-evaluable population, 26 patients received romidepsin at 14 mg/m2 over 4 h.  The max. mean increases from the preantiemetic baseline for QTcF and heart rate were 10.1 ms (upper 90% CI, 14.5 ms) and 18.2 beats per min, resp.  No patient in this study had an abs. QTcF value >450 ms and only one patient had an increase from the preantiemetic baseline of >60 ms.  There was a mild redn. in the PR interval and no meaningful changes in the QRS interval.  Despite the use of QT-prolonging antiemetics, treatment with romidepsin did not markedly prolong the QTc interval through 24 h.  Increases in calcd. QTc may have been exaggerated as a consequence of transient increases in heart rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_tT1B5qNJbVg90H21EOLACvtfcHk0lhZpmAzb_xu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yqsbvI&md5=2cfb095479d4dafad28703fa66f4773e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcam4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.467%26sid%3Dliteratum%253Aachs%26aulast%3DSager%26aufirst%3DP.%2BT.%26aulast%3DBalser%26aufirst%3DB.%26aulast%3DWolfson%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DPilot%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DElectrocardiographic%2520effects%2520of%2520class%25201%2520selective%2520histone%2520deacetylase%2520inhibitor%2520romidepsin%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D1178%26epage%3D1185%26doi%3D10.1002%2Fcam4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nydam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen-Freda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scher, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2224-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=10.1007%2Fs00280-013-2224-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=23820963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=537-544&author=D.+E.+Rathkopfauthor=J.+Picusauthor=A.+Hussainauthor=S.+Ellardauthor=K.+N.+Chiauthor=T.+Nydamauthor=E.+Allen-Fredaauthor=K.+K.+Mishraauthor=M.+G.+Porroauthor=H.+I.+Scherauthor=G.+Wilding&title=A+phase+2+study+of+intravenous+panobinostat+in+patients+with+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2224-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer</span></div><div class="casAuthors">Rathkopf, Dana E.; Picus, Joel; Hussain, Arif; Ellard, Susan; Chi, Kim Nguyen; Nydam, Thomas; Allen-Freda, Erin; Mishra, Kaushal Kishor; Porro, Maria Grazia; Scher, Howard I.; Wilding, George</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins assocd. with growth and survival of malignant cells.  This phase 2 study evaluated the efficacy of i.v. (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy.  The primary end point was 24-wk progression-free survival.  Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline.  Methods: IV panobinostat (20 mg/m2) was administered to patients on days 1 and 8 of a 21-day cycle.  Tumor response was assessed by imaging every 12 wk (4 cycles) according to modified response evaluation criteria in solid tumors (Scher et al. in Clin Cancer Res 11:5223-5232, 23), and PSA response was defined as a 50 % decrease from baseline maintained for ≥4 wk.  Safety monitoring was routinely performed and included ECG monitoring.  Results: Of 35 enrolled patients, four (11.4 %) were alive without progression of disease at 24 wk.  PSA was evaluated in 34 (97.1 %) patients: five (14.3 %) patients demonstrated a decrease in PSA but none ≥50 %; one patient (2.9 %) had carcinoembryonic antigen as a marker of his prostate cancer, which declined by 43 %.  Toxicities regardless of relationship to panobinostat included fatigue (62.9 %), thrombocytopenia (45.7 %), nausea (51.4 %), and decreased appetite (37.1 %).  Conclusions: Despite promising preclin. data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clin. activity to pursue further investigation as a single agent in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIfYnqVJ-7Vg90H21EOLACvtfcHk0lhZpmAzb_xu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrt7bM&md5=1fbbe53ab514fa6949677e5a7b7918f3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2224-8%26sid%3Dliteratum%253Aachs%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DEllard%26aufirst%3DS.%26aulast%3DChi%26aufirst%3DK.%2BN.%26aulast%3DNydam%26aufirst%3DT.%26aulast%3DAllen-Freda%26aufirst%3DE.%26aulast%3DMishra%26aufirst%3DK.%2BK.%26aulast%3DPorro%26aufirst%3DM.%2BG.%26aulast%3DScher%26aufirst%3DH.%2BI.%26aulast%3DWilding%26aufirst%3DG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520intravenous%2520panobinostat%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D537%26epage%3D544%26doi%3D10.1007%2Fs00280-013-2224-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B','PDB','4O2B'); return false;">PDB: 4O2B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69','PDB','4A69'); return false;">PDB: 4A69</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i131"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00413">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_44431"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00413?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00413</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Copies of Compounds <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, HPLC spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_002.csv">CSV</a>)</p></li><li><p class="inline">4A69 (HDAC3 PDB) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_003.pdb">PDB</a>)</p></li><li><p class="inline">4O2B (Tubulin PDB) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_001.pdf">jm1c00413_si_001.pdf (9.2 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_002.csv">jm1c00413_si_002.csv (5.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_003.pdb">jm1c00413_si_003.pdb (447.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00413/suppl_file/jm1c00413_si_004.pdb">jm1c00413_si_004.pdb (789.91 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00413&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00413%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00413" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b6b806ea02212","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
